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ABSTRACT 
Electospray ionisation mass spectrometry (ESI-MS) has been used to study the non-
covalent interactions in dsDNA-drug complexes, a protein-protein complex of DNA 
polymerase III of E. coli and binding specificity of cisplatin in the formation of 
bifunctional adducts with DNA. 
 
ESI conditions have been developed to maximize the detection of dsDNA and drug-
DNA complexes in the positive ion mode, with comparable and/or superior results to 
those achieved previously using negative ions. The gas phase stabilities of complexes 
of dsDNA with different classes of drugs have been examined. Different classes of 
drugs exhibit differences in sequence selectivity, modify DNA in various ways and 
are also known to stabilise or destabilise dsDNA. ESI-MS/MS, desolvation 
temperature variation, and in-source collision-induced dissociation experiments have 
been employed to examine the relative stabilities of drug-dsDNA complexes. The 
binding of complexes of a new class of metallointercalators containing Ru with 
dsDNA has also been examined by ESI-MS. Conditions were developed for optimal 
detection of these complexes in the negative ion mode and their stoichiometries and 
sequence selectivity have been probed. The relative order of binding affinities was 
found to correlate with solution studies carried out with related ruthenium 
compounds containing the extended planar ligands dpq, dpqC and dppz. 
 
ESI-MS has also been used to supply a “snapshot” of components of mixtures of two 
proteins ε186 and θ, that form a complex in DNA polymerase III. The stability of the 
θ-ε186 complex has been studied under various solution and instrumental conditions. 
The behaviour of this complex was consistent with significant contribution of 
 
hydrophobic interactions to its stability, and contrasted with the previously reported 
behaviour of the Tus-Ter complex. In addition, ESI-MS experiments suggested that 
the θ subunit is involved in stabilization of ε186. This is consistent with earlier 
experiments in which θ was shown to stabilise ε against thermal inactivation. 
 
Finally the thesis has examined binding specificity of cisplatin in the formation of 
bifunctional adducts at three well-characterized binding sites on ssDNA.  A novel 
method for better reaction conditions and purification of ssDNA-cisplatin adducts 
HPLC has been developed. The bifunctional ssDNA-cisplatin adducts at 5′-GG-3′, 
5′-AG-3′ and 5′-GA-3′ sites have been characterized by enzymatic digestion 
followed by ESI mass spectrometry for identification of binding sites. 
  
 
 
ABBREVIATIONS 
(dpq)  dipyrido[3,2-d:2′,3′-f]quinoxaline  
(dpqC)  dipyrido[3,2-a:2′,3′-c](6,7,8,9-tetrahydro)phenazine  
(dppz)  dipyrido[3,2-a:2′,3′-c]phenazine  
(phen)  1,10-phenanthroline  
A  adenine  
amu  atomic mass unit 
bp  base pairs 
C  cytosine  
CD  circular dichroism 
CID  collision induced dissociation 
Da  daltons  
DAPI  4′-6-diamidine-2-phenyl indole 
Dn  daunomycin 
DNA  deoxyribonucleic acid 
dsDNA  double-stranded DNA 
Dst  distamycin 
E. coli  Escherichia coli 
ESI  Electrospray Ionisation 
G  guanine  
Hc  Hoechst 33258 
HMG  high mobility group 
HPLC  high performance liquid chromatography 
m/z  Mass-to-charge 
MALDI-MS  matrix assisted laser desorption ionisation mass spectrometry
Mr  relative molecular mass 
MS  mass spectrometry 
MS/MS  tandem mass spectrometry 
NMR  nuclear magnetic resonance 
PA  proton affinity 
Pd I  phosphodiesterase I 
Pd II  phosphodiesterase II 
pol III  DNA polymerase III 
RNA  ribonucleic acid 
ssDNA  single-stranded DNA 
T  thymine  
Tm  melting temperature (of DNA) 
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Chapter 1: Introduction 
1. 1 Introduction to Protein and DNA structure 
Proteins and nucleic acids are vital molecules involved in almost all the functions in 
an organism. For example, proteins provide energy via metabolic reactions as 
enzymes, collagen gives mechanical support to the body, actin and myosin are the 
key proteins in muscles that help in the movement of the body. Immunoglobulins are 
involved in the defense of the body against foreign organisms and hemoglobin and 
myoglobin are proteins that carry oxygen to the cells [1]. 
 
Nucleic acids, DNA (deoxyribonucleic acid) carry the genetic information and via 
RNA (ribonucleic acid) convert this information in protein synthesis. The elucidation 
of the double stranded structure of DNA by Watson and Crick [2] led to a major 
revolution of genetic and molecular biology over the ensuing thirty years. Proteins 
are the direct products of genes and also carry nearly all the cellular functions. 
Proteins interact with other proteins and biomolecules such as DNA, RNA, 
polysaccharides, phospholipids and different ligands to convey vital functions of life 
such as growth, development, repair and reproduction [3]. Changes in a protein 
(either post-translational modifications or induced upon such interactions) may alter 
its function [4]. The dysfunction of the protein may lead to problems in 
macromolecular recognition, cell cycle regulation, diseases such as cancer, cell 
invasion and amyloidoses [5]. Worldwide there is an enormous effort devoted to the 
study of protein function to enable a better understanding of the relationship between 
protein sequence, structure and function.  
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The linear arrangement of amino acids constitutes the primary structure of 
proteins. For a length of 50 amino acids, there can be 5020 different sequences of 
protein, but this arrangement is highly specific for each molecule of protein 
(excluding post-translational modifications). Based on the arrangement of amino 
acids in a polypeptide chain, there may be structures including α-helices or β-
strands. These highly ordered structures are the secondary structures in proteins  as 
shown in Figure 1.1. In a polypeptide chain, there can be series of α-helices or β-
strands alone or, combinations of α-helices and β-strands. Further folding of 
secondary structures in a polypeptide chain results in tertiary structures of proteins. 
These include structures such as β-barrels and Greek-key motifs. Quaternary 
structure is the next level of complexity when a number of polypeptide chains 
(subunits) interact with one another to form a functional protein. Based on the 
number of chains interacting, a protein can be monomeric, dimeric, trimeric or 
tetrameric and so on [6]. 
 
Nucleic acids (DNA and RNA) also contain different levels of complexity. The basic 
repeating unit here is replaced by nucleotides as compared to amino acid in proteins. 
Primary structure in nucleic acids is determined by the sequence of nucleotides 
along the polynucleotide chain. All the genetic information is stored in the primary 
structure of DNA. Each nucleotide contains a pentose sugar (deoxyribose), a 
phosphate residue, and one of the heterocyclic bases (A) adenine, (G) guanine, (C) 
cytosine or (T) thymine. RNA also contains four bases except thymine is replaced by 
uracil (U) and the sugar is ribose [7]. 
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Figure 1.1: Different levels of protein structures observed in proteins, adapted from 
[8]. 
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The secondary structure of DNA was proposed by Watson and Crick in 1953 [2]. 
This was one of the most significant events in the history of science. In three 
dimensions, DNA exists as a double helix with two complementary strands running 
anti-parallel to each other. The dominant form in solution (B-DNA) exists as a right- 
handed helix and the two strands are held together by interstrand H-bonding; A pairs 
with T, and G pairs with C. Space between the backbones of two strands leads to the 
formation of major and minor groove. These grooves enable binding of different 
ligands to DNA and are shown in Fig. 1.2. 
 
Three types of conformations are known in DNA: A-form, B-form and Z-form. The 
B-form was the basis for the model proposed by Watson and Crick. The A-form is a 
right handed and Z-form is a left handed double helix. Supercoiling in DNA can lead 
to formation of tertiary structures as is observed for example, in Escherichia coli. 
(E. coli.) whose circular DNA contains about 4 million base pairs. In many instances 
palindromic sequences in DNA and RNA lead to the formation of other secondary 
and tertiary structures such as cruciforms, multistrands, hairpins, bulges and loops 
some of which are illustrated in Fig. 1.3 [9]. 
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Figure 1.2: Basic structural patterns in secondary structure of B-DNA, adapted from 
[7]. 
Figure 1.3: Common secondary and tertiary structures observed in DNA and RNA, 
adapted from [7]. 
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1. 2 Modern approaches to drug design 
Different levels of complexity and functions of proteins and nucleic acids involved in 
different biological processes make them primary targets of modern drugs. Owing to 
the lack of detailed understanding of cell biology at that time, early approaches to 
drug discovery targeted the pathogenic cells as a whole. There were a few 
serendipitous discoveries of naturally-occurring drugs like pencillin by Alexander 
Fleming in 1929 that gave some insight into the mechanism of antibiotics [10]. Even 
today most commonly used drugs are from natural sources. The influence of 
biochemistry in the early and mid-twentieth century led to more directed targeting of 
some enzymes and receptors e.g. sulfa drugs/sulfonamides [11]. 
 
It was only after the discovery of DNA as the hereditary molecule, however that 
molecular biology started to play a larger role in drug discovery. Different classes of 
anticancer drugs have been developed that interact with DNA in different ways. 
There can be non-covalent interaction by intercalation (e.g. daunomycin and 
ethidium bromide) or minor groove binders (e.g. distamycin A and Hoechst 22358) 
(more later). Others bind covalently to DNA including cisplatin and mitomycin, and 
some cause backbone cleavages e.g. bleomycin [12]. Many of these drugs show 
sequence selectivities which makes them potential targets for DNA from different 
sources. For example, minor groove binders preferentially bind to AT-rich sequences 
whereas intercalators have been proposed to prefer GC-rich sequences [12-15] (more 
below). 
 
The discovery of cisplatin as an antitumour agent led to an intense interest in metal 
complexes as anticancer drugs. Metals are electron deficient as opposed to 
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biomolecules such as DNA and proteins that have many electron rich binding sites 
leading to strong interactions between them. After the success of cisplatin, different 
transition metals have been used in antitumour drugs such as: gallium (Ga), 
ruthenium (Ru), rhodium Rh), titanium (Ti), vanadium (V) and tin (Sn) [16]. Metal-
containing (and other) drugs can have drawbacks both in terms of toxicity and the 
development of drug resistant tumours. This has further fueled the search for more 
specific, target-directed drugs.   
 
Combinatorial chemistry is a relatively recent development that involves automated, 
high volume synthesis and characterization of potential new target drugs. 
Combinatorial chemistry aims to generate small molecules that have the ability to 
interfere with a disease-related biological pathway in cells by targeting either 
proteins or DNA [17]. To effectively target such a biomolecule, however, it is 
necessary to understand the role it plays in a disease related pathway. Most of the 
proteins/nucleic acids function in complicated biological events with other molecules 
as a part of bigger complexes. Genomes of pathogens (bacteria and viruses) and most 
recently, the human genome have been sequenced using high-throughput DNA 
sequencing methods [18]. The proliferation of genome sequence data has generated 
the need and opportunity to the study of the functional units of cellular processes, in 
a field often referred to as functional genomics. Four levels of analysis are possible: 
genes (the genome), messenger RNA (the transcriptome), proteins (the proteome), 
and metabolites (the metabolome) [19].  
 
The total number of genes is relatively constant between species. For example, the 
total number genes in humans is similar to the number of genes in the nematode 
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worm Caenorhabditis elegans [20]. This suggests that the complexity in an organism 
arises largely from differences in the gene products depending upon the 
physiological and developmental state of the species and thus the full complement 
their function cannot be predicted from gene sequence alone.  
 
A proteome is all the expressed proteins from a cell at a given time in a given 
environment, and proteomics refers to the characterization of these proteins. 
Proteomics is arguably the most complicated and the most important “omes” because 
a protein may undergo different modifications and behave differently in different 
environments acting by itself, or in a complex of proteins and other biomolecules. 
Proteomics requires both new, more powerful analytical techniques and more work 
in well-defined “model organisms”. In the case of genetic forms of cancer, many 
genes that are altered in diseased states have structural or functional homologs in 
model genetic systems such as the yeasts Saccharomyces cerevisiae and 
Schizosaccharomyces pombe, the nematode Caenorhabditis elegans and the fruitfly 
Drosophila melanogaster [21].  
 
The accumulation of this information will enable new targets for modern drug design 
to be identified. Enzymes or receptors that function abnormally in diseased states are 
the main target of these drugs. Alternatively, gene therapy aims to replace a diseased 
receptor or enzyme (or gene) or to incorporate agents into the body that would allow 
the host to make its own therapeutic protein through gene-based therapy. The use of 
“biotech” drugs is an expanding world market. In a recent study of 50 drug 
companies it was reported that 26.3% of the total drugs introduced in 1998 were 
“biotech” drugs in contrast to 10.7% in 1997 [22].  
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Interactions in biomolecular complexes 
Biomolecules interact by non-covalent interactions such as hydrogen bonding, 
electrostatic interactions, dipole-dipole interactions, van der Waals forces and 
hydrophobic interactions. These are weak interactions that in combination play 
important roles in determining the stability of different biomolecules and their 
complexes e.g. DNA duplexes, folded proteins, enzyme-substrate complexes, drug-
receptor complexes and different protein-protein complexes. As the importance of 
these interactions in biomolecules was realized, different techniques been developed 
to study them. Since modern drugs interact with DNA or proteins as non-covalent 
complexes, the study of such interactions is an area of on-going importance and 
widespread significance.  
1.3 Drug-DNA complexes 
A variety of drugs (peptides, small organic molecules and inorganic complexes) can 
bind to DNA and interfere in processes like transcription and replication. The 
interaction of anticancer drugs with DNA is generally highly specific but not 
necessarily selective. DNA has many specific sites for these interactions including 
the polyanionic phosphate-sugar backbone and various hydrogen acceptor and 
donors on bases in major and minor grooves. In guanine, for example, the exocyclic 
N2 in the minor groove, and more commonly the N7 in the major groove, are binding 
sites for alkylating agents and metal ions. The N3 atoms of both guanine and adenine 
in the minor groove are also common drug binding sites [12]. Drugs can be classified 
into the categories, intercalators, minor groove binders, alkylating agents and 
inorganic coordinative complexes depending on their mode of interaction with DNA. 
In some cases drugs bind via more than one mode (e.g. intercalating alkylators such 
as hedamycin). 
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1.3.1 Intercalators 
Intercalators are generally comprised of polycyclic planar aromatic heterocyclic 
rings, that may carry a positive charge. The chromophore units have the capability of 
sliding horizontally into stacked base pairs of DNA. The polycyclic aromatic rings 
facilitate charge delocalization making them good electron acceptors as compared to 
base pairs of DNA that are good electron donors. Electrostatic forces, charge-transfer 
forces, hydrogen bonds and hydrophobic interactions play an important role in 
intercalation and stability [23]. 
 
Figure 1.4 shows the structures of some common intercalators. Ethidium (Fig 1.4 (a)) 
and acridine (Fig 1.4 (b)) are examples of simple intercalators. Other, more complex, 
compounds exhibit better selectivity and binding. Anthracycline antibiotics are an 
important class of intercalators that in many cases have antineoplastic activities and 
several are currently being used as clinical chemotherapeutic agents. Daunomycin 
(daunorubicin, Dn) (Fig 1.4 (c)) and adriamycin (doxorubicin) (Fig 1.4 (d)) are the 
most important drugs in this class. Many derivatives (such as nogalamycin, Ng, Fig 
1.4 (e)) of the above two molecules have been studied first, in attempts to lower the 
toxicity, and second to overcome the resistance acquired by different cell lines to the 
drugs. The first detailed structure of a drug-DNA complex reported was a crystal 
structure of 2:1 daunomycin-d(-CGTACG)2 [24]. Anthracyclines have three 
functional domains and their binding is more complex than simple intercalators. 
These are an aglycon ring system that intercalates perpendicular to the long axis of 
stacked bases, an amino sugar that may act as minor groove binding agent and 
functional groups on ring A of anthraquinone ring system [25]. These functional 
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groups interact with DNA bases by hydrogen bonding and help to stabilise the 
resulting complex.  
Figure 1.4: Some common intercalators: (a) ethidium, (b) acridine, (c) daunomycin, 
(d) adriamycin and (e) nogalamycin. 
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Another major class of intercalators are metallointercalators that bind to DNA 
noncovalently and have attracted considerable interest [26]. The first intercalators 
containing transition metals were studied in the late seventies by Lippard and co-
workers. These were platinum(II) complexes with square planar geometry containing 
an aromatic heterocyclic ligand [27]. This was soon extended to octahedral 
complexes with a three dimensional structure which gave these complexes specificity 
for DNA sequences based on the shape, symmetry and functionality. DNA binding 
of different metal complexes of zinc, cobalt, and ruthenium with tris(phenanthroline) 
has been studied and it has been shown that these complexes can interact with DNA 
by three different modes: electrostatic, hydrophobic in the minor groove and 
intercalation [28-31]. Some of the most well studied metallointercalators (including 
in this work) are: [Ru(phen)3]2+, [Ru(phen)2(dpq)]2+, [Ru(phen)2(dppC)]2+ and 
[Ru(phen)2(dppz)]2+  (Fig. 1.5). The latter three metallointercalators are the 
derivatives of [Ru(phen)3]2+ that have three 1,10-phenanthroline (phen) ligands 
bound to Ru(II) metal.  In these last three metallointercalators one (phen) ligand of 
[Ru(phen)3]2+ is replaced by dipyrido[3,2-d:2′,3′-f]quinoxaline (dpq), dipyrido[3,2-
a:2′,3′-c](6,7,8,9-tetrahydro)phenazine (dpqC) and dipyrido[3,2-a:2′,3′-c]phenazine 
(dppz) in  [Ru(phen)2(dpq)]2+, [Ru(phen)2(dppC)]2+ and [Ru(phen)2(dppz)]2+  
respectively (Fig. 1.5) [32]. As most of these metallointercalators are chiral, they 
show discrimination in preference for the chiral DNA duplex depending upon the 
symmetry of the complex matching with the handedness of the DNA duplex [33-36].                                    
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Figure 1.5: Metallointercalators based on ruthenium: (a) [Ru(phen)3]2+, (b) 
[Ru(phen)2(dpq)]2+, (c) [Ru(phen)2(dpqC)]2+ and (d) [Ru(phen)2(dppz)]2+. 
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1.3.2 Groove binders 
Most of the groove binding small molecules studied to date bind to the minor groove 
of DNA duplex as their overall curvature matches to the floor of the minor groove; 
they have hydrogen bond donors on the inside and have at least one positive charge. 
Distamycin, netropsin, and Hoechst 33258 are three minor groove binders that have 
been studied extensively. Their structures are shown in Figure 1.6. 
 
All these drugs show binding preference to sequences with at least four AT base 
pairs. Both distamycin and netropsin contain pyrrole rings with amide linkages that 
give them a crescent shape which matches to the floor of minor groove. The minor 
groove of AT sequences is preferred by these drugs as it is narrower than the minor 
groove of GC sequences. This gives ‘DNA enhanced’ van der Waals contact between 
the surfaces of the drugs and the walls of the groove. Further, the charged end of the 
drug generally lies near N3 of adenine at the bottom of the groove that is the most 
negative electrostatic potential site of AT-rich region. Finally, N2 amino groups in 
guanine provide steric hindrance and hinder drug binding to GC-rich sequences [37-
39].  
 
For example, 1:1 complex of distamycin with 12 mer DNA requires the sequence 
d(CGCGAATTCGCG)2 [40,41]. An NMR spectroscopy study of distamycin 
complexes with d(CGCAAATTGGC)2 showed that when distamycin was present in 
two-fold excess, two distamycin molecules were observed in the complex, each 
contacting one strand and running antiparallel to each other [42]. To accommodate 
the two molecules of the drug, the minor groove width expanded, suggesting 
flexibility of B-DNA. Wemmer et al. showed that the DNA with AAAAA sequences 
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disfavor the 2:1 complex relative to the 1:1 complex, with the binding constant of the 
former 100 times lower than the latter. In contrast, in TATAT sequences, the binding 
constant of the 2:1 dramatically increased and was  ~100 times greater than that of 
the 1:1 complex [42]. 
Figure 1.6: Commonly studied minor groove binders: (a) distamycin, (b) netropsin 
and  (c) Hoechst 33258. 
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1.3.3 Coordinate complexes 
The structures of several DNA-binding Pt-complexes are shown in Figure 1.7. 
Cisplatin (cis-diamminedichloroplatinum (II) or cis-[Pt(NH3)2]Cl2) (Fig. 1.7 (a)) was 
first synthesized in 1845, but its cell inhibition activity was not revealed till the 
1960’s, with a serendipitous discovery by Rosenberg [43]. A study of the effect of 
electric field on E. coli cell growth was being carried out when it was observed that a 
compound formed by the reaction of platinum electrode and ammonium chloride 
buffer stopped cell division and induced filamentous growth in bacteria [44]. 
Cisplatin entered phase I trials in 1971 and received approval for the treatment of 
testicular and ovarian cancer in 1978 [45]. The vast success of cisplatin triggered a 
huge research effort focused on platinum-based anticancer drugs. Over 3000 Pt-
based compounds have been tested but only 28 have entered clinical trials [46,47]. 
 
Cisplatin binds to DNA preferentially at two adjacent guanine bases on the same 
strand. Coordination takes place at N7 atoms of guanine (and/or adenine) being the 
most nucleophilic site(s). Cisplatin also binds to AG, GNG (i.e. non adjacent 
guanines) and interstrand GG, but to a lesser extent [48]. Cisplatin binding has 
various affects on DNA structure and stability. Cisplatin modifies DNA by bending, 
unwinding and shortening (up to 50%). NMR, gel electrophoresis and X-ray 
crystallography data have shown that cisplatin-GG modified duplex is bent towards 
the major groove by 34-60° and unwinds the DNA by 13° [49]. Spectroscopic and 
thermal denaturation studies showed there was change of DNA conformation from B 
to A type, thermal stability was lowered by ~9°C and thermodynamic stability by 6.3 
kcal/mol [50]. Recently, two classes of proteins have been recognized that bind to 
cisplatin-modified DNA. One is the repair-related proteins and the other are the 
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proteins that contain a DNA-binding motif, and commonly called high mobility 
group (HMG) proteins. The repair proteins such as XPA (xeroderma pigmentosum 
group A) and XPE (group E) or UV-DRP (ultraviolet-damage recognition protein) 
identify DNA modification and are involved in the repair of damaged strands. The 
HMG proteins are known to bind distorted structures of DNA such as four-way 
junctions, kinked DNA and bulged DNA. The geometric feature induced in DNA by 
cisplatin favors binding of HMG proteins [51]. The binding of HMG proteins is 
thought to induce antitumor activities in the cells by interfering with DNA in binding 
to other cellular proteins (Figure 1.8). There has been some evidence that 
transcription factors cannot bind to cisplatin-modified DNA and cells are therefore 
arrested in the G2 phase of the cell cycle [52,53]. 
 
Figure 1.7: Coordinate DNA binding complexes: (a) cisplatin, (b) carboplatin and 
(c) BBR3464. 
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Because cisplatin has been so effective against tumor cells, the mechanism of its 
binding has been studied extensively to gain an insight of the mode of action of the 
drug in relation to cell function. Apart from testicular and ovarian cancer, cisplatin is 
also used against carcinomas of bladder, lung, head, neck and cervix [54]. 
Figure 1.8: Cartoon representation of the mechanism of two classes of proteins that 
recognize cisplatin modified DNA. (A) damage recognition proteins recognize 
cisplatin modified DNA and repair it by attracting repair machinery, (B) Binding of 
HMG proteins prevents the repair by blocking repair recognition sites on DNA [55]. 
 
One of the major drawbacks of cisplatin treatment for tumors is its toxic side effects 
like severe nausea and vomiting, loss of sensation in hands, ototoxicity, neurotoxicity 
and emetogensis. Further, tumors may be resistant to cisplatin or develop resistance 
with course of time [56]. This led to a search for a second generation of cisplatin 
analogues as effective as cisplatin but less toxic. Out of 28 platinum compounds that 
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have entered clinical trials, only carboplatin, (cis-diammine-1, 1’-cyclobutane-
dicarboxylate platinum (II) or [Pt(C6H6O4)(NH3)2] (Fig. 1.7 (b)) has been accepted 
universally and is regularly used clinically. Owing to its much lower toxicity and 
reactivity than cisplatin, it can be given at a much higher dose (2000 mg/dose) [57]. 
 
One of the drawbacks of carboplatin is that it is active against the same tumours as 
cisplatin and is cross-resistant. Resistance to first and second generation drugs has 
resulted in development of new generation mononuclear, di- and trinuclear platinum 
compounds. The search for new drugs is based on the hypothesis that new clinically 
useful platinum compounds would need to have novel structures unrelated to those 
currently used [58]. An example of a novel trinuclear compound that entered phase 1 
trials in June 1998 is BBR3464 (Fig. 1.7 (c)); (trans-{bis[trans-diammine-
chloroplatinum(II)(µ1,6hexanediammine)]}diammineplatinum(II)tetranitrate [59]. 
 
1.4 Non-covalent complexes of proteins 
Various proteins which function as transcription factors and play an important role in 
decoding the genetic information from DNA into mRNA.  Further, translation 
involves interactions of different RNA with proteins. Several important transcription 
factors have been studied extensively, such as trp repressor in E. coli, vitamin D and 
estrogen receptor, zinc fingers and homeobox proteins [60-62]. 
 
Replication is a highly complex process and many studies have involved E. coli, 
being a simpler model as compared to eukaryotes. Complexity of proteins in their 
structure and function is demonstrated by their high efficiency and accuracy (1000 
nucleotides are added per second with less than 10-9 error frequency). Some of the 
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proteins involved include: initiator protein, DnaA (that binds to the origin of 
replication), DnaB helicase (an unwinding protein that binds to the DNA with the 
help of DnaC protein), primase (synthesizes the RNA primer), holoenzyme DNA 
polymerase III (with ten subunits) containing a polymerase, ATPases, a 3′ → 5′ 
exonuclease for proofreading, and a sliding clamp [63]. 
 
Other proteins recognize conformational changes in DNA. These include: repair 
proteins and HMG proteins (discussed above). There have been some interesting 
studies done [64] with different minor and major groove binding drugs with proteins 
recA and deoxyribonclease I using flow linear dichroism. RecA protein binds to the 
DNA minor groove and deoxyribonuclease I digests DNA by interacting through the 
minor groove. It was seen that minor groove binding drugs were hindered from 
binding dsDNA in the presence of these proteins. Interestingly, a major groove 
binder (methyl green in this case) also showed similar results but to a lesser extent. 
These results suggest protein binding can be affected by even moderate 
conformational changes in DNA [64]. 
 
Many proteins interact not only with nucleic acids but also with other proteins. An 
example of such is DNA polymerase III. The catalytic core of the polymerase 
contains three subunits: α, ε and θ. These three subunits interact with each other and 
carry out different functions such as DNA polymerisation and proof reading 
(discussed in more detail in chapter 4). Another example is DnaB. DnaB has six 
subunits interacting with each other maintaining its integrity. DnaB also forms a 
complex with DnaC in the presence of ATP to load onto DNA to enable unwinding 
activity ahead of the replication fork. 
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1.5 Mass Spectrometry 
1.5.1 History 
Mass spectrometry is an analytical spectroscopic technique used to study molecules 
by separation according to their masses and can be used to analyse small molecules 
through to polymers such as proteins. J. J. Thomson laid the foundations of mass 
spectrometry in early 1900s with his observations on positive ions and their 
application to chemical analysis. The units “Thomson” (Th) for mass/charge (m/z) 
ratio is used today in recognition of his pioneering contribution. 
 
The advances in the instrumentation and ionisation techniques have seen mass 
spectrometry develop to the present state where biomolecules over a vast size range 
can be analysed, e.g. from insulin (5,734 Da) to whole virus particles (in MDa range) 
[65]. The early ionisation methods, chemical ionisation (CI), and electron ionisation 
(EI) were restricted to volatile molecules. Both of these processes involves ionisation 
of the volatile molecules by either reagent gas ions (formed by ionisation of a reagent 
gas through electric discharge) or an electron beam (generated by a heated filament 
in the ion source) [66].  Plasma desorption (PD) was another breakthrough in the 
analysis of biomolecules. This method uses high-energy ions from 252Cf fission 
fragments to desorb and ionise molecules [67]. With plasma desorption and other 
bombardment techniques, substantial fragmentation of the analyte molecules was 
observed. A milestone was achieved with the development of fast atom 
bombardment (FAB) [68] which is a soft ionisation technique causing minimal 
fragmentation. In a typical FAB analysis, the sample is usually dissolved in matrix 
such as glycerol that reduces damage to the analyte caused by the high-energy 
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bombarding particles. None of these ionisation techniques, however, allow routine 
accurate determination of molecular masses above 30 kDa. 
 
The advent of electrospray ionisation mass spectrometry (ESI-MS) opened the way 
for MS to be applied widely in biochemistry and biotechnology. This technique was 
a major advance as it allows the analysis of large, non-volatile molecules directly 
from the liquid phase. Dole in 1968 described the electrospray principle but problems 
with mass detection precluded widespread adoption of technique [69]. It was John 
Fenn in 1989 who demonstrated ESI-MS of biomolecules enabling mass 
determination of polypeptides and proteins with an accuracy of 0.01% [70]. The 
above work was an outcome of the work started by Fenn and co-workers in 1984 
[71]. During the same period, a group of Russian scientists made significant 
contributions in similar work [72-75]. The other important ionisation technique that 
evolved during this time and is complementary to ESI-MS in the study of 
biomolecules, is matrix-assisted laser desorption ionisation mass spectrometry 
(MALDI-MS). This was demonstrated by Tanaka et al. [76] and Karas and 
Hillenkamp at about the same time [77]. Here laser light is used as the energy source 
for ionisation/volatilisation of samples in a small spot of liquid or solid embedded in 
a matrix [77]. 
 
1.5.2 Electrospray Ionisation Mass Spectrometry (ESI-MS) 
ESI-MS is a gentle ionisation technique that produces gas phase ions directly from 
solution. The gentleness of this process minimises unwanted fragmentation and 
preserves the weakly bound non-covalent interactions in biomolecular complexes. 
Although ESI-MS has demonstrated versatility in the study of different interactions 
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in a range of molecules, the focus here will be non-covalent interactions in 
biomolecules, particularly proteins and DNA. 
 
All mass spectrometers, including ESI mass spectrometers, contain three main 
components: the source (where ions are generated), the mass analyser (where ion 
separation or mass analysis takes place) and the detector. In an ESI-MS source, a 
liquid sample is passed through a metal capillary held at high potential (2-5 kV). The 
electric field gradient developed by the high voltage, generates a spray of highly 
charged droplets. As these droplets move towards the analyser owing to potential and 
pressure gradients, heat and/or dry gas is applied to assist in evaporation of the 
solvent. The droplets decrease in size owing to evaporation of the solvent and/or 
Coulombic repulsion causing fission of the droplets and finally desolvated ions are 
produced. Until recently, the mechanism of the formation of gaseous ions from small 
droplets was in dispute. The two well considered models are: charge residue model 
(CRM) [69] and the ion evaporation mechanism (IEM) [78]. Recently, there has been 
strong evidence that suggests that both the mechanisms operate to some extent 
during the ionisation/ evaporation process.  
 
Depending on the ion mode of the mass spectrometer (polarity of the applied 
voltage), positive or negative charged ions are formed by protonation or 
deprotonation of basic or acidic groups respectively. These ions carrying single or 
multiple charges are focused through a series of lenses or multipoles into the mass 
analyser where they are separated according to their mass/charge ratio (m/z). 
Following detection, the m/z values are displayed in a spectrum from which the exact 
Chapter 1: Introduction 
 24 
molecular mass is determined by one of the several methods, the most common 
being the original algorithm developed by Fenn and Mann [79]. 
 
Though data obtained with MS gives invaluable information about the identity of the 
biomolecule, generally it does not provide much structural detail. Tandem mass 
spectrometry (MS/MS) provides the additional information based on fragmentation 
of the analyte. In this technique an ion of interest (precursor ion) selected from the 
first analyser is isolated, and acquires energy by collision with an inert gas such as 
helium or argon in the collision cell and fragments giving rise to product ions which 
may be characteristic of the original structure. The product ions are analysed in a 
second mass analyser. This activation method is also called collision-induced 
dissociation (CID) or collisionally activated dissociation (CAD); the term CID will 
be used in this study [80,81]. 
 
1.5.3 Highlights in the development of ESI-MS 
ESI-MS enables exact molecular masses (± 0.01 %) of large biomolecules such as 
protein complexes to be determined. In addition to accuracy, ESI-MS can provide the 
exact identity as well as the stoichiometry of the components in a complex. ESI-MS-
based sequencing methods, usually involving tandem mass spectrometry, are 
proliferating and replacing, or complementing, the traditional biochemical methods. 
One of the major advantages of ESI-MS compared with other desorption/ionisation 
techniques is that gas phase ions show many similarities with solution phase states. 
There is now considerable evidence to suggest that some conformational properties 
of biomolecules are preserved during ESI and the transient time the ion exists in the 
mass spectrometer [82]. 
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Early work with proteins involved low pH solutions for better sensitivity (as it 
increases the extent of multiple charging). Work done by Chowdhury et al. with 
cytochrome c, showed a correlation between charge state distribution and solution 
conformation. Three different charge state distributions at three different pH values 
suggest that the protein was in different conformations (folded states) and confirmed 
the studies done in solution [83]. The same group did a similar study with myoglobin 
and reported the effect of pH and organic solvent on the native state of protein [84]. 
Subsequent studies reported the effect of pH, temperature, solvent composition and 
ionic strength on charge state distribution or conformation of biomolecules [85-88]. 
 
The early 1990s saw the first reports involving DNA-DNA, DNA-drug, protein-
ligand, protein-protein, and protein-DNA complexes (covered separately in 
subsequent sections). Attempts at studying higher order structures of proteins using 
near physiological solution conditions showed that proteins exhibited a narrower 
charge distribution at higher m/z range compared to in acidic solutions. This 
suggested the proteins retain their native state with fewer charge sites exposed (or the 
extent of charging in gas phase is decreased owing to increased Coulombic 
contributions by the compact protein structure) [89]. These observations generated 
demand for mass spectrometers with quadrupoles having a higher m/z range (mass 
spectrometers with m/z range of less than 3000 were commonly used at that time). 
There were subsequent ESI-MS reports on non-covalent complexes with mass 
analysers having m/z ≥ 5000, but sensitivity and mass resolution was still an issue 
[89-91]. 
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Standing and co-workers were the first to demonstrate the use of electrospray 
ionisation time-of-flight (ESI-TOF) mass spectrometry to study large protein 
complexes [92]. High sensitivity, mass resolution and mass accuracy with higher m/z 
ranges have made ESI-TOF an instrument of choice for studying large non-covalent 
associations in MS as well as in MS/MS modes when combined with quadrupole-
TOFs [93]. 
 
Nanospray or nanoflow electrospray is a refinement technique from ESI-MS with 
small size droplets from a 1-2 µm spraying orifice at a flow rate of ~20 nL/min [94]. 
Nanospray is thought to improve the transfer from solution to the gas phase because 
smaller droplets require more gentle conditions for evaporation as compared to 
conventional ESI [95]. Coupling of nanospray with TOF has further refined the 
technique and has made it possible to study simple dimeric complexes to more 
complex  macromolecular structures and even small particles such as viruses [65,96-
98]. 
 
1.6 ESI-MS of non-covalent complexes 
1.6.1 ESI-MS of double-stranded DNA 
Double stranded DNA (dsDNA) contains two antiparallel strands with polyanionic 
phosphate-sugar backbone. Double-stranded DNA is stabilised by the presence of 
cations shielding the repulsion between the two negatively charged strands. A high 
concentration of salt, however, can lead to suppression of the ion current in ESI-MS 
analysis and also dispersion of the ion current owing to the formation of multiple 
adduct peaks of the same ion. 
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Another important issue in the analysis of dsDNA is that sequences of the same 
length can have very similar masses, e.g. 16 mer dsDNA used in this study: D1, D2 
and D5 have masses of 9764.5, 9763.5 and 9764.5 respectively (see table 2.2 for 
sequence). Many studies used self-complementary oligonucleotides owing to ease in 
sample preparation, purification and spectral analysis. Ambiguities in peak analysis 
of self-complementary oligonucleotides arise as single- and double-stranded 
oligonucleotides with even number of charges can have the same m/z ratio for 
different species. For example a 16 mer self-complementary sequence 5′-
CGTCATGGCCATGACG-3′ (Mr 4882.2) can be stabilised either by forming 
dsDNA or by folding on itself. A single strand with 3- charge would have the same 
m/z (1627.1) value as that of duplex with 6- charge. This problem can be solved by 
using non-self-complementary sequences, but in some cases the difference in m/z 
ratio could still be small [63].  
 
The first ESI-MS of dsDNA in 1993 was a significant step towards the study of its 
secondary structure in gas phase [99]. Non self-complementary, 20 mer dsDNA 5′-
CCTTCCTCCCTCTCTCCTCC-3′/5′-GGAGGAGAGAGGGAGGAAGG-3′ was 
selected for this study. Samples were annealed prior to ESI-MS analysis, (i.e. 
oligonucleotides in 10 mM NH4OAc were heated at 90-100°C for 5 minutes and then 
cooled at room temperature for 3 hours). Oligonucleotides were annealed in the 
presence and absence of ammonium acetate. The importance of counterions to 
stabilise the secondary structure of DNA was demonstrated as in the absence of salt, 
no ions from dsDNA were detected. It has been shown that gentle conditions like low 
capillary-skimmer interface voltage, and low temperature preserve the non-covalent 
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interactions when transferred from solution to gas phase [100]. As DNA is negatively 
charged at physiological pH, most of the studies initially were done in the negative 
mode [99]. In the same year, Ganem et al. reported another study of dsDNA in which 
tandem mass spectrometry was also employed to confirm that the nature of base pair 
binding was non-covalent in gas phase [101]. In another study by Bayer et al., 
chemically-modified and unmodified duplexes were investigated.  The effect of 
triethylamine on the stability of eight different duplexes (8-30 mer) was studied. It 
was reported that length plays an important role in the stability of dsDNA as with the 
increase in the length of complementary strand, signals from single stranded DNA 
decreased and that from dsDNA increased [102]. 
 
Ding et al. carried out a study to investigate whether dsDNA detected in the gas 
phase was the result of specific or nonspecific dimer formation. The study involved 
6-15 mer dsDNA and the effects of base sequence, concentration and instrument 
conditions were investigated. Specific and nonspecific homo- and hetero-dimers 
were observed which seem to be concentration dependent and appeared only if the 
concentration of analyte was ≥100 µM. The observed ratios of the relative 
abundances of the homo- and hetero-dimers to those from the specific interactions 
between the two strands agreed with the predicted ratio [103]. McLuckey et al. 
detected duplex ions from non self-complementary 10 and 20 mers using a 
quadrupole ion trap. Tandem mass spectrometry of a 10 mer duplex was 
demonstrated for the first time in the study highlighting the stability of dsDNA in 
harsh conditions [104].  
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Williams et al. [105] used blackbody infrared radiative dissociation (BIRD) in a 
Fourier transform mass spectrometer to show that Watson-Crick base pairing is 
conserved in gas phase. They studied dissociation kinetics of different lengths and 
sequences of complementary and non-complementary DNA strands. There was 
various evidence to support formation of Watson-Crick base pairs. The activation 
energy for dissociation of the duplex with complementary strands, d-(A7.T7)3- to 
single strands was significantly higher than for the dissociation of non-
complementary d-(A7.A7)3- and d-(T7.T7)3- strands. Loss of a neutral adenine base 
was observed for d-(A7.C7)3- and d-(A7.A7)3- but not for d-(A7.T7)3- as specific base 
pairing was proposed to prevent base loss. The values for the measured activation 
energy of dissociation to single strands agreed with the dimerization enthalpy (-∆Hd) 
in solution and molecular dynamics results indicated the preservation of non-
covalent base pairing in d-(A7.T7)3- [105].  
 
A study carried out by Wan et al. [106] also supported the presence of dsDNA in the 
gas phase. They studied collision-induced dissociation (CID) using an ion-trap mass 
spectrometer of eleven, 6-12 mer duplexes with varying GC and AT sequences. A 
half wave collision energy (E1/2) term was defined that corresponded to the collision 
energy at which the precursor ion had a relative intensity of 0.5. The data showed 
that dissociation of dsDNA increased with increasing collision energy in typical s-
shaped curves. Fragmentation of duplexes showed two trends based on the base 
sequence. For the same length of dsDNA, strands with a higher percentage of GC 
sequences were more stable in gas phase. This is consistent with solution data and is 
consistent with a greater stability of GC base pairs (3H-bonds) over AT base pairs (2 
H-bonds). Furthermore, guanine has a higher proton affinity (PA) than T, so it was 
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reported that GC base pairs at the terminal facilitate unzipping so the duplexes were 
less stable than those with terminal AT sequences. Loss of G and C bases was 
observed, whereas loss of A or T was not that prominent [106].  
 
Similar work was done by Gabelica et al. [107] where relative stabilities of 16 mer 
dsDNA (non self-complementary) determined using in-source CID were compared 
with stabilities determined by thermal denaturation studied by UV 
spectrophotometry. As expected, DNA of same length with a higher percentage of 
GC had better thermal stability. Here a melting voltage (Vm) term was defined as the 
capillary-skimmer voltage at which half the DNA was dissociated. A linear 
relationship between voltage (V) and temperature (T) was observed when Vm was 
compared with Tcap (capillary temperature). This approach was similar to that used 
by Rogniaux et al. [108] and comparable to E1/2 and E50 used previously in CID or 
MS/MS experiments [106,109]. 
 
Another MS/MS study was carried out by Gabelica et al. [110] using 12 mer dsDNA 
with different GC percentages using two instruments. Two different types of 
dissociation were seen by fast (using a hybrid quadrupole-TOF instrument) and slow 
activation (using a quadrupole ion trap) of (dsDNA)5- ions. Fast activation led to 
non-covalent duplex dissociation into single strands that was entropy-favored, 
whereas slow activation led to covalent bond dissociation with neutral base loss. 
 
As noted earlier, DNA is negatively charged at physiological or near physiological 
pH, so most of the ESI-MS work has been done in negative ion mode. Loo et al. 
[111] studied different DNA and RNA sequences in the positive ion mode. The 
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counter ions neutralize the phosphate backbone of DNA or RNA and positive charge 
is carried by the protonated bases. There are some studies on duplex systems in 
positive ion where PCR products with 1525 bp, 1982 bp and 2677 bp were analysed 
using charge detection mass spectrometry (CDMS). A major drawback of this study 
was that dsDNA with less than 1525 base pairs could not be detected with the 
configuration of CDMS at that time [112]. 
 
1.6.2 ESI-MS of DNA-Drug complexes 
The role of DNA in controlling many cellular processes such as transcription and 
replication is mediated by its interaction with different ligands, metal ions and other 
biomolecules. There are different types of ligand-DNA interactions depending on the 
nature of ligand involved. These interactions are irreversible (coordinative or 
covalent, especially alkylation binding) or reversible  (non-covalent). Many 
techniques are used to study complexes formed with DNA. ESI-MS represents a 
major advance in the study of DNA-ligand complexes in terms of speed and 
sensitivity. There has been a comprehensive review by Beck et al. [63] that gives 
detailed information on the use of ESI-MS to study oligonucleotide complexes with 
drugs, metals and proteins. Given this review much of that information will not be 
elaborated on further here. Rather, the focus will be on non-covalent interactions 
between DNA and drugs and cisplatin-DNA complexes, areas that are relevant to the 
present study and work that has appeared since that review. 
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1.6.2a Non-covalent binding drugs 
Double-stranded DNA contains several types of sites for non-covalent binding with 
different drugs. These include: the (1) polyanionic backbone that interacts 
electrostatically with positively charged ligands, (2) planar ring systems of base pairs 
that offer sites for intercalation, and (3) the minor and major grooves with many 
acceptors and donors for H-bonding. Intercalators and minor groove binders are the 
two major classes of non-covalent binders, and have been a focus of the majority of 
MS studies. Some of the major issues with ESI-MS analysis of non-covalent 
complexes such as: counter ion stabilization and ambiguity due to self-complentary 
sequences of same length of duplexes have been addressed above (in section 1.6.1). 
Similar considerations apply to DNA-drug complexes. The m/z values for dsDNA 
with an even number of drug molecules bound and even number of charges are the 
same for ssDNA with half the number of bound drug molecules and half the number 
of charges. The length of the duplex could be another important factor in the 
specificity of complexes. Many of the NMR, X-ray and MS studies have used 
dsDNA less than ten base pairs long because it makes data interpretation easier, 
however, given that there are ten base pairs in each turn of B-form DNA duplex, the 
structure formed by ≤ 10 mer may not be truly representative of larger structures 
[63]. 
 
Soon after the first ESI-MS report of detection of dsDNA [99], the same group 
detected the first dsDNA-drug non-covalent complex [113]. The complex contained 
the well known minor groove binding antibiotic, distamycin A (Dst) with 12 mer 
self-complementary dsDNA. The DNA with the sequence 5′-CGCAAATTTGCG-3′ 
was chosen as it was extensively studied with and without drugs using different 
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techniques such as NMR and X-ray crytallography. Both the 1:1 and 2:1 Dst/ds-
DNA complexes detected in this study agreed with data obtained from solution 
studies. Apart from the importance of the gentle techniques used, the importance of 
different salts was also highlighted. For example, 10 mM NaCl, KCl, Tris, MgCl2, 
NH4OAc and ammonium citrate were examined and it was found that NH4OAc and 
ammonium citrate at pH 8.3 were the most effective of all these buffers. Here again 
dsDNA annealed without the presence of above buffers was not detected. More 
detailed work with non self-complementary oligonucleotides and three different 
minor groove binders (distamycin A, pentamidine and Hoechst 33258) followed 
[114]. The unique mass of each strand further cleared ambiguity concerning whether 
the interactions in the gas phase were specific. Only sequence-specific dsDNA was 
observed, and there was no evidence of random non-specific aggregation. The 
stability of the complexes was studied by collision induced dissociation, and all these 
minor groove binders stabilised dsDNA. Furthermore, the stability of 2:1 Dst/dsDNA 
complex was greater than the 1:1 Dst/dsDNA and in agreement with solution studies 
[114]. 
 
Most ESI-MS studies of dsDNA-drug complexes have been in the negative ion mode 
[99,106,114-116]. In all those studies, a significant percentage of the total ion current 
in spectra was observed from ssDNA. A main focus of these studies has been for 
maximizing signals from dsDNA and to minimize non-specific interactions. Another 
focus of these studies was to investigate if there is any correlation between gas phase 
intensities and the relative abundances of species in solution [106,115-120]. The 
effect of annealing the DNA prior to mass analysis has been studied by various 
authors [114,116,119]. There is strong evidence that the annealing process 
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maximizes the presence of ions from dsDNA in ESI mass spectra. In most of the 
dsDNA studies by MS a high concentration of NH4OAc (0.1 - 1 M) has been the 
solvent of choice for annealing [106,115,116,118,119]. 
 
Kapur et al. [119] studied the binding of daunomycin and nogalamycin to self-
complementary dsDNA, 8 mers and 12 mers. Stoichiometries of up to four 
nogalamycin and six daunomycin molecules bound to 12 mer dsDNA was observed 
that agreed with the neighbour exclusion principle. Recently, there have been a few 
investigations relating to sequence specificity of minor groove binders and 
intercalators towards different dsDNA. Gabelica et al. [118] studied sequence 
specificity of three intercalators (ethidium bromide, amsacrine and ascididemin) and 
five minor groove binders (Hoechst 33258, netropsin, distamycin A, berenil and 
DAPI) with a non-self complementary 12 mer dsDNA (5′-GGGGATATGGGG-
3′/5′-CCCCATATCCCC-3′). The two by two competition experiments showed 
relative binding affinities of netropsin > distamycin A >  DAPI > Hoechst 33258 > 
berenil for the above sequence. No conclusive results were obtained for the 
intercalators. Similarly, Wan et al. [116] investigated ten different compounds 
including minor groove binders, porphyrins and metalloporphyrins. They reported 
that minor groove binders showed preference in binding to AT-rich dsDNA, that 
actinomycin D favoured GC-rich sequences, whereas porphyrins and 
metaloporphyrins either exhibited preference for AT-rich sequences or mixed 
binding. The binding affinities determined in the gas phase were: Hoechst 33342 > 
Hoechst 33258 > Distamycin > berenil. It is interesting to note that the order of 
binding affinities found by Gabelica et al. [118] is different. This could be due to 
differences in oligonucleotide sequence and/or different instrument and solvent 
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conditions. Many solution studies have shown that minor groove binders preference 
AT-rich sequences [15,121]. 
 
Wan et al. [106] used the half wave collision energy (E1/2) method (collision energy 
at which the precursor ion had a relative intensity of 0.5) to study the intrinsic 
stabilities of DNA-drug complexes. They suggested that drugs with similar mode of 
binding adopt similar conformations in the gas phase as they have similar 
dissociation profiles. Minor groove binders displayed tighter binding with dsDNA as 
the non-covalent complexes were stable until they underwent covalent dissociation, 
whereas the dsDNA-intercalators, showed both non-covalent (separation to single 
strands) and, to a certain extent, fragmentation of covalent bonds. 
 
1.6.2b ESI-MS of DNA-metal ion complexes 
Many MS studies have been done on Pt-based complexes with DNA.  There are 
some early reports of FAB MS of oligomers [122,123]. As it is well established that 
most of the Pt-based complexes preferably bind guanine base pairs of DNA, the 
majority of the studies have been carried out using guanine-containing oligomers of 
both ssDNA and dsDNA [59,124-130]. 
 
It is well established that cisplatin preferably binds to two adjacent purines on a 
single DNA strand (~ 65% and 25% GpG and ApG respectively of the total 
platinated DNA) [131,132]. There have been many attempts to shed further light on 
the mechanism of platinum interactions with DNA by MS. Wickham et al. [124] 
studied the reaction of cisplatin with three self-complementary hexamers using ESI-
MS. The relative binding affinities inferred using the relative intensities of ions from 
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the complex compared to free oligonucleotide was reported as: 5′-AGGCCT-3′ > 5′-
TACGTA-3′ > 5′-CACGTG-3′. This work was extended to ESI-MS/MS as ESI alone 
could not be used to find the exact binding site of cisplatin [133]. Two adducts were 
observed in the reaction between cisplatin and 5′-CACGTG-3′, 1,3-GG being the 
major and 1,3-AG being the minor crosslink. 
 
Gonnet et al. [126] used ESI-MS and MALDI-TOF to study the kinetics of the 
reaction between 5′-TTGGCCAA-3′ and the platinum complex [Pt(NH3)3(H2O)]2+. 
As [Pt(NH3)3(H2O)]2+ has only one labile –OH2 bond, it can only form mono-
adducted species. The rates of platination at the 5′-G and 3′-G were compared. ESI-
MS was used to calculate the global rate constant. Enzymes such as exonucleases 
and endonucleases are known to digest at different sites on DNA. This technique of 
enzymatic digestion is used widely for the study of modified and unmodified 
oligonucleotides [128,134-136]. Enzymatic digestion of platinated and non-
platinated adducts was analysed using MALDI-TOF and the ratio determined was 
5′G /3′G ≈ 2. Platination of DNA was found to occur eight times faster in water as 
compared to that in 0.1 M NaClO4 [126]. 
 
Lowe et al. [127] studied the binding of a potential bis-intercalator, 4,4′-
vinylenedipyridine bis[2,2′ :6′,2′′-terpyridine platinum(II)] with a self-comp-
lementary hexamer 5′-CGTACG-3′. LC-MS of the reaction mixture after enzymatic 
digestion showed that the drug was bound to the guanine at the 3′-end. Carte et al. 
[137] studied the non-covalent binding of [Pt(NH3)4]2+ with 20 mer single stranded 
and dsDNA. Outer-space complexes (involving non-covalent interactions with the 
DNA backbone) were observed and as expected were independent of the number of 
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guanine bases in the sequence. Hence it was concluded that these complexes do not 
play an important role in the sequence selectivity of cisplatin. Troujman et al. [128] 
studied 8 mer 5′-CTGGCTCA-3′ and 18 mer 5′-AACGGTTAACCGTTAATT-3′ 
with [Pt(NH3)2(H2O)2]2+ and [Pt(NH3)3(H2O)]2+ and the separation of complexes 
was performed using HPLC and capillary electrophoresis (CE). Though CE had 
better resolution and was less time consuming than HPLC, lack of quantitative output 
and universality still gives HPLC an advantage [128]. All the separated complexes 
were analysed using a MALDI mass spectrometer.  
 
Kloster et al. [59] examined the binding of the trinuclear platinum compound 
BBR3464 (Fig. 1.7) which is representative of a new class of anticancer drug. The 
presence of three platinum atoms gives a complex isotope pattern, so ESI-FTICR 
mass spectrometry with high resolution capabilities was used to study the complexes 
with 20 mer single stranded and dsDNA. Xu et al. [130] used the same high 
resolution technique and reported a drug-dsDNA-protein complex. Interaction of 20 
mer cisplatin-modified and unmodified dsDNA was studied with the protein, (XPA-
MBD), human XPA (xeroderma pigmentosum group A) minimal binding domain. 
Both 2:1 and 1:1 XPA-MBD dsDNA complexes were observed for Pt-modified 
dsDNA whereas only 1:1 complex was observed for unmodified dsDNA. 
 
Metallointercalators are another class of metal complexes that have received some 
attention in ESI-MS studies. There have been reports of these complexes involved in 
covalent binding with ssDNA [138,139], and one report involving non-covalent 
dsDNA. Wan et al. studied porphyrins and metalloporphyrin complexes with 6 or 12 
mer duplexes and the order of binding affinity was defined. Based on their 
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stereochemistry, the complexes showed different affinities for AT- and GC-rich 
sequences [116]. 
 
1.6.3 ESI-MS of DNA-protein complexes 
The first ESI-MS study of non-covalent interactions in DNA-protein complex was 
reported in 1995 [140]. Greig et al. [140] studied the binding of serum albumin with 
a 20 mer DNA and also measured the dissociation constant for the complex. There 
have been subsequent reports suggesting that the characteristics of the complexes 
studied in gas phase are similar to those observed in solution [141-146]. The studies 
have been done in both positive and negative ion mode in consideration of the 
polyanionic nature of DNA and because most ESI-MS of proteins is done using 
positive ion mode.  
 
It is seen that electrostatic interactions play a major role in the stability of DNA-
protein complexes. These complexes do not dissociate easily and are quite stable at 
high interface energies, which suggest that electrostatic interactions may be 
strengthened in gas phase [147]. 
 
Smith and co-workers carried out two studies involving complexes of two different 
proteins with ssDNA and dsDNA [141,142]. Gene V protein from bacteriophage f1 
displayed sequence specific binding to ssDNA. Stoichiometries of 2:1 (protein: 
DNA) were observed for DNA less than 15 bp while 16 mer DNA showed 4:1 
binding that was consistent with solution stoichiometries measured by size exclusion 
chromatography [141]. The second study involved transcription factor, PU.1 protein 
and 17 mer wild type and 19 mer mutant dsDNA sequences. Only protein complexes 
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with wild type dsDNA (consensus sequences) were observed in agreement with a gel 
electrophoresis mobility shift assay [142]. Another study highlighting the sequence 
specificity of transcription proteins for consensus sequence in DNA duplex was 
reported by Potier et al. [143] Trp apo-repressor (TrpR) protein binds specifically to 
two symmetrically arranged CTAG sequences. It was shown that correct consensus 
spacing (4 bp) was required to form stable interactions with TrpR.  
 
The ability to observe specific interaction using ESI-MS suggests that the peaks 
observed in ESI mass spectra are not the result of non-specific interactions 
originating in gas phase. Craig et al. studied a multimeric, high molecular weight 
complex involving human vitamin D receptor (VDR), retinoid X receptor-α 
(RXRα), dsDNA (osteopontin vitamin D response element, OP VDRE) and the 
endogenous ligand 1α,25-dihydroxyvitamin D3 (1α,25-[OH]2D3) [145]. This is the 
largest multimeric, DNA-protein complex reported to date (118,200 Da). Conversely, 
when the dsDNA sequence was randomized, no complex was detected. Kapur et al. 
studied the complex of dsDNA with protein Tus involved in the termination of DNA 
replication in E. coli. Tus protein binds specifically to DNA sequences (Ter) halting 
the replication in E. coli chromosome. The interactions observed by ESI-MS were 
highly specific as Tus protein did not bind to random dsDNA sequences. The relative 
order of binding affinity of Tus and various Tus mutants with random sequences was 
investigated in the study. The dissociation of the complex was increased with an 
increase in salt (NH4OAc) concentration, reflecting the important role of electrostatic 
interactions in the stability of the complex. The calculated dissociation constant 
values agreed with the solution studies [146]. Donald et al. cloned and purified a 
protein (Gc1R) from the Ic1R family (involved in acetate metabolism) and designed 
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a 29 bp synthetic DNA based on binding region of Gc1R and Ic1R proteins. Both the 
proteins formed non-covalent complexes with dsDNA and the stoichiometries 
determined were 4:1 (protein monomer: dsDNA) [148]. 
 
Very recently, ESI-MS of the catalytic domain of bacteriophage λ enzyme integrase 
(λ-Int) showed ions from three different species; folded, unfolded and dimer. It is 
suggested that binding of hairpin DNA (40 mer) stabilises the global fold of the 
protein because in the presence of DNA, ions from the complex and the folded form 
only were detected [149]. 
 
1.6.4 ESI-MS of protein-protein and protein-ligand complexes 
As discussed above, protein-DNA complexes are quite stable as a result of numerous 
intermolecular interactions including strong electrostatic interactions that are 
strengthened in gas phase in the absence of solvent. The stability of complexes 
involving proteins with other proteins, peptides, cofactors and ligands may be 
comparatively less in the gas phase where weaker interactions such as van der Waals 
forces and hydrophobic effects are the principal modes of interaction [147]. Some 
studies have shown that hydrophobic interactions are weakened in the gas phase 
compared to solution [150,151]. Rostom et al. suggested that the nature of 
interactions in the complex determines the stability of complex in the gas phase, with 
those involving ionic interactions displaying greater stability compared to 
hydrophobically-driven binding [152]. 
 
After the first report of a non-covalent protein-ligand complex, (receptor-ligand 
complex) detected by ESI-MS [153] there have been numerous reports on a wide 
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range of non-covalent complexes such as: enzyme-substrate [154], apoenzyme and 
prosthetic groups [84], enzyme inhibitor [155], protein-nucleotide [156], protein-
peptide [157] and the list goes on. A number of reviews are available on ESI-MS of 
proteins and protein complexes [100,158-165]. In an excellent review [147], the 
author compares the information derived from other techniques available for protein 
characterization with mass spectrometry and discusses the issue of agreement of gas 
phase complexes with solution studies. More recently, Robinson has reviewed the 
latest approaches in ESI-MS to detect transient and stable interactions in protein 
complexes [166]. The reviews also cover recent developments such as the detection 
of whole cell organelles and viruses and the monitoring of real-time reactions for 
understanding of dynamic macromolecular complexes [166,167]. Keeping in mind 
the enormous body of literature available, only specific, recent examples with 
different techniques and developments will be highlighted here. 
Recent applications of ESI-MS in the study of protein complexes 
The introduction of ESI-TOF mass spectrometry with high sensitivity, mass 
resolution and extended m/z range by Standing and co-workers was an important 
achievement for the study of macromolecular complexes [92]. This study was one of 
the first to address the need for extended mass range to analyse large non-covalent 
complexes. In a further study by this group, the quaternary structure of the 
oligomeric enzyme 4-oxalocotonate tautomerase (4-OT) was investigated (Mr 
40866, four other analogues were prepared by modifying, deleting or replacing 
proline or methionine residues, wild type 4-OT being a hexamer of 62 amino acid 
residues. Hexamer species of all the analogues including 4-OT were observed except 
for two analogues where species predominantly from monomers were detected. 
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These observations were consistent with structural data from CD spectroscopic 
studies [168]. 
 
One of the techniques used extensively in both NMR and MS is hydrogen-deuterium 
exchange labeling (H/D exchange) which uses the concept of difference in the rate of 
exchange of deuterium with hydrogen at protein surfaces compared to those involved 
in maintenance of secondary structure. H/D exchange coupled with MS is now well 
developed for the study of secondary structures in individual protein subunits as well 
as protein complexes [169]. With recent developments, not only subunit 
stoichiometries but also conformational dynamics and subunit interfaces, can be 
studied by ESI-MS [170,171]. 
 
The role of chaperones in protein folding has been probed by mass spectrometry to 
gain an insight of their function in vitro and in vivo by ESI-MS [172,173]. Weber-
Ban et al. determined the function of bacterial protein, ClpA (HSP100 family) [174]. 
C1pA is involved in the degradation of proteins in a ATP-dependent pathway by 
recognizing specific sequences on the proteins. An 11-amino acid specific sequence 
was tagged to green fluorescence protein (GFP11). The incubation of both the 
proteins with ATP, followed by H/D exchange experiments showed that exchange of 
the folded core of GFP11. In contrast, when the proteins were incubated with the 
non-hydrolyzable analogue of ATP (ATPγS, an analog of ATP with a sulfur atom 
replacing one of the oxygen atoms in the γ phosphate area) protected internal 
deuterons were not lost, showing that protein remained folded. The results 
demonstrate that C1pA can unfold stable, native proteins in the presence of ATP 
[174]. 
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Metal ions play important catalytic, regulatory or structural roles in proteins and the 
role of different metal ions such as Fe, Cu and Zn has been well studied 
[144,145,175,176]. Electrospray ionisation combined with Fourier transform ion 
cyclotron resonance (ESI-FTICR) mass spectrometry can provide an extra dimension 
to these studies because the high resolution facilitates determination of the oxidation 
state of bound metal ions in proteins [177]. Recently, it was demonstrated that the 
oxidation state of a metal centre in the protein, cytochrome c, was stable in positive 
and negative ion modes of ESI-MS [177]. In another recent study, ESI-FTICR mass 
spectrometry coupled with yeast two-hybrid system was used to provide the first 
evidence for the interaction between calmodulin protein a S100A4 and S100A1 in 
vivo. S100A4 plays an important role in promoting tumor metastasis. A proteomic 
strategy (yeast two-hybrid system) was used to identify hetero-dimerization in the 
above calmodulin proteins which was confirmed by ESI-FTICR and fluoresence 
spectroscopy [178]. 
 
A recent study by Sobott et al. is a huge leap forward in the application of ESI-MS 
towards understanding of dynamic macromolecular complexes. Real time monitoring 
of subunit exchange between small heat shock proteins was performed [179]. Two 
plant heat shock proteins, PsHSP18.1 from pea and TaHSP16.9 from wheat with a 
total molecular mass of ~200 kDa were studied using nanospray ESI-MS. CID 
experiments showed that both the proteins exist as dodecamers in solution. Mixtures 
of both the proteins were studied at different ratios and exchange of subunits between 
the two proteins was observed. The results revealed that exchange of subunits 
predominantly takes place as dimers. The reaction was monitored with time and 
reached equilibrium under the experimental conditions after 40 minutes. The 
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composition of the predominant species detected was in agreement with the 
composition predicted by the statistical composition [179]. 
 
Finally, it would be worthwhile to mention mega Dalton mutiprotein 
macromolecules. Ribosomes in E. coli containing 55 different proteins and three 
large RNA molecules have been shown to remain intact in ESI-MS [180]. Recently, 
intact rice yellow mottle virus (6.5 MDa) and tobacco mosaic virus consisting of 
2140 identical protein subunits and an RNA molecule (40.5 MDa) have been 
detected by ESI-MS [65].  
 
1.7 Outline of this study 
The use of ESI-MS for the detection and characterization of non-covalent complexes 
of biomolecules is an emerging field and there are numerous examples of non-
covalent interactions that have been studied in the gas phase including those between 
protein subunits, proteins and nucleic acids, drugs and DNA, and enzymes and 
substrates.  
 
This study aims to develop conditions to use ESI-MS and MS-MS to study non-
covalent interactions between protein subunits, and dsDNA and major classes of 
drugs. Chapter three describes the use of ESI-MS to study complexes of dsDNA and 
metallodrugs. A protein-protein complex between proteins involved in E. coli 
replication is examined in chapter four. This chapter also examines the use of 
varying solution conditions to probe binding in macromolecular complexes. Finally, 
chapter five further extends the use of ESI-MS to study metal-dsDNA complexes. 
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Chapter 2: Materials, Methods and Instrumentation 
2.1 Materials 
All the organic solvents and acids were of the highest grade commercially available 
(Ajax Chemicals, Seven Hills, NSW, Australia). Milli-Q water (purified to 18.2 
MΩ/cm2) was used in the preparation of all the solutions. Daunomycin 
(daunorubicin) and distamycin A were obtained from Sigma (St Louis, MO, USA). 
Cisplatin was from Aldrich (Milwaukee, WI, USA). The ruthenium compounds:  
[Ru(phen)3]2+ as chloride salt was from Aldrich (Milwaukee, WI, USA) and 
[Ru(phen)2(dpq)]2+, [Ru(phen)2(dppC)]2+ and [Ru(phen)2(dppz)]2+ as (PF6) salts 
were a kind gift from Dr Janice Aldrich-Wright (University of Western Sydney). 
Ammonium acetate was from Ajax Chemicals (Seven Hills, NSW, Australia). All the 
oligonucleotides were purchased from GeneWorks (South Australia) as “trityl on” 
derivatives. Phosphodiesterase I (from Crotalus adamamteus venom), 
phosphodiesterase II (from bovine spleen), and alkaline phosphatase (from E. coli) 
were obtained from Sigma (St Louis, MO, USA) and nuclease P I (from bovine 
pancreas) was obtained from Boehringer Mannheim (Indianapolis, IN, USA). The E. 
coli DNA polymerase III proteins θ, ε186 and θ-ε186 complex were a kind gift from 
Dr Nicholas Dixon (Australian National University). 
 
2.2 Methods 
2.2.1 Preparation of oligonucleotides 
Oligonucleotides used in this study are shown in Table 2.1. Oligonucleotides were 
purified as described previously [124] using a Beckman high performance liquid 
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chromatograph (HPLC) with 127s solvent module and a UV visible 166 detector that 
was set at 254 nm to measure absorbance. A C18 octadecylsilyl column (8 x 100 mm 
Waters Delta Pak Radial Pak Cartridge) was used in all purifications. 
 
Concentrations of single-stranded oligonucleotides were estimated using the Beer-
Lambert Law by measurement of UV absorbance at 260 nm using approximate 
values of ε260 based on the proportion of adenine, guanine, cytosine and thymine in 
the oligonucleotide with ε260 of 15400, 11700, 7300 and 8300 M-1 cm –1 respectively. 
Melting temperature (Tm) of DNA was calculated using the website Oligonucleotide 
Properties Calculator [181]. The average molecular mass (Mr) and values of m/z 
expected for electrospray series of single-stranded oligonucleotides were calculated 
using the website Mongo Oligo Mass Calculator v2.05 [182]. 
 
2.2.2 DNA-binding drugs 
Daunomycin and distamycin A were dissolved in water to give stock solutions of          
1 mM. Cisplatin was dissolved in 0.1 M NH4OAc, pH 6.8 to give a stock 
concentration of 1.5 mM. Stock solutions of [Ru(phen)2(dpq)]2+, 
[Ru(phen)2(dpqC)]2+ and [Ru(phen)2(dppz)]2+ (as (PF6)2 salts) all at a concentration 
of 200 µM in 0.1 M NH4OAc at pH 8.5 were prepared immediately prior to use. 
[Ru(phen)3]2+ (as the chloride salt) was dissolved in the same solvent to a 
concentration of 1 mM. 
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Table 2.1: Oligonucleotides used in the study with the labels that are used in the text. 
Oligonucleotide sequence (5′-3′) Label Mr 
Double-stranded DNA   
CCTCTCTGGACCTTCC (D1a)/GGAAGGTCCAGAGAGG (D1b)  
GCTGCCAAATACCTCC (D2a)/GGAGGTATTTGGCAGC (D2b) 
GCATCGAAAAAGCTACG(D3a)/CGTAGCCGATGC(D3b) 
CCTCGGCCGGCCGACC(D4a)/GGTCGGCCGGCCGAGG (D4b) 
CCTCATGGCCATGACC (D5a)/GGTCATGGCCATGAGG (D5b)  
CCTCAAAATTTTGACC (D6a)/GGTCAAAATTTTGAGG (D6b)  
D1 
D2 
D3 
D4 
D5 
D6 
9764.5 
9763.5 
8858.9 
9768.4 
9764.5 
9760.5 
Single-stranded DNA   
CCTCTCTGGACCTTCC 
CCTCTCCGGTCCTTCC 
CCTCTCCGGACCTTCC 
CCTCTCCAGTCCTTCC 
CCTCTCCGATCCTTCC 
TCCGGACC 
TCCAGTCC 
TCCGATCC 
GGAGGTATTTGGCAGC 
GCTGCCAAATACCTCC  
ATACATGGTACATA 
Enz1 
Enz2 
Enz3 
Enz4 
Enz5 
Enz6 
Enz7 
Enz8 
Enz9 
Enz10 
AT14 
4744.1 
4720.1 
4729.1 
4704.1 
4704.1 
2370.6 
2345.6 
2345.6 
4977.3 
4786.2 
4270.9 
 
2.2.3 Preparation of double-stranded DNA and drug-DNA complexes 
Double-stranded DNA (Annealing of DNA) 
Double-stranded DNA (dsDNA) was prepared by heating the complementary strands 
to 20°C above their calculated melting temperature in 0.1 M NH4OAc pH 6.8 for 15 
min and annealing by cooling slowly overnight. The concentration of dsDNA was in 
the range of 0.5-2 mM for all experiments.  
 
Complexes of drugs with dsDNA 
Double-stranded DNA complexes with daunomycin and distamycin A were prepared 
by freeze-drying the appropriate volumes of the two complementary strands together 
with the drug and redissolving them in a small volume of 0.1 M NH4OAc, pH 8.5 so 
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that the final concentration of dsDNA was 1-2 mM (depending on the experiment). 
For example, to obtain a drug-dsDNA complex at 3:1 ratio, 150 µL of drug and 50 
µL of DNA (each at 1 mM) were freeze-dried and redissolved in 50 µL of 0.1 M 
NH4OAc at pH 8.5 final concentrations of drug and dsDNA of 3 and 1 mM, 
respectively. The reaction mixture was heated to 20°C greater than the Tm and 
annealed overnight as outlined above. Mixtures were frozen at –20°C prior to 
analysis. For ESI-MS, mixtures were diluted 100-fold in 0.1 M NH4OAc at pH 8.5.  
 
DsDNA-drug complexes with ruthenium-based intercalators were prepared by 
mixing dsDNA prepared previously, with the appropriate volume of stock ruthenium 
compound in 0.1 M NH4OAc, pH 8.5, so that the final concentration of dsDNA was 
25 µM. The reaction mixture was left in the dark at room temperature overnight and 
was diluted to 10 µM (concentration of dsDNA) in 0.1 M NH4OAc at pH 8.5 for 
ESI-MS analysis. For example, to prepare a mixture of 3:1 ruthenium compound-
dsDNA, 2 µL of dsDNA (1 mM), 30 µL of ruthenium compound (200 µM) and 
48µL of 0.1 M NH4OAc at pH 8.5 were mixed and incubated overnight at room 
temperature prior to addition of another 120 µL of solvent and analysing it by ESI-
MS. To prepare mixtures containing other ratios of drugs and dsDNA, the volume of 
drug and solvent were varied, but the final volume was always 200 µL.  
 
Preparation of cisplatin adducts with ssDNA 
{cis-[Pt(NH3)2]Enz1} was prepared by reacting single-stranded oligonucleotide 
(Enz1, see Table 2.1) with cisplatin in 5 mM NH4OAc pH 6.8, in equimolar amounts 
(0.2-0.5 mM) in a volume of 200-500 µL depending on the experiment. All the 
reagents without cisplatin was heated at 70°C for 15 minutes followed by cooling on 
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ice for another 15 minutes. Cisplatin was then added to the mixture and heated at 
73°C, pH 6.8 for 4-5 hours in dark. {cis-[Pt(NH3)2]Enz1} was separated by HPLC 
from unreacted (Enz1) using a Nucleosil 300-5 C8 HPLC column (4.6 x 250 mm) 
equilibrated with 0.01 M NH4OAc (ammonium acetate) at 1 mL /min and eluting 
with a 0-10% linear gradient of acetonitrile over 60 minutes. The elution was 
monitored at a fixed wavelength of 254 nm. Cisplatin adducts with other single 
stranded oligonucleotides- Enz2, Enz3, Enz4, Enz5, Enz6, Enz7 and Enz8 (Table 
2.1) were also prepared and purified using this method. 
 
{cis-[Pt(NH3)2]Enz1} was freeze-dried using Savant SpeedVac and re-dissolved in 
Milli Q water. Equimolar amounts of {cis-[Pt(NH3)2]Enz1} and its complementary 
strand 5′- (GGAAGGTCCAGAGAGG)-3′ were mixed together in 0.1 M NH4OAc at 
pH 8.5 and annealed as outlined above. The dsDNA-cisplatin adduct was stored at –
20°C prior to analysis by ESI-MS at a final concentration of ~6 µM in 0.1 M 
NH4OAc at pH 8.5. 
 
2.2.4 Replication proteins θ, ε186 and θ-ε186 complex from E. coli 
The purified proteins θ, ε186, and θ-ε186 complex [183-185] were stored at –80°C 
in 25 mM Tris. HCl, pH 7.6, 10% in glycerol, 100-150 mM NaCl, 2 mM DTT and 1 
mM EDTA. The concentrations of stock solutions of θ and ε186 were 1.5 and 3.5 
mg/mL, respectively. These correspond to a concentration of 170 µM for each 
protein. θ-ε186 complex was prepared by mixing equimolar amounts of θ and ε186 
that had been previously dialysed against 10 mM NH4OAc, pH 6.8. Protein solutions 
were maintained at 4°C during these procedures. Protein concentrations were 
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determined by measurement of the absorbance at 280 nm using a UV-vis-NIR, Cary 
500 Scan Spectrophotometer from Varian. The molar extinction coefficients for θ, 
ε186 and θ-ε186 used to calculate the protein concentration from the Beer-Lambert 
law were 6400, 8250 and 14650 M-1 cm-1, respectively [186]. 
 
2.2.5 ESI-MS investigations of θ, ε186 and θ-ε186 complex  
The proteins or protein-protein complex (typically 300 µL) were dialysed against 2 L 
of 10 mM NH4OAc, pH 6.8 at 4°C (5 changes). Immediately prior to ESI-MS 
analysis the proteins (6.5-78.0 µM) were diluted using the appropriate solvent to a 
final concentration of 2 µM.  
 
Study of the effect of different organic solvents on θ, ε186 and θ-ε186 complex 
The effects of treatment of θ, ε186 and θ-ε186 complex with different concentrations 
of various organic solvents were investigated by obtaining ESI mass spectra. Table 
2.2 shows the organic solvents used with their stock concentrations and dielectric 
constants [187]. In all the experiments, the final concentrations of proteins and 
NH4OAc were 2 µM and 100 mM respectively, at pH 8. Samples were prepared 
immediately before mass spectrometric analysis. Typically, 2 µL NH4OAc (5 M at 
pH 8), appropriate amounts of MilliQ water and organic solvent were mixed, 
followed by addition of a small volume of stock protein (1-3 µL), giving a final 
volume of 100 µL.  
 
In experiments aimed at measuring precipitation of components of these mixtures, 
light scattering was monitored by following the absorbance of solutions at 360 nm. 
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These experiments were carried out using the same concentrations of proteins, 
organic solvent and ammonium acetate as used in the ESI-MS experiments. A larger 
final volume (500 µL) of sample was required for these experiments. Organic 
solvent, Milli Q water at pH 8 and 5 µL NH4OAc (10 M at pH 8) were mixed 
followed by addition of the appropriate volume of stock protein or protein-protein 
complex (25-40 µL). In these experiments observations of solutions were carried out 
for the same time period over which ESI-MS experiments were conducted. 
 
Table 2.2: Organic solvents with their stock concentrations and dielectric constants. 
Organic solvent Stock concentration (M) Dielectric constant (at 25° C) [187] 
Methanol 24.7 32.6 
Ethanol 17.2 24.3 
1-Propanol 13.3 20.1 
1-Butanol 10.9 17.1 
Acetonitrile 19.0 38.8 
Isopropanol 13.0 18.3 
Acetone 13.6 20.7 
 
2.2.6 Enzymatic digestion of cisplatin adducts with ssDNA 
All the ssDNA-cisplatin adducts were synthesised as already described in section 
2.2.3. Phosphodiestrase I (Pd I), Phosphodiestrase II (Pd II) and nuclease P1 were 
prepared immediately before use or used within one week of preparation and stored 
at 4°C. 3 mg of Pd I (0.33 units/mg solid) and 0.3 mg of Pd II (10.8 units/mg solid) 
were each dissolved in 300 µL of milliQ H2O. In all the experiments, Pd I was used 
after 1 in 10 dilution whereas Pd II was used without further dilution. For nuclease 
P1, a small amount was dissolved in 1 mL of millliQ H2O. Alkaline phosphatase was 
used without dilution or as otherwise stated in the text. The binding of cisplatin to 
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ssDNA was studied using two different procedures, partial and total digestion. In 
partial digestion, either one of the two phophodiestrases was used, whereas in total 
digestion both the phosphodiestrases, Pd I and PdII were used. In a typical enzymatic 
digestion, the final volume of digestion mixtures was 200 µL, 150 µL was 60 mM 
NH4OAc, pH 7.5 and 50 µL of the digestion mixture contained ssDNA/ ssDNA-
ciplatin adduct, enzyme(s) and milliQ H2O in different proportions, depending on the 
type of digestion being carried out. Table 2.3 summarizes the volumes of reagents 
used in two digestions employed in this study. The final concentration of ssDNA or 
ssDNA/cisplatin adducts used in digestion mixtures was 6-10 µM. 
 
Table 2.3: Summary of the proportions of reagents used in the two types of 
digestions used in the study. 
ssDNA/ssDNA-
cisplatin adduct 
Pd I Pd II NH4OAc 
 (60 mM, pH 7.5) 
MilliQ 
H2O 
Final 
Volume (µL) 
Volume of reagent used (µL) 
                Partial digestion 
Adj1 5 - 150 Adj 200 
Adj - 10 150 Adj 200 
                Total digestion 
Adj 5 10 150 Adj 200 
1 Adj means that these amounts were varied depending on the experiment. The final concentration of 
ssDNA was in the range 6-10 µM. 
 
2.2.7 ESI-MS of digested mixture of ssDNA/ssDNA-cisplatin adducts 
The digestion of ssDNA/ssDNA-cisplatin adducts was studied by taking an aliquot 
(50 µL) of the reaction mixture at different time intervals and analysing by ESI-MS. 
The aliquot was mixed with an equal volume of ice cold 50% CH3CN in 5 mM 
NH4OAc (to stop the reaction). The mixture was left on ice before ESI-MS analysis. 
The ESI-MS conditions are outlined in Table 2.5. 
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2.3 Instrumentation 
2.3.1 Electrospray Ionisation Mass Spectrometry (ESI-MS) 
The electrospray ionisation mass spectra were acquired using a Micromass Q-Tof-
2TM mass spectrometer (Wyntheshawe, UK) with a Z-spray ionisation source (Figure 
2.1). This hybrid quadrupole time-of-flight mass analyser has a m/z range of 10,000. 
All the samples were directly injected using a Harvard model 22 syringe pump 
(Natick, MA, USA) at a flow rate of 10-20 µL/ min. In most experiments, spectra 
were acquired over the range m/z 100-5000. Typically, 10-50 acquisitions were 
summed up to obtain representative spectra. Caesium iodide solution (750 µM) was 
used to calibrate the data over the same range. Data acquisition and processing was 
performed using the Mass Lynx (version 3.5) NT Software system (Micromass). MS 
parameters used in the study are summarised in the Table 2.4 and 2.5. 
Figure 2.1: Schematic representation Micromass Q-Tof-2 TM. Adapted from Waters 
website [188]. 
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All the ESI mass spectra acquired for studies of non-covalent drug-dsDNA (Chapter 
3) were performed in both positive and negative ion modes over the m/z range of 
500-3000. Generally, most of the work was done in positive ions apart from the 
experiments involving ruthenium intercalators that were performed in negative ion 
mode unless specified in the text. All the mass spectra were acquired using a cone 
voltage of 50 V. Typically, 25-50 acquisitions were summed up to obtain 
representative spectra. The summed spectra were background subtracted and 
smoothed using standard algorithms provided in the Mass LynxTM software. Other 
MS parameters are shown in Table 2.4. 
 
All the ESI mass spectra acquired for studies of θ, ε186 and θ-ε186 complex 
(Chapter 4) were performed in positive ion mode over the m/z range of 500-5000. All 
the mass spectra were acquired using a cone voltage at 30 V. Typically, 25-50 
acquisitions were summed to obtain representative spectra. The summed spectra 
were background subtracted and smoothed using standard algorithms provided in the 
Mass LynxTM software. Other MS parameters are shown in Table 2.4.  
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Table 2.4: Typical tuning parameters for ESI-MS studies of non-covalent complexes 
on the Q-Tof-2 TM mass spectrometer. 
Tuning parameters Protein studies 
(+ve Ion mode) 
DNA-drug studies 
(+ve Ion mode) 
DNA-drug studies 
(-ve Ion mode) 
Source parameters    
Capillary 
Cone 
HV lens 
Extractor 
RF Lens 
Source block temperature 
Desolvation temperature 
Desolvation gas flow rate 
2.5 kV 
30 V 
500 V 
0 
1.29 V 
60  
150 
300 L/hr 
2.5 kV 
50 V 
500 V 
0 
1.29 V 
40, 60 
40, 80 
300 L/hr 
2.3 kV 
50 V 
500 V 
0 
1.50 V 
40, 60 
40, 80 
300 L/hr 
MS    
LM resolution 
HM resolution 
Collision Energy 
Ion Energy 
Steering 
Entrance 
Multiplier 
MCP 
5.0 
5.0 
10.0 
1.7 
-2.55 
62 
550 
2300 
5.0 
5.0 
10.0 
1.7 
-2.55 
62 
550 
2300 
10.0 
10.0 
10.0 
1.9 
0.0 
62 
550 
2300 
MS2    
Transport 
Aperture 
Acc. V 
Focus 
TOF 
Reflectron 
Trans RF Offset 
Trans RF Gain 
Coll RF Offset 
Coll RF Gain 
Pre-Filter 
Time 
Mass 1 
Time 1 
Ramp 1 
Mass 2 
Time 2 
Ramp 2 
Mass 3 
2.0 V 
13.0 V 
200 V 
0.0 V 
9.1 kV 
35.71 
0.60 
0.00 
0.60 
0.00 
6.0 
0.0 µs 
500 amu 
5.0 % 
5.0 % 
2333.0 amu 
30.0 % 
60.0 % 
2333.0 amu 
2.0 V 
13.0 V 
200 V 
0.0 V 
9.1 kV 
35.71 
0.60 
0.00 
0.60 
0.00 
6.0 
0.0 µs 
400 amu 
20.0 % 
60.0 % 
1000.0 amu 
20.0 % 
0.0 % 
1000.0 amu 
2.0, 4.0 V 
12.0, 16.0 V 
200 V 
0.0 V 
9.1 kV 
35.71 
0.60 
0.00 
0.60 
0.00 
5.5 
0.0 µs 
400 amu 
20.0 % 
60.0 % 
1000.0 amu 
20.0 % 
0.0 % 
1000.0 amu 
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All the ESI mass spectra acquired for DNA-cisplatin studies (Chapter 5) were 
performed in both positive or negative ion mode over the m/z range of 100-3000. The 
work involving the development of reaction conditions for cisplatin and ssDNA was 
done in negative ion mode whereas enzymatic studies of DNA-cisplatin adducts were 
performed in positive ion mode. All the mass spectra were acquired using a cone 
voltage of 50 V. Typically, 10-50 acqusitions were summed to obtain representative 
spectra. The summed spectra were background subtracted and smoothed using 
standard algorithms provided in the Mass LynxTM software. Other MS parameters are 
shown in Table 2.5.  
 
2.3.2 Electrospray Ionisation Tandem Mass spectrometry (ESI-MS/MS) 
The Micromass Q-Tof-2 TM was used for ESI-MS/MS analyses. All the spectra were 
acquired in positive ion mode under the same conditions as used for ESI-MS. The 
spectra were acquired over the m/z range appropriate to observe product ions from 
the selected precursor ion. Typically 10-20 acquisitions were summed to obtain 
representative spectra. Tuning parameters used were the same as for ESI-MS studies 
with variations in collision energy. The range of collision energy used in all the 
experiments was 4- 35 V and argon was used as collision gas. 
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Table 2.5: Typical tuning parameters for ESI-MS study of DNA-cisplatin adducts on 
the Q-Tof-2 TM mass spectrometer. 
 
Tuning parameters DNA-cisplatin studies 
(+ve Ion mode) 
DNA-cisplatin studies 
(-ve Ion mode) 
Source parameters   
Capillary 
Cone 
HV lens 
Extractor 
RF Lens 
Source block temperature 
Desolvation temperature 
Desolvation gas flow rate 
2.5 kV 
50 V 
500 V 
0 
1.29 V 
60 
150 
300 L/hr 
2.3 kV 
50 V 
500 V 
0 
1.50 V 
60 
150 
300 L/hr 
MS   
LM resolution 
HM resolution 
Collision Energy 
Ion Energy 
Steering 
Entrance 
Multiplier 
MCP 
5.0 
5.0 
10.0 
1.7 
-2.55 
62 
550 
2300 
10.0 
10.0 
10.0 
1.9 
0.0 
62 
550 
2300 
MS2   
Transport 
Aperture 
Acc. V 
Focus 
TOF 
Reflectron 
Trans RF Offset 
Trans RF Gain 
Coll RF Offset 
Coll RF Gain 
Pre-Filter 
Time 
Mass 1 
Time 1 
Ramp 1 
Mass 2 
Time 2 
Ramp 2 
Mass 3 
2.0 V 
13.0 V 
200 V 
0.0 V 
9.1 kV 
35.71 
0.30 
0.00 
0.30 
0.00 
6.0 
0.0 µs 
100, 200 amu 
20.0 % 
60.0 % 
250, 700.0 amu 
20.0 % 
0.0 % 
250, 700.0 amu 
2.0 V 
12.0 V 
200 V 
0.0 V 
9.1 kV 
35.71 
0.30 
0.00 
0.30 
0.00 
5.5 
0.0 µs 
200 amu 
20.0 % 
60.0 % 
700.0 amu 
20.0 % 
0.0 % 
700.0 amu 
 
Chapter 3 
 58 
Chapter 3: ESI-MS of complexes of dsDNA with antibiotics and 
metallodrugs 
3.1 Introduction 
Double-stranded DNA (dsDNA) contains different sites for non-covalent interactions 
with small molecules such as the polyanionic backbone, planar ring systems of the 
bases, and specific sites on bases aligned in the minor and major grooves. These 
interactions can play an important role in stabilization of the secondary structure of 
DNA. Apart from interactions with small molecules, there are many other 
contributing factors to the stability of dsDNA and its non-covalent complexes. These 
include:  length of DNA, DNA sequence, sample preparation, and solvents used.  
 
The different classes of compounds that bind to DNA and their modes of binding 
were discussed in Chapter 1 (section 1.3). In summary, cisplatin binds in a strong 
coordinate bond to DNA preferably at two adjacent purines, 5′-GG-3′ and 5′-AG-3′ 
[49], minor groove binders such as distamycin bind across AT-rich sequences [15] 
and many studies have shown that intercalators prefer GC-rich sequences [116,189]. 
Minor groove binders and intercalators have been shown to stabilise dsDNA 
[114,116], whereas cisplatin destabilises the duplex by bending and unwinding [49]. 
Examples of each these major classes of DNA-binding molecules are included in the 
experiments described in this chapter.  
 
Another type of DNA-binding compounds is the metallointercalators containing 
ruthenium [26]. Preliminary studies (based on photophysical studies and NMR 
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spectroscopy) on the binding of tris(phenanthroline) complexes of metals such as 
zinc (II), cobalt (III) and ruthenium (II) with DNA suggested three modes of binding: 
electrostatic and hydrophobic interactions in the minor groove and partial 
intercalation [190].  
 
The unimpressive binding affinity of the complexes involving tris(phenanthroline) 
led to the search for metal ligands with a larger surface area with potential for 
intercalative interactions with DNA. One such ligand dipyrido[3,2-a:2',3'-
c]phenazine (dppz) with a large aromatic surface area exhibits high binding affinity 
for DNA (>106 M-1) when complexed to ruthenium (II) metal [191]. Complexes 
containing ruthenium and dppz such as [Ru(bpy)2(dppz)]2+, [Ru(phen)2(dppz)]2+  and 
related derivative complexes exhibit the interesting property of photoluminescence 
when bound to DNA and thus can be used as molecular light switches [191,192]. 
That is, in an aqueous solution, in the presence of DNA, photoluminescence of the 
complexes is observed which is absent in aqueous solution without DNA [26]. The 
luminescence property can be exploited to show that DNA discriminates between 
optical isomers [193,194]. Of the two isomers Δ-[Ru(phen)2(dppz)]2+  and Λ-
[Ru(phen)2(dppz)]2+, the right handed complex (Δ) has been shown to bind more 
deeply within the (right-handed) dsDNA helix as evidenced by a larger excited state 
lifetime [194]. Four metallointercalators have been examined in this chapter: 
[Ru(phen)3]2+, [Ru(phen)2(dpq)]2+, [Ru(phen)2(dpqC)]2+ and [Ru(phen)2(dppz)]2+  
(Fig 1.5). Studies with these [Ru(phen)3]2+ derivatives have indicated they exhibit a 
mixture of binding modes [29,31,195,196]; [Ru(phen)2(dppz)]2+ is thought to bind to 
DNA by intercalation [191,197], and there is also evidence of intercalative binding 
by [Ru(phen)2(dpq)]2+ and [Ru(phen)2(dpqC)]2+ [30,198,199]. 
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3.2 Scope of this chapter 
There have been many reviews on dsDNA and its complexes with different classes of 
drugs [12,15,121,200-202]. Over the last five years, ESI-MS has been used to study a 
number of these complexes [106,115,116,118,119,203]. Most of the ESI-MS studies 
have been carried out in negative ion mode. Many of the early reports of dsDNA-
drug complexes by ESI-MS showed spectra with significant amounts of single-
stranded DNA (ssDNA) [99,106,114-116]. Further, analysis of negatively charged 
ions only, often presents difficulties for the study of complexes with metal-
containing drugs, particularly for MS/MS experiments [125]. In the present study, 
the aim was to optimize and develop ESI conditions to maximize the detection of 
dsDNA and drug/DNA complexes in positive ion mode. Following the optimization 
of conditions, the gas phase stabilities of complexes of dsDNA with different classes 
of drugs were studied. Different classes of drugs exhibit differences in sequence 
selectivity, modify DNA in various ways and are also known to stabilise or 
destabilise dsDNA. ESI-MS/MS, desolvation temperature variation, and in-source 
collision-induced dissociation experiments were carried out. Some drug/DNA 
complexes were also studied in negative ion mode for comparison with spectra 
acquired in positive ion mode. 
 
The second part of these studies involved investigation of complexes of 
metallointercalators with dsDNA using negative ion ESI-MS. This is one of only two 
ESI-MS studies done on transition metal metallointercalators/DNA complexes [116]. 
Conditions were developed for optimal detection of these complexes in the negative 
ion mode and their stoichiometries and sequence selectivity were probed. 
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3.3 Results and Discussion 
3.3.1 Studies involving drugs from major classes with dsDNA 
3.3.1a Optimization of ESI-MS conditions for the detection of dsDNA 
Consistent with results from solution studies, longer DNA sequences have greater 
stability in the mass spectrometer [102]. Furthermore, for the same length of dsDNA, 
GC base pairs have greater stability than AT base pairs [102]. Non-self 
complementary sequences prevent ambiguity in analysis of results and mild 
instrument interface conditions are required to maximize preservation of the solution 
structure in gas phase (discussed in section 1.6.1). 
 
Non-self complementary 16 mer double-stranded DNA sequences were selected for 
this study. The sequences of the two duplexes studied in this work were: 
(D1), 5′-CCTCTCTGGACCTTCC-3′(D1a)/5′-GGAAGGTCCAGAGAGG-3′(D1b) 
and, 
(D2), 5′-GCTGCCAAATACCTCC-3′(D2a)/5′-GGAGGTATTTGGCAGC-3′(D2b). 
 
The duplex D1 contains a binding site for cisplatin (GG at the centre of D1a). 
Overall, the sequence is GC-rich and this is expected to stabilise its complexes with 
daunomycin [189]. Furthermore, the X-ray crystal structure of cisplatin modified D1 
bound to HMG1 protein has been solved by Lippard’s group (Fig. 3.1) [204]. D2 
contains two 5 base-pair sites on different strands, 5'-AAATA-3', known to bind up 
to two distamycin molecules from circular dichroism and kinetic differentiation 
studies [205]. Furthermore, 5'-ATTTG-3' has been shown by X-ray crystallography 
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to bind one Hoechst 33258 molecule [206]. The structures of daunomycin, 
distamycin, Hoechst 33258 and cisplatin are shown in Figures 1.4, 1.6 and 1.7. 
Figure 3.1: X-ray structure of cisplatin-modified dsDNA bound to HMG1 protein. 
Cisplatin is shown in green, dsDNA in red and blue, and HMG1 protein with its three 
helices is in yellow [204]. 
Titration of DNA strands 
The formation of secondary structure within single strands of DNA may introduce 
error in the concentration calculated from UV absorbance readings. In order to 
determine that equimolar amounts of complementary strands were used in each 
experiment, single strands were titrated against one another as follows. Different 
ratios of the two single strands were mixed and annealed as outlined in Chapter 2. 
Briefly, complementary strands were mixed in a 1:1 ratio as calculated from UV 
absorbance readings; other mixtures were prepared in which one strand was in excess 
over the other. Same protocol was followed for all the complementary single strands 
of dsDNA. Fig. 3.2 shows positive ion ESI mass spectra of three of the ratios tried in 
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the titration experiment with two complementary strands of D1. Table 3.1 gives 
calculated values of m/z for all DNA and drug/DNA mixtures used in this study. As 
seen in Fig. 3.2 the predominant ions were from dsDNA, [D1 + 5H]5+, [D1 + 6H]6+ 
and [D1 + 7H]7+ at m/z values of 1953.7, 1628.3 and 1395.8 respectively, where D1 
is the mass of the dsDNA (D1). In Fig. 3.2(c) where strand D1b was in excess over 
D1a (as judged by UV measurements) there were no ions of significant abundance 
from single strands of DNA as compared to the other mixtures shown in Fig. 3.2(a) 
and 3.2(b). The ratio used to obtain the spectrum shown in Fig. 3.2(c) was used 
throughout the following study for duplex D1. Similar titrations were carried out 
before proceeding with any work involving other dsDNA sequences to ensure that 
strands were present in equimolar amounts. 
 
In all experiments, care has been taken to avoid non-specific binding. Non-self 
complementary sequences were selected to avoid ambiguous results (already 
discussed in section 1.6.1). Furthermore, the final concentration of all samples was 
≤10 µM when analysed in the mass spectrometer [103,207]. Different solvents have 
been used in ESI-MS studies carried out in negative ion mode that include: 10 mM 
NH4OAc [99,101,119], 10 mM NH4HCO3 [102,103], and 10 mM 
NH4OAc/ammonium citrate, pH 8.3 [113]. More recently, higher salt concentrations 
have been used: 50 mM NH4OAc/50% MeOH [106] and 80 mM NH4OAc/20% 
MeOH or 50 mM NH4OAc [115,118]. All the ESI mass spectra presented in those 
studies showed ions of considerable abundance from ssDNA. 
 
 
 
Chapter 3 
 64 
 
 
Figure 3.2: Titration of the complementary strands of duplex D1. Ratios of volumes 
of D1a/D1b mixed for annealing: (a) 1:1; (b) 1:1.2; (c) 1:1.8; D1b (); dsDNA (). 
 
Counter ions play an important role in the stability of dsDNA [113]. The 
phosphodiester backbone of DNA is negatively charged at physiological pH. This 
excess of negative charges can lead to ubiquitous sodium adducts causing 
suppression of signals and poor resolution of the peaks in ESI mass spectra [207]. 
The presence of a volatile salt such as ammonium acetate reduces the excess charge 
and simplifies the mass spectrum making data interpretation easier [208]. We studied 
different DNA complexes in 10 mM and 100 mM NH4OAc at pH 8.5. Fig. 3.3 shows 
ESI mass spectra of duplex D1 and {cis-[Pt(NH3)2] D1} in the different 
concentrations of NH4OAc acquired in negative and positive ion modes. 
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Table 3.1: Calculated m/z for ions from free and complexed DNA used in this study. Sequences of DNA strands are given in Table 2.1. 
(Calculated m/z values for negative ions were similar to the corresponding values in positive ions with a difference of 2.0 Da). 
Oligonucleotide/Complex Calculated m/z 
ssDNA 
  [M+6H]6+ [M+5H]5+ [M+4H]4+ [M+3H]3+ 
D1a  791.7 949.8 1187.0 1582.4 
D1b  837.7 1005.1 1256.1 1674.5 
D2a  798.7 958.2 1197.5 1596.4 
D2b  830.6 996.5 1245.3 1660.1 
AT14  712.7 855.2 1068.7 1424.6 
  [D1a+Pt(NH3)2+4H]6+ [D1a+Pt(NH3)2+3H]5+ [D1a+Pt(NH3)2+2H]4+ [D1a+Pt(NH3)2+H]3
+ 
{cis-[Pt(NH3)2] (D1a)  829.5 995.2 1243.8 1656.1 
dsDNA 
  [D1+7H]7+ [D1+6H]6+ [D1+5H]5+ [D1+4H]4+ 
D1 +  1395.9 1628.4 1953.9 2442.1 
Daunomycin (Dn) +1 Dn 1471.2 1716.2 2059.3 2573.8 
 +2 Dn 1546.5 1804.1 2164.7 2705.6 
 +3 Dn 1621.8 1891.9 2270.1  
 +4 Dn 1697.1 1979.7   
  [D2+7H]7+ [D2+6H]6+ [D2+5H]5+ [D2+4H]4+ 
D2 +  1395.8 1628.3 1953.7 2441.9 
Distamycin (Dst) +1 Dst  1708.5 2050.0  
 +2 Dst  1788.8 2146.3  
Hoechst 33258 (Hc) +1 Hc 1456.4 1699.0 2038.6 2548.0 
 +2 Hc  1769.7 2123.5  
  [D1+Pt(NH3)2+5H]7+ [D1+Pt(NH3)2+4H]6+ [D1+Pt(NH3)2+3H]5+  
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{cis-[Pt(NH3)2] D1}  1428.4 1666.3 1999.3  
Figure 3.3: ESI mass spectra of D1 and {cis-[Pt(NH3)2] D1} obtained under different conditions. (a) negative ions in 10 mM NH4OAc, pH 8.5 
of D1; (b) negative ions in 100 mM NH4OAc, pH 8.5 of D1; (c) positive ions in 100 mM NH4OAc, pH 8.5 of D1; (d) negative ions in 10 mM 
NH4OAc, pH 8.5 of { cis-[Pt(NH3)2] D1}; (e) negative ions in 100 mM NH4OAc, pH 8.5 of {cis-[Pt(NH3)2] D1}; (f) positive ions in 100 mM 
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NH4OAc, pH 8.5 of {cis-[Pt(NH3)2] D1}. Single strands of either strand (); single-stranded cis-{[Pt(NH3)2] D1a} (); dsDNA ();{cis-
[Pt(NH3)2 D1]} ().There were no ions at m/z >2100. 
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There were significant amounts of ssDNA observed when ESI mass spectra of D1 or 
{cis-[Pt(NH3)2] D1} were acquired using 10 mM NH4OAc as compared to 100 mM 
NH4OAc as solvent (cf. Fig 3.3(a) with 3.3(b) and Fig. 3.3(d) with 3.3(f)). These 
results are consistent with solution studies where dsDNA was more stable at high 
concentration of counterions [209,210]. It is interesting to note that in the spectra 
acquired in positive ion mode under the same sample and instrument conditions, 
there was a significant decrease in the amount of ssDNA. Figure 3.3 clearly shows 
that the intensities of ions from ssDNA where spectra were acquired in positive ion 
mode is lower than in those acquired as negative ions for duplex D1 using 100 mM 
NH4OAc, pH 8.5, as solvent. A similar effect was observed for {cis-[Pt(NH3)2] D1} 
(cf. Fig. 3.3(b) with 3.3(c) and 3.3(e) with 3.3(f)). Similar results were obtained for 
other duplexes as well as dsDNA complexes with daunomycin or distamycin (data 
not shown). 
 
Different explanations for the greater abundance of ssDNA in negative ion ESI mass 
spectra were considered. One of the possibilities could be that there are few 
positively charged ions from ssDNA. This possibility was tested by adding different 
amounts of AT14 to previously annealed D1 (ratios of AT14: D1 from 0.1:1 to 1:1). 
AT14 is not self-complementary and is not expected to be involved in significant 
base pairing with D1. Figure 3.4 shows ESI mass spectra of 0.25:1 mixtures of 
AT14:D1. In Fig. 3.4 it can be clearly seen that ions from ssDNA are detected under 
all the conditions. AT14 ions, [M+4H]4+ and [M+5H]5+ were at m/z 1068.6 and 
1424.4 respectively, in positive mode and the corresponding ions in negative mode, 
[M-4H]4- and [M-5H]5-, were at m/z 1066.6 and 1422.4.  It was seen that the ion 
current from AT14 increased linearly as increasing amounts of AT14 were added in 
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both positive and negative ion mode (data not shown). This supports the proposal 
that positive ions from ssDNA are formed and are transported to the mass analyser. 
 
The presence of ions from ssDNA in ESI mass spectra of dsDNA obtained in 
negative mode and their absence under the identical conditions in positive mode 
suggests that positively charged dsDNA may be more stable through ionisation and 
transmission than negatively charged dsDNA under the conditions employed here. 
Figure 3.4: ESI mass spectra of 0.25:1 mixtures of ATA14 and D1: (a) negative ions 
with 10 mM NH4OAc, pH 8.5 as solvent; (b) negative ions with 100 mM NH4OAc, 
pH 8.5 as solvent; (c) positive ions with 100 mM NH4OAc, pH 8.5 as solvent. Single 
strands from D1 (); single strands from AT14 (); dsDNA (). 
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3.3.1b Stability of complexes 
The stability of the duplexes is expected to be differentially influenced by the 
binding of drugs with different binding modes. In solution, for example, cisplatin 
destabilises the helix [50,211], whereas intercalators (such as daunomycin) and 
minor groove binders (such as distamycin and Hoechst 33258) are known to enhance 
the stability both in the solution [212-214] and gas phases [106,115,116,118,119]. 
These gas phase studies were carried out using negative ion mode. In the 
experiments described below, the gas phase stabilities of the two duplexes, D1 and 
D2 and a mixture of daunomycin with D1, distamycin with D2, Hoechst 33258 with 
D2 and {cis-[Pt(NH3)2]2+ D1} were investigated using positive ion ESI-MS by 
varying the desolvation temperature and in CID experiments.   
Effect of desolvation temperature 
The effect of desolvation temperature on positive ion ESI mass spectra of duplex D1 
and a 5:1 mixture of daunomycin with D1 is shown in Figure 3.5. In the spectrum in 
Fig. 3.5(a) obtained under normal conditions outlined in section 2.3.1 (+ve ions, 100 
mM NH4OAc pH 8.5), the most abundant ion is [D1 + 2Dn + 6H]6+. There are also 
present ions from D1 alone, and from complexes containing one, two, three and four 
(low intensity) daunomycin molecules. The binding stoichiometry observed is in 
agreement with the work done earlier in this laboratory that involved binding of the 
intercalators, daunomycin and nogalamycin to self-complementary oligonucleotides 
[119]. Classical intercalators (with minimum substitution on the aromatic rings, 
minimizing steric hindrance) show multiple stoichiometries because they are capable 
of binding every second base pair of dsDNA [215]. So in a 16 base pair dsDNA the 
binding of three to four Dn molecules seems reasonable. Figures 3.5(b) and (c) show 
the spectra for the 5:1 Dn/DNA mixture and for uncomplexed D1, respectively, using 
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an elevated desolvation temperature (100°C). In the spectrum of the Dn/DNA 
mixture, there are no ions from ssDNA. The ions with three or four Dn molecules 
bound are absent and there is an increase in the amount of free dsDNA and dsDNA 
with one or two Dn molecules bound. In contrast, the ESI mass spectrum of free 
dsDNA under these conditions shows that there has been considerable strand 
separation (Fig. 3.5(c)). The enhanced stability of the DNA with bound daunomycin 
is consistent with increased stability of intercalated DNA observed in solution and 
with other mass spectrometric studies [106,119]. 
 
The same experiment was carried out for a 3:1 mixture of distamycin (Dst)/D2 and 
for {cis-[Pt(NH3)2]2+ D1}. Figure 3.6(a) shows an ESI mass spectrum obtained 
under the conditions outlined in section 2.3.1 (+ve ions, 100 mM NH4OAc pH 8.5). 
Ions from free dsDNA as well as from one and two Dst molecules bound to dsDNA 
are present. There were no ions of significant abundance from ssDNA. Figures 3.6(b) 
and (c) show the spectrum for the 3:1 Dst/DNA mixture and for free D2, 
respectively, using an elevated desolvation temperature (100°C). As observed in the 
spectrum where the desolvation temperature was 40°C (Fig. 3.5(a)), there are no ions 
from ssDNA in Dst/DNA mixture. The intensity of ions from D2 with one or two Dst 
molecules bound is decreased and there is an increase in the amount of free dsDNA. 
In contrast, in the spectrum of uncomplexed dsDNA obtained using a higher 
desolvation temperature there has been considerable strand separation (Fig. 3.6(c)). 
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Figure 3.5: Positive ion ESI mass spectra of D1 and a 5:1 mixture of 
daunomycin/D1. (a) a 5:1 mixture of daunomycin/D1 using source block and 
desolvation temperatures of 40°C and 40°C, respectively; (b) a 5:1 mixture of 
daunomycin/D1 using source block and desolvation temperatures of 80°C and 
100°C, respectively; (c) uncomplexed D1 using source block and desolvation 
temperatures of 80°C and 100°C, respectively. Single strands of either strand ();  
free dsDNA (); dsDNA + 1 Dn (); dsDNA + 2 Dn (); dsDNA + 3 Dn (); 
dsDNA + 4 Dn (). 
 
A similar experiment was carried out using {cis-[Pt(NH3)2] D1}. In contrast to the 
results with the daunomycin/dsDNA or distamycin/dsDNA mixtures, single DNA 
strands for D1 were observed at elevated desolvation temperature in similar 
abundance to that observed for uncomplexed dsDNA. That is, there was significant 
dissociation of DNA strands to give {cis-[Pt(NH3)2]2+ D1a}and D1b. As expected, 
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platination of DNA did not enhance its stability. There was also some fragmentation 
of covalent bonds of D1b (data not shown). In this experiment, it was not possible to 
make the subtle distinction between the stabilities of the cisplatin-bound dsDNA 
compared to dsDNA. 
 
Figure 3.6: Positive ion ESI mass spectra of D2 and a 3:1 mixture of distamycin/D2. 
(a) a 3:1 mixture of distamycin/D2 using source block and desolvation temperatures 
of 40°C and 40°C, respectively; (b) a 3:1 mixture of distamycin/D2 using source 
block and desolvation temperatures of 80°C and 100°C, respectively; (c) 
uncomplexed D2 using source block and desolvation temperatures of 80°C and 
100°C, respectively. Single strands of either strand (); free dsDNA (); dsDNA + 
1 Dst (); dsDNA + 2 Dst (). 
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The above results show that minor groove binders and intercalators stabilise dsDNA 
in gas phase as studied at elevated temperatures. This agrees with other MS studies 
as well as solution studies. In contrast, cisplatin did not stabilise dsDNA.  
 
Effect of increasing cone voltage (in-source CID) 
The stabilities of the D1 and Dn/D1 complexes were probed by in-source collision-
induced dissociation experiments. It was seen that for Dn/D1 complexes as the cone 
voltage was increased from 50 to 65 V, there was an increase in the amount of free 
D1, but there were no ions arising from single strands (D1a or D1b). In contrast, 
when D1 was studied under the same conditions, there was evidence of significant 
strand separation at 60 V. Under these conditions, the summed intensities of all ions 
from ssDNA was about half that for the summed intensities of all ions from dsDNA 
(data not shown). These results  are consistent with an increase of stability of dsDNA 
with a bound intercalator over uncomplexed dsDNA. 
 
Distamycin (Dst) is an extensively studied minor groove binder. A 1:1 Dst/DNA 
complex has been observed with the following AT-rich sequence: 
d(CGCGAATTCGCG)2 (Fig. 3.7(a)) [40,41]. When there are more than four 
consecutive AT base pairs (sequence: d(CGCAAATTGGC)2) a 2:1 complex is 
observed (Fig. 3.7(b)). In the latter complex, two distamycin molecules sit alongside 
each other, contacting one strand and running antiparallel to each other [42]. To 
accommodate the two molecules of the drug, the minor groove width expanded by 
3.5-4 Å (Fig. 3.7) [42,121]. The sequence contained within the oligonucleotides used 
in these experiments, D2, has been shown in circular dichroism experiments to 
cooperatively bind two molecules of distamycin [205]. 
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Figure 3.7: NMR structure of distamycin/dsDNA complexes. (a) 1:1 complex with 
dsDNA containing an AATT site, (b) 2:1 complex with dsDNA containing an 
AAATT site. Distamycin molecules are shown in color and DNA backbone is shown 
dark gray to highlight the change in the width of the minor groove [121]. 
 
Figure 3.8 shows ESI mass spectra of 1:1, 3:1 and 5:1 mixtures of distamycin with 
D2, acquired in positive and negative ion modes. In both the positive and negative 
ion ESI mass spectra, the relative amounts of dsDNA with various stoichiometries of 
bound distamycin (one or two molecules of Dst bound to dsDNA) did not change 
significantly when the ratio of distamycin:dsDNA was increased from 3:1 to 5:1, 
although as expected, the relative amount of free dsDNA decreases. This is 
consistent with saturation of the drug binding site(s) and suggests a specific 
interaction of the minor groove-binder with DNA, rather than non-specific multiple 
interactions. The positive ion spectra (Fig. 3.8(a)-(c)), show ions with increasing 
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amounts of an adduct (m/z ~17) as the amount of distamycin is increased suggesting 
that a positively charged impurity (presumably ammonium ions) is being added 
along with distamycin. 
 
In both the ion modes, ESI mass spectra show evidence for the presence of dsDNA 
with both one and two molecules of  distamycin present in mixture as expected from 
solution studies. However, there is an important difference between positive and 
negative ion ESI mass spectra of these complexes under these conditions. 
 
In negative ion mode, the most abundant ion detected carries 6- charges in which two 
molecules of distamycin are bound (m/z 1787.6). In positive ion mode, the most 
abundant ion detected is the 5+ ion in which one molecule of distamycin is bound 
(m/z 2049.9). The above species were detected using a cone voltage of 50 V. When 
the effect of cone voltage in positive ion mode of the 3:1 mixture was studied, the 
relative amounts of complexes where either two or one distamycin molecules were 
bound changed (Fig. 3.9). At cone voltages of 30-40 V, the complex with two Dst 
molecules predominates. This is similar to that observed in negative ion mode under 
cone voltage of 50 V for the same Dst/dsDNA mixture where the ion with 6 charges, 
attributed to dsDNA + 2Dst, is the most abundant, (Fig. 3.8(e)). It is seen that when 
the cone voltage is increased to 60 V (Fig. 3.9(c)), the amount of dsDNA free from 
Dst is increased as the complex dissociates. These results show that conclusions 
about relative abundances of various complexes transferred from solution to gas 
phase cannot be made from an ESI mass spectrum acquired under only one set of 
conditions. 
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Figure 3.8: Positive ion ESI mass spectra of mixtures of distamycin with D2 as positive ions: (a) 1:1 mixture; (b) 3:1 mixture; (c) 5:1 mixture; 
and as negative ions: (d) 1:1 mixture; (e) 3:1 mixture; (f) 5:1 mixture.  Single strands of either strand (); free dsDNA (); dsDNA + 1 Dst (); 
dsDNA + 2 Dst (). 
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Figure 3.9: Effect of cone voltage on positive ion ESI mass spectra of 3:1 mixtures 
of distamycin with D2. (a) 30 V; (b) 40 V; (c) 60 V. Single strands of either strand 
(); free dsDNA (); dsDNA + 1 Dst (); dsDNA + 2 Dst (). 
 
The similarity of the spectra in positive mode at 30-40 V and negative mode at 50 V 
may simply be a consequence of a difference in focusing effects of the cone in the 
source region on positive and negative ions [216]. The other explanation for the 
difference in the relative amounts of the two species observed in gas phase (one or 
two Dst molecules bound in positive or negative ion mode, respectively, at the cone 
voltage 50 V) may arise from the interactions of distamycin molecules with the 
atoms on DNA that have a differential effect on the positive charge formation. Loo 
and co-workers [111] proposed that positive ions in ESI mass spectra are derived 
from protonated bases present in solution, typically ammonium acetate. Then, if the 
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gas phase proton affinity of a nucleobase is higher than that of ammonia, then under 
conditions where CID is minimized, the following reaction will occur giving a 
positive charge on the oligo(deoxy)ribonucleotide. 
 
Nucleobase + NH4+ →  NucleobaseH+ + NH3   (3a) 
 
Therefore, in positively charged DNA, the phosphate groups will be neutral and 
positive charges most likely reside on the bases. Since the binding of distamycin 
occurs through non-covalent interactions with the bases, it is possible that the 
binding of the second molecule disrupts the base/NH4+ interactions to such an extent 
that the propensity of the dsDNA + 2Dst complex to accommodate multiple positive 
charges is reduced. As cone voltage is increased, the already weakened base/NH4+ 
interactions are dissociated resulting in a dsDNA + 2Dst complex that cannot 
accommodate positive charges. In the case of the negatively-charged complexes, the 
charges most likely reside on the phosphodiester backbone so the presence of a 
second Dst molecule is not expected to influence the capacity to carry charge.  
 
The data from these experiments are represented graphically in Figures 3.10. The 
intensities of ions from a particular species as a percentage of the total intensity of all 
ions in a spectrum was plotted against the different stoichiometries observed in gas 
phase for the cone voltages 30-60 V. As seen in Fig. 3.10, in positive ion ESI mass 
spectra a decrease in the intensities of ions from one and two Dst bound to D2 
occurred with increasing cone voltage with a concomitant increase in free D2. This 
suggests that at higher cone voltage, the Dst molecule(s) are dissociating from the 
dsDNA. The relative abundance of ions from D2 + 2Dst is relatively low under these 
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conditions. This suggests that positively charged D2 + 2Dst is relatively unstable. In 
contrast, in negative ion ESI mass spectra, D2 + 2Dst predominates under all 
conditions. This is consistent with solution data [205]. The instability observed in 
positive ion spectra may result from charge-charge repulsion between positively 
charged Dst molecules and positively charged DNA nucleobases. 
 
The same experiment as above was carried out with Hoechst 33258 (Hc) and the 
effect of different cone voltages was observed in positive and negative ion mode. 
Hoechst 33258, like distamycin, is a well studied minor groove binder and binds AT-
rich sequences [217-219]. Moreover, AT-rich tracts such as in the middle of D2 
promote binding of Hoechst in a 1:1 stoichiometry. X-ray crystallographic studies 
have shown that Hoechst 33258 binds at the five base-pair site 5'-ATTTG-3' (present 
in D2b) in 1:1 stoichiometry. Figure 3.11 shows that under all conditions the species 
D2 + 1Hc is the most abundant. In positive ion ESI mass spectra as cone voltage was 
increased, some dissociation of D2 + 1Hc was observed, resulting in an increase in 
free D2. In contrast, in negative ion mode, the species D2 + 1Hc was stable. The 
higher stability of negatively dsDNA-drug complexes was also observed for Dst 
(above), but was greater. The above differences observed in negative and positive ion 
mode suggest that positively charged minor groove binder/dsDNA complexes are 
less stable in positive ion mode than in negative ion mode. This will be discussed in 
more detail in section 3.3.2a. 
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Figure 3.10: Relative intensities of different species from a 3:1 mixture of Dst/D2 
observed in ESI mass spectra at different cone voltages in positive and negative ion 
mode. Cone voltage: 30 V (); 40 V (); 50 V () and 60 V ().  
 
 
Figure 3.11: Relative intensities of different species from a 3:1 mixture of Hoechst 
33258/D2 observed in ESI mass spectra at different cone voltages in positive and 
negative ion mode. Cone voltage: 30 V (); 40 V (); 50 V () and 60 V (). 
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It should be noted that the stabilities of complexes determined by monitoring the 
effects of changing desolvation temperatures and cone voltages reflect not only the 
intrinsic stability of the complex, but might also be affected by differing desolvation 
rates as well as the extent to which complex ions are clustered with other species. 
 
Tandem mass spectrometry (ESI-MS/MS) study of dsDNA/drug complexes 
The stabilities of the drug/DNA complexes were probed further using tandem mass 
spectrometry (MS/MS). The study was carried out using dsDNA D1, {cis-
[Pt(NH3)2]2+ D1}, D1 + 1Dn, D1 + 2Dn , D1 + 3Dn and also D2 + 1Hc. In each 
study the ion with 6+ charges was selected as precursor. 
 
Figure 3.12 shows dissociation of D1 with increasing collision energy. As seen in 
3.12(a), at a collision energy of 10 V, the precursor ion, [D1 + 6H]6+ (m/z 1628.4) 
from D1 (), is present in greatest abundance, with a small percentage of product 
ion from a loss of guanine (G) from D1 (), [D1 + 6H-G]5+ at m/z 1923.7. At a 
collision energy of 20 V, (Fig. 3.12(b)), product ions from single stranded D1a and 
D1b appear (), [(D1a or D1b) + 3H]3+, in addition to the two ions seen in (a). At 30 
V (Fig. 3.12(c)), there is complete dissociation of the duplex D1 into single strands 
accompanied by numerous peaks owing to covalent bond breakage. The precise 
assignment of these peaks was difficult owing to there being coincidence in masses 
of ions from each strand. Many peaks in the spectra could be from the loss of G and 
C from the duplex or single strands and other covalent cleavages. When the same 
experiment was carried out using negative ion mode, dissociation of dsDNA to single 
strands was observed at comparatively low collision energy (20-25 V; data not 
shown). 
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Figure 3.12: Positive ion ESI MS/MS of free D1. ([D1 + 6H]6+) at different collision 
energies: (a) 10 V, (b) 20 V and  (c) 30 V. Single strands of either strand (); free 
D1 (); D1 – 1G (). 
 
Similar experiments were carried out using D1 + 1Dn and D2 + 1Hc. As shown in 
Figure 3.13(a), for the Dn/DNA complex, at a collision energy of 10 V, the major 
product ion from the precursor ion [D1 + 1Dn + 6H]6+ (m/z 1716.2) is dsDNA, D1 
(), [D1 + 5H]5+. At higher collision energies of 20 and 30 V the loss of the Dn 
molecule from D1 is observed along with covalent bond dissociation resulting in loss 
of one and two G (Fig. 3.13(b) and (c)). For the Dn/DNA complex at 30 V, there 
were no ions from single strands of D1 suggesting that dsDNA D1 was still intact. In 
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contrast, free D1 (no Dn bound) was dissociated into single strands at this collision 
energy (Fig. 3.12(c)). A similar effect was observed with D2 + 1Hc (m/z 1699.0). As 
collision energy was increased, the complex dissociated into free dsDNA but there 
was no dissociation into single strands (Fig. 3.13(d)-(f)). This shows that the 
presence of Dn or Hc stabilises the dsDNA. 
 
Daunomycin and Hoechst 33258 stabilised the DNA double helix to different 
extents. As seen in Fig. 3.13(b) and (e), under the same instrument conditions, at a 
collision energy of 20 V, the relative abundance of Hc/dsDNA compared with free 
DNA is significantly greater than for Dn/dsDNA. Interestingly there is no covalent 
dissociation due to the loss of G from dsDNA in Hc/DNA as compared to covalent 
dissociation observed in Dn/DNA. The greater stabilization effect of the minor 
groove binder over daunomycin (intercalator) has been observed in solution [200]. 
Another reason for difference in the stabilities of Hc/D2 and Dn/D1 complexes may 
be due to different intrinsic stabilities of the different sequences of D1 and D2. This 
seems less likely however, as D1 and D2 have 10 and 9 GC base pairs with melting 
temperatures (Tm) of 53°C and 51°C respectively [181]. 
 
Similar studies were carried out by the Gross group where they studied gas phase 
stabilities of self-complementary oligonucleotides and drug/DNA complexes using 
an ESI ion trap mass spectrometer in the negative ion mode [106]. It was observed 
that duplexes displayed greater stability in the presence of minor groove binders as 
compared to intercalators. Two fragmentation pathways were observed, covalent 
dissociation of complexes by base loss and non-covalent dissociation by separation 
of strands. It was seen that in complexes with drugs known to intercalate from 
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solution studies, non-covalent dissociation predominated over covalent dissociation. 
Duplexes in the presence of minor groove binders displayed better stability as the 
dissociation was accompanied by cleavage of covalent bonds with little non-covalent 
dissociation. These workers did not observe dissociation of the drug with the dsDNA 
remaining intact [106].  
 
In contrast, in our study, non-covalent dissociation of the drug/dsDNA complexes 
into two single strands was not observed. The only non-covalent dissociation 
observed was dissociation of drug from the dsDNA to yield free D1 and covalent 
dissociation of D1 by loss of G terminal bases. There are several possible 
explanations for these differences. These include the different sequences used (16 
mer non-self complementary in this study as compared to 12 mer self-
complementary), different instruments, and ion modes used to acquire ESI mass 
spectra. Under the conditions used here, in particular with longer DNA sequences 
which are more stable than shorter sequences, it appears that the interactions between 
the strands are stronger than between the drug and the dsDNA. 
 
 As in case of the work described above, the loss of G was also observed as the 
predominant cleavage of covalent bonds in other studies [106,220]. Consistent with 
this study, in ESI tandem mass spectrometry of positively charged oligonucleotides, 
loss of neutral base G and C was frequently observed due to the higher proton 
affinity of G and C compared with A and T respectively. 
 
ESI MS/MS experiments were also carried out with using the 6+ ions of {cis-
[Pt(NH3)2]2+ D1}, D1 + 2Dn and D1 + 3Dn as precursor. Figure 3.14 shows ESI-
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MS/MS spectra of {cis-[Pt(NH3)2]2+ D1}, D1 + 2Dn and D1 + 3Dn at a collision 
energy 30 V in (a), (b) and (c) respectively. In the tandem mass spectrum of the 6+ 
ion of {cis-[Pt(NH3)2]2+ D1} at 30 V, Fig. 3.14(a), ions were observed from loss of 
G from {cis-[Pt(NH3)2]2+ D1} (shown as  (-G)), loss of cisplatin ((Pt(NH3)2) and a 
G from {cis-[Pt(NH3)2]2+ D1} (shown as ), and a separated single strand with 
cisplatin bound (shown as ). These results are similar to that for free D1 (Fig. 3.12) 
showing that the binding of cisplatin did not enhance the stability of D1. As shown in 
Fig. 3.14 (b) and (c), the most abundant product ions from D1 + 2Dn and D1 + 3Dn 
were D1 () and D1 + 1 Dn (), respectively. Furthermore, product ions of lower 
intensities were observed from loss of one and two G after loss of the drug(s) bound 
(shown as  and  respectively) and loss of G from single drug bound to D1 
(shown as -G).  
 
The ESI-MS/MS results shown in Figs 3.13 and 3.14 are consistent with previous 
results; Dn and Hc stabilised the dsDNA. The dsDNA with no drugs bound 
dissociated into single strands at lower collision energy than Dn/D1 and Hc/D2. It 
was observed that for Dn/dsDNA complexes, the complexes with greater numbers of 
Dn molecules bound were more stable to dissociation by MS/MS. The results also 
suggest greater stabilization of dsDNA by Hc (minor groove binder) than Dn 
(intercalator). The cisplatin/dsDNA complexes did not stabilise dsDNA. 
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Figure 3.13: Positive ion ESI MS/MS of D1 + 1Dn and D2 + 1Hc bound. [D1 + 1Dn + 6H]6+ at different collision energies, (a) 10 V, (b) 20 V 
and  (c) 30 V; [D2 + 1Hc + 6H] 6+ at collision energies: (d) 10 V, (e) 20 V and  (f) 30 V. Free D1 or D2 (); D1/D2 + 1Dn/Hc (); D1/D2 – 1G 
(); D1/D2 – 2G  (). 
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Figure 3.14: Positive ion ESI-MS/MS of {cis-[Pt(NH3)2]2+ D1}and D1/Dn at a 
collision energy of 30 V. (a) [{cis-[Pt(NH3)2]2+ D1} + 4H]6+; (b) [D1 + 2 Dn + 6H]6+ 
and  (c) [D1 + 3Dn + 6H]6+. Free D1 (); D1 + 1Drug (cisplatin/Dn) ();{cis-
[Pt(NH3)2]2+ D1a} (); D1 – 1G (); D1 – 2G  (); Dn dimer (). The precursor 
ions have been fragmented (lost) under these conditions. 
 
3.3.1c Sequence selectivity 
It is well established that minor groove binders such as distamycin, Hoechst 33258 
and beneril prefer AT-rich sequences of DNA. In particular, the drugs that are 
positively charged at physiological pH have a high affinity for the negative 
electrostatic potential in the minor groove of AT-rich regions [13,14]. In contrast, 
many intercalators have a preference for G and C rich sequences of DNA [189].  
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Both D2 and AT16 are AT-rich and should promote minor groove binding whereas 
D1 is GC-rich and therefore is expected to bind minor groove binding drugs less 
effectively. Hoechst 33258 binds at the five base-pair site 5'-ATTTG-3' (present in 
D2b) in 1:1 stoichiometry [206,221]. Calf thymus DNA, rich in AT has shown 
stoichiometries of one to six (with 5 AT base pairs) with Hoechst 33258 [222]. The 
sequences of dsDNA D1 and D2 are shown in Table 2.1 and the sequence of AT16, a 
self-complementary oligonucleotide is: 5′-ATATATACGTATATAT-3′ 
 
The sequence selectivities of Hoechst 33258 (Hc) for D1, D2 and AT16 were probed 
by comparing 3:1 drug/dsDNA mixtures. Fig. 3.15 shows ESI mass spectra of a 3:1 
mixture of Hc with three different dsDNA sequences: D1, D2 and AT16. In the 
spectrum in Fig. 3.15(a) the most abundant ions are from free D1, [D1 + 6H]6+, [D1 
+ 7H]7+ and [D1 + 5H]5+ (see Table 3.1 for calculated m/z values).  There are also 
ions of low abundance from D1 + 1Hc and D1 + 2Hc.  Comparison of 3:1 mixtures 
of Hoechst 33258 with D2 and D1 revealed different relative abundances of 
stoichiometries. The ESI mass spectrum in Fig. 3.15(b) shows that the most abundant 
ions are from D2 + 1Hc. This stands in contrast to the data for D1 where ions from 
free dsDNA were the most abundant. This is in agreement with X-ray 
crystallographic [206] and solution studies [221] that suggest 1:1 binding of Hoechst 
and supports that Hc binds with greater affinity to D2 than with D1. There were also 
ions from free D2 and D2 + 2Hc. For a 3:1 mixture of Hc with AT16 (with more AT 
bases than D2), ions from free dsDNA were of lower abundance. In Fig 3.12(c) the 
most abundant ions are from AT16 + 2Hc (m/z 2123.5, 1769.7 and 2654.1 assigned 
to [AT16 + 2Hc +5H]5+, [AT16 + 2Hc +6H]6+ and [AT16 + 2Hc +4H]4+) with ions 
from free AT16 (m/z 1953.7 and 2441.9 assigned to [AT16 + 5H]5+ and [AT16 + 
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4H]4+) of very low intensity. There are also ions from one (m/z 1699.0, 2038.6 and 
2548.0 assigned to ions with 7+, 6+ and 5+ charges respectively), three (m/z 1840.5, 
2208.3 and 2760.2  assigned to ions with 7+, 6+ and 5+ charges respectively) and 
four (m/z 1911.2 and 2293.2 assigned to ions with 6+ and 5+ charges respectively) 
Hc molecules bound to AT16. This is probably due to the presence of more than one 
AT rich tract for the binding of Hoechst and is in agreement with the solution studies 
where up to six molecules of Hoechst bound to AT rich sequences [222]. 
 
The sequence selectivities of daunomycin for D1 and D2 were also studied. 
Daunomycin displayed higher selectivity towards D1 than D2. In ESI mass spectra of 
a 3:1 mixture of Dn with D1 the most abundant ion was [D1 + 1Dn + 5H]5+  whereas 
in case of D2, the most abundant ion was from free D2 ([D2 + 5H]5+ and [D2 + 
6H]6+; data not shown).  
 
The experiments described above show that the minor groove binders Hoechst 33258 
and distamycin prefer AT-rich sequences of dsDNA whereas the intercalator 
daunomycin has a preference for GC-rich sequences of dsDNA which is in 
agreement with other gas phase and solution studies. 
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Figure 3.15: Sequence selectivity of Hoechst 33258 for three different dsDNA 
sequences in 3:1 mixtures: (a) D1; (b) D2; (c) AT16. Free dsDNA (); dsDNA + 1 
Hc (); dsDNA + 2 Hc (); dsDNA + 3 Hc (); dsDNA + 4 Hc (). 
 
3.3.2 ESI-MS studies of complexes of Ru-based intercalators with dsDNA 
As for the drug/DNA studies above, non-self complementary 16 mer DNA sequences 
were selected for this work. The sequences of the three duplexes, with different 
numbers of GC and AT base pairs, used in this work were: 
D4, 5′- CCTCGGCCGGCCGACC -3′/5′-GGTCGGCCGGCCGAGG-3′; 
D5, 5′- CCTCATGGCCATGACC-3′/5′-GGTCATGGCCATGAGG-3′ and 
D6, 5′- CCTCAAAATTTTGACC-3′ /5′-GGTCAAAATTTTGAGG-3′. 
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The greater percentage of GC base pairs in D4 and D5 was expected to enhance 
binding by ruthenium compounds that can intercalate [116,189] whereas D6, with a 
greater AT base pair content, was expected to enhance binding by compounds that 
bind along the minor groove [13].   
 
The ruthenium compounds used here are all complexes based on Ru (II). The ligands 
are extended aromatic systems based on phenanthroline (see Fig. 1.5). All the 
compounds have the same charge and therefore are expected to show a similar 
degree of electrostatic attraction towards the anionic phosphodiester backbone of 
DNA. Consequently any significant differences in binding may arise from variations 
in their ability to act as intercalators or minor groove binders. The ability of these 
compounds to intercalate varies significantly owing to the replacement of one 
phenanthroline ligand in [Ru(phen)3]2+ with larger ligands than can be inserted into 
the DNA base stack more readily (refer to section 3.1 of this chapter). 
 
As the positive ion ESI-MS studies described above gave interesting results, the 
initial ESI-MS study involving metallointercalators was attempted in positive ion 
mode. All the four metallointercalators: [Ru(phen)3]2+, [Ru(phen)2(dpq)]2+, 
[Ru(phen)2(dpqC)]2+ and [Ru(phen)2(dppz)]2+ were studied at different drug/dsDNA 
ratios: 1:1, 1.5:1, 3:1 and 6:1 with D5. There were no ions observed from drug/DNA 
complexes at any of the above ratios in positive ion mode. In negative ion mode, ions 
from drug/DNA complexes were observed. Figures 3.16(a) and (c) show mixtures of 
[Ru(phen)2(dpq)]2+ or [Ru(phen)2(dpqC)]2+ with D5 at a ratio of 3:1 in positive ion 
mode, Fig. 3.16(b) and (d) show negative ion ESI mass spectra of the same mixtures. 
As clearly seen in Fig. 3.16(a) and (c) there are no ions present from drug/DNA 
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complexes, the only ions are from free D5 or single strands from D5. In negative ion 
mode under same experimental conditions (b) and (d), ions from D5, D5 + 1dpq, D5 
+ 2 dpq and D5 + 3dpq are observed. For the [Ru(phen)2(dpqC)]2+ D5 mixture, ions 
from  D5, D5 + 1dpqC, D5 + 2dpqC, D5 + 3dpqC and  D5 + 4dpqC are observed.  
These spectra were obtained within minutes of one another using the same samples 
for the positive and negative ion spectra. 
 
3.3.2a Where are the charges present on DNA in positive ion mode? 
The metallointercalators studied here have been shown to form complexes with 
dsDNA [26]. The apparent discrepancy between these studies and the results from 
positive ion ESI mass spectra raises an important question as to the validity of using 
ESI-MS to study non-covalent complexes. The differences observed between 
positive and negative ion spectra were particularly interesting. 
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Table 3.2: Calculated m/z for negative ions from free and complexed DNA with Ru-based intercalators. In all the metallointercalators/DNA 
complexes, 2 extra protons were lost (as compared to dsDNA) for one drug bound to dsDNA, 4 extra protons for two drugs, 6 extra for three 
drugs, 8 extra for four and 10 extra protons were lost for five drugs bound to dsDNA. 
 
Oligonucleotide/Complex Calculated m/z 
dsDNA 
  [D5-7H]7- [D5-6H]6- [D5-5H]5- [D5-4H]4- 
D5 +  1393.9 1626.4 1951.9 2440.1 
  [D5+1Ru-9H]7- [D5+1Ru-8H]6- [D5+1Ru-7H]5- [D5+1Ru-6H]4- 
[Ru(phen)3]2+ +1 1485.4 1733.1 2079.9 2600.2 
  [D5+2Ru-11H]7- [D5+2Ru-10H]6- [D5+2Ru-9H]5- [D5+2Ru-8H]4- 
 +2 1576.8 1839.8 2207.9 2760.2 
[Ru(phen)2(dpq)]2+ +1  1492.8 1741.8 2090.3 2613.1 
 +2  1591.7 1857.1 2228.7 2786.2 
 +3  1690.5 1972.5 2367.2  
 +4  1789.4 2087.8 2505.6 2441.9 
[Ru(phen)2(dpqC)]2+ +1  1500.5 1750.8 2101.1 2626.7 
 +2  1607.1 1875.1 2250.4 2813.2 
 +3  1713.7 1999.5 2399.6 2999.7 
 +4 1820.3 2123.9 2548.8  
[Ru(phen)2(dppz)]2+ +1  1499.9 1750.1 2100.3 2625.6 
 +2  1606.0 1873.8 2248.7 2811.2 
 +3  1712.0 1997.5 2397.2 2996.7 
 +4 1818.0 2121.2 2545.6  
 +5 1924.0 2244.9 2694.0  
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As already discussed (section 3.3.1b), positive charges in ESI mass spectra of DNA 
are thought to be present on nucleobases [111]. It is possible that the reason for the 
differences between positive and negative ion ESI-MS of metallointercalator/dsDNA 
mixtures could be due to the location of charge at different sites in positive and 
negative ion modes. Most likely, in positive ion mode, the charge is present on the 
bases whereas in negative ion mode the charge is present on the phosphate groups of 
the backbone. The metallointercalators studied here containing ruthenium are 
positively charged (ruthenium metal is in a 2+ oxidation state in all the 
metallointercalators studied). In positive ion mode, if the positive charge on the DNA 
is present on the bases (most abundant ion was the 6+ ion), it is possible that there is 
repulsion between the positive charges on the drugs and bases, causing the non-
covalent complexes to be less stable. In negative ion mode since the negative charge 
is present on phosphate groups, the positively charged intercalators do not experience 
any charge repulsion and ions are observed that correspond to drug/dsDNA 
complexes (Fig. 3.16). 
 
Similar observations were made in an earlier study performed in our laboratory 
(Beck and Kapur, unpublished results).  That study involved ESI-MS of complexes 
of different drugs: nogalamycin, daunomycin, ethidium bromide, hedamycin and 
retamycin with dsDNA. As in case of the metallointercalators, ethidium bromide is 
also positively charged at pH 8.5. In ESI-MS studies, it was observed that in a 3:1 
mixture of ethidium bromide and dsDNA, no ions from ethidium bromide were 
observed in positive ion ESI mass spectra whereas in negative ion mode 1-5 drug 
molecules were bound to 16 mer dsDNA.  
 
Chapter 3 
 96 
Figure 3.16: ESI mass spectra of reaction mixtures containing either 
[Ru(phen)2(dpq)]2+  ((a) and (b)), or [Ru(phen)2(dpqC)]2+  ((c) and (d)) with D5 in 3:1 
mixture. Positive ion mode, (a) and (c); negative ion mode, (b) and (d). Single 
strands of either strand (); free dsDNA (); dsDNA + 1 drug (); dsDNA + 2 
drugs (); dsDNA + 3 drugs (); dsDNA + 4 drugs (). 
 
Comparisons between ESI mass spectra of dsDNA alone and in the presence of 
positively charged drugs provide further evidence for the above proposal. For all the 
dsDNA sequences studied (D1, D2, D4, D5 and D6), for dsDNA alone, the ESI mass 
spectra contain ions with charge states: 5+, 6+ and 7+ or 5-, 6- and 7- in positive and 
negative ion modes, respectively (e.g. Fig. 3.3(b) and (c) show D1 in negative and 
positive ion spectra, respectively). In the presence of drugs however, in positive ion 
ESI mass spectra there are ions from drug/DNA complexes as well as free dsDNA 
with a charge state of 4+ (e.g. Fig. 3.8 shows Dst/D2 complexes in 1:1, 3:1 and 5:1 
mixtures in both ion modes). In contrast, in negative ion mode, the 4- charge state is 
not observed whether drugs are present or absent. This effect was seen for all drugs 
binding by intercalation and also for minor groove binders. This effect was not seen 
for cisplatin and it is understandable as it has a different mode of binding: strong 
coordinate bond with the N7 atoms of adjacent guanine bases. 
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Most likely, for drug/dsDNA complexes analysed in positive ion ESI mass spectra, 
the reason for free dsDNA gaining one less proton and displaying a 4+ charge state 
instead of a 5+ charge state could be due to the inability of nucleobase gain a proton 
owing to the presence of a positive drug molecule. If the drug experiences any 
repulsion during desolvation, it would dissociate from the DNA. Depending upon the 
desolvation stage the ion is in and whether it has access to solvent, it may gain a 
proton and carry a 5+ charge. Alternatively, if there is no solvent in the environment 
it will carry a 4+ charge in the gas phase. This effect is not observed in negative ion 
mode as the charges are present on phosphate groups on the DNA backbone and the 
drugs studied here likely interact with DNA by minor groove binding or 
intercalation. 
 
There is some further support for this proposal from the present study involving 
metallointercalators. Our results show that [Ru(phen)2(dpqC)]2+ has better binding 
affinity for dsDNA than [Ru(phen)2(dpq)]2+, consistent with other binding affinity 
studies of related compounds. As shown in Figure 3.16(b) and (d), negative ion ESI 
mass spectra of a 3:1 mixture of [Ru(phen)2(dpqC)]2+ with dsDNA show greater 
binding affinity for dsDNA than [Ru(phen)2(dpq)]2+. This is evidenced by the 
presence of ions corresponding to higher [Ru(phen)2(dpqC)]2+:dsDNA 
stoichiometries than in the [Ru(phen)2(dpq)]2+:dsDNA mixture. The presence of 
these ions supports that drug/DNA complexes are formed with different 
stoichiometries and are transferred successfully into gas phase. In contrast, in ESI 
mass spectra in positive ion mode there are no ions from drug/DNA complexes; only 
ions from free dsDNA are observed (Fig. 3.16(a) and (c)). This suggests that drugs 
are dissociating from the dsDNA in the mass spectrometer or that there are no 
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positively charged drug/dsDNA complexes. The latter proposal seems unlikely since 
positive ions from dsDNA are present, and the drugs themselves have a 2+ formal 
charge.  Furthermore, (Fig. 3.16(c)), the most abundant ion from dsDNA carried 4+ 
charges. The presence of this ion comments critically on the proposal that unstable 
positively charged dsDNA/drug complexes were formed but did not remain intact 
through the stage of mass analysis. In all +ve ion (and –ve ion) ESI mass spectra of 
this (and other) free 16 mer dsDNA sequences acquired under the conditions outlined 
in this work, the 4+ ion was of low to negligible abundance. We propose that, this 
ion is from dsDNA that was complexed with [Ru(phen)2(dpqC)]2+ in solution. In the 
gas phase after positive ion formation the [Ru(phen)2(dpqC)]2+ molecule(s) 
dissociated from the DNA as a result of repulsion between positively charged DNA 
bases and the drug. This dissociation event occurred once the DNA was desolvated 
and did not allow for the gaining of a proton from the solvent (Figure 3.17). 
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Figure 3.17: Proposed behaviour of dsDNA in positive ion ESI-MS in the gas phase 
and its interaction with drugs. (a) dsDNA alone carries a certain number of charges 
when analysed by ESI-MS (b) In positive ion ESI-MS, dsDNA-drug complex 
dissociates leaving different charges on both the molecules. 
 
3.3.2b Relative affinity of metallointercalators with different dsDNA sequences 
As negative ion mode gave results consistent with results expected from solution 
studies and since most of the literature concerning ESI-MS of DNA has used 
negative ion mode, subsequent studies of metallointercalator/DNA complexes were 
carried out in negative ion mode. ESI mass spectra were obtained of reaction 
mixtures containing different ratios of the metallointercalators ([Ru(phen)3]2+, 
[Ru(phen)2(dpq)]2+, [Ru(phen)2(dpqC)]2+ and [Ru(phen)2(dppz)]2+ and D5. The 
ruthenium:dsDNA ratios examined here were:  1:1, 1.5:1, 3:1 and 6:1. With an 
increase in the ratio of drug:dsDNA, there was an increase in the number of drug 
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molecules bound to D5. Figure 3.18 shows ESI mass spectra of mixtures of either 
[Ru(phen)2(dpq)]2+ or [Ru(phen)2(dpqC)]2+ with D5 at different ratios. At the 1:1 
ratio of [Ru(phen)2(dpq)]2+:D5 (Fig. 3.18 (a)) the most abundant ions were from free 
D5 at m/z 1626.5 and 1951.9 assigned to [D5 - 6H]6- and [D5 - 5H]5-, respectively 
(see Table 3.2 for calculated m/z values of drug/dsDNA complexes observed in this 
study). A small proportion of ions are from D5 + 1[Ru(phen)2(dpq)]2+ at m/z 1742.0 
and 2090.6 assigned to [D5 + 1[Ru(phen)2(dpq)]2+ - 8H]6- and [D5 + 
1[Ru(phen)2(dpq)]2+ - 7H]5-, respectively. At the same ratio, the 
[Ru(phen)2(dpqC)]2+/D5 mixtures showed similar results (Fig. 3.18(d)). Apart from 
ions from free D5 at m/z values stated above and from D5 + 1[Ru(phen)2(dpqC)]2+ at 
m/z 1751.0 and 2101.5 assigned to [D5 + 1[Ru(phen)2(dpqC)]2+ - 8H]6- and [D5 + 
1[Ru(phen)2(dpqC)]2+ - 7H]5-, a small percentage of ions were also observed from D5 
+ 2[Ru(phen)2(dpqC)]2+ at m/z 1875.7 assigned to [D5 + 2[Ru(phen)2(dpqC)]2+ - 
10H]6-. 
 
As the ratio of drug:D5 was increased to 3:1 (Fig 3.18, (b) and (e)) and 6:1 (Fig. 
3.18, (c) and (f)) the abundance of these ions also increased and ions from two, three 
and four drugs bound to D5 were also observed. It is also evident that 
[Ru(phen)2(dpqC)]2+  displayed greater affinity for D5 than [Ru(phen)2(dpq)]2+. This 
can be seen by reference to Fig. 3.18. At the ratio 3:1, the most abundant ions in 
spectrum 3.18(b) are from D5 + 1[Ru(phen)2(dpq)]2+ whereas at the same ratio for 
[Ru(phen)2(dpqC)]2+, (Fig. 3.18(e)), the most abundant ions are from D5 + 
2[Ru(phen)2(dpqC)]2+. Also at a ratio of 6:1, for [Ru(phen)2(dpq)]2+ the most 
abundant ions are from one and two [Ru(phen)2(dpq)]2+ bound whereas it is three 
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[Ru(phen)2(dpqC)]2+ bound to D5 for [Ru(phen)2(dpqC)]2+, (Fig. 3.18(c) and (f) 
respectively). 
 
Similar mixtures of [Ru(phen)3]2+ and [Ru(phen)2(dppz)]2+ with D5 were prepared 
and analysed. Negative ion ESI mass spectra of reaction mixtures containing various 
ratios of [Ru(phen)2(dppz)]2+/D5, or D5 alone are shown in Fig. 3.19. Uncomplexed 
D5 (Fig. 3.19(a)) showed ions at m/z 1626.5 and 1951.9, assigned to [D5–6H]6– and 
[D5–5H]5–, respectively. When the ratio drug D5 was 1.5 1 the ESI mass spectrum 
(Fig. 3.19(b)), showed ions of medium or high abundance attributable to free D5 and 
a complex in which one [Ru(phen)2(dppz)]2+ was bound to D5. Fig. 3.19(b) also 
shows ions of weak to medium abundance attributable to complexes containing two 
and three [Ru(phen)2(dppz)]2+ bound to D5. As the ratio of drug D5 was increased, 
the abundance of these ions also increased. When the ratio of drug D5 was 6 1, the 
most abundant ion in the spectrum (Fig. 3.19(d)) was from a complex containing four 
[Ru(phen)2(dppz)]2+ bound to D5. Also present in this spectrum were ions from three 
and five [Ru(phen)2(dppz)]2+ molecules bound to D5.  
 
Fig. 3.19(e) shows the spectrum of a solution containing a 20 1 ratio of [Ru(phen)3]2+ 
and D5. Despite the high ratio, the most abundant ion in the spectrum was assigned 
to free D5. The spectrum also contained ions of medium to high abundance from a 
complex containing one [Ru(phen)3]2+ bound to D5, and ions of low abundance from 
a complex containing two [Ru(phen)3]2+ bound to D5. [Ru(phen)2(dppz)]2+ displayed 
the greatest affinity for D5 among all the metallointercalators whereas [Ru(phen)3]2+ 
was least effective at binding dsDNA.  
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Figure 3.18: Negative ion ESI mass spectra of reaction mixtures containing D5 and either [Ru(phen)2(dpq)]2+ or [Ru(phen)2(dpqC)]2+ with D5 in 
a 3:1 mixture. Reaction mixture of [Ru(phen)2(dpq)]2+:D5 at 1:1, 3:1 and 6:1 in (a), (b) and (c) respectively. Reaction mixture of 
[Ru(phen)2(dpqC)]2+:D5 at 1:1, 3:1 and 6:1 in (d), (e) and (f) respectively. Free dsDNA (); dsDNA + 1 drug (); dsDNA + 2 drugs (); 
dsDNA + 3 drugs (); dsDNA + 4 drugs (). 
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Figure 3.19: Negative ion ESI mass spectra of reaction mixtures containing D5 and 
either [Ru(phen)2(dppz)]2+ or [Ru(phen)3]2+. (a) D5 alone; (b) [Ru(phen)2(dppz)]2+:D5 
= 1.5 1; (c) [Ru(phen)2(dppz)]2+:D5 = 3 1; (d) [Ru(phen)2(dppz)]2+:D5 = 6 1; (e) 
[Ru(phen)3]2+:D5 = 20 1. Free D5 ();D5 + 1 drug (); D5 + 2 drugs (); D5 + 3 
drugs (); D5 + 4 drugs (); D5 + 5 drugs (). 
 
These results are consistent with those obtained using other techniques, that showed 
that ruthenium(II) compounds containing the dppz ligand have the highest affinity for 
DNA of compounds of this type. For example, the binding constants for association 
of ∆ and Λ-[Ru(phen)2(dppz)]2+ with calf thymus DNA are 3.2 × 106 and 1.7 × 106 
M–1, respectively [198].  These values are significantly greater than those for binding 
of ∆ and Λ-[Ru(phen)3]2+ to calf thymus DNA, which are 9 × 103 and 1.1 × 104 M–1, 
respectively [223]. 
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A competition experiment was conducted to directly compare the binding affinities 
of the four metallointercalators with dsDNA D5. Six reaction mixtures were set up 
each containing two of the drugs at a ratio of 3:1 drug: D5. The reaction mixtures 
were set up as described in chapter 2 and ESI-MS analysis was performed. In 
summary, it was observed that dppz displaced all the other drugs, dpqC displaced 
dpq and [Ru(phen)3]2+, dpq displaced [Ru(phen)3]2+ and [Ru(phen)3]2+, was displaced 
by all the drugs. Figure 3.20 shows spectra from three of the reaction mixtures. Fig. 
3.20(a) shows the ESI mass spectrum of the reaction mixture containing 
[Ru(phen)3]2+ and [Ru(phen)2(dpq)]2+. Ions from only one and two 
[Ru(phen)2(dpq)]2+ molecules bound to D5 and free D5 were observed. In the case of 
competition between [Ru(phen)2(dpq)]2+  and [Ru(phen)2(dpqC)]2+ under the same 
conditions as above, ions from two, three, four and five [Ru(phen)2(dpqC)]2+  
molecules bound to D5 were observed (Fig. 3.20(b)), whereas for competition 
between [Ru(phen)2(dpqC)]2+  and [Ru(phen)2(dppz)]2+, ions from three, four and 
five [Ru(phen)2(dppz)]2+ bound to D5 were observed (Fig. 3.20(c)). 
 
These results showed that all the metallointercalators used in this study bind with 
dsDNA and each display different affinities and thus various stoichiometries with 
dsDNA. The order of binding affinities was: [Ru(phen)2(dppz)]2+ > 
[Ru(phen)2(dpqC)]2+  > [Ru(phen)2(dpq)]2+ > [Ru(phen)3]2+. This is consistent with 
the proposal that the drugs with more extended, planar ligands bind to dsDNA more 
readily than [Ru(phen)3]2+ (see section 3.3.2).  
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Figure 3.20: Competition experiments between the metallointercalators with duplex 
D5. Negative ion ESI mass spectra of 3:1 reaction mixtures containing D5 and two of 
the drugs: [Ru(phen)3]2+, [Ru(phen)2(dpq)]2+, [Ru(phen)2(dpqC)]2+ and 
[Ru(phen)2(dppz)]2+. (a) [Ru(phen)3]2+ and [Ru(phen)2(dpq)]2+ with D5, (b) 
[Ru(phen)2(dpq)]2+ and [Ru(phen)2(dpqC)]2+ with D5 (c) [Ru(phen)2(dpqC)]2+ and 
[Ru(phen)2(dppz)]2+ with D5. Free D5 ();D5 + 1 drug ();D5 + 2 drugs ();D5 + 
3 drugs ();D5 + 4 drugs ();D5 + 5 drugs (). 
 
These results are in agreement with those obtained using other techniques, that 
showed that ruthenium(II) compounds containing the dppz ligand have the highest 
affinity for DNA of compounds of this type [26,191,224,225]. Related ruthenium 
compounds also containing the extended planar ligands dpq, dpqC and dppz, but 
replacing 1,10-phenanthroline with 2,2´-bipyridine have binding constants for calf 
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thymus DNA of: 5.9 x 104, 8.5 x 104 and > 106 M-1 for dpq, dpqC and dppz, 
respectively [224].  
 
A summary of the data from ESI mass spectra showing the relative affinities of all 
the compounds for D5 is presented in Fig. 3.21(a). The graph was constructed using 
relative abundances from spectra of reaction mixtures containing a 6:1 ratio of a 
single ruthenium compound and D5. Relative abundances were obtained by dividing 
the combined ion current from the 5-, 6- and 7- ions (all the ions) assigned to a 
specific DNA complex, by the total ion current from all 5-, 6- and 7- ions from all 
the complexes and free dsDNA (if present). 
 
Figure 3.21(a) shows that [Ru(phen)2(dppz)]2+ and [Ru(phen)2(dpqC)]2+ formed the 
highest percentage of DNA complexes containing 4 and 5 molecules of the four 
ruthenium compounds studied. This suggests that these complexes had the greatest 
affinity for D5. Comparison of the data for the other metal compounds shows that 
[Ru(phen)2(dpq)]2+ had the next highest binding affinity, and [Ru(phen)3]2+ the lowest 
affinity towards D5. Similar results were obtained for the graphs representing 
metallointercalators with other duplexes, D4 and D6 (see Table 2.1) (Fig. 3.21(b) and 
(c) respectively). As seen in Figure 3.21(b) and (c) [Ru(phen)2(dpqC)]2+ and 
[Ru(phen)2(dppz)]2+ showed the highest affinity for dsDNA (D4 or D6) followed by 
[Ru(phen)2(dpq)]2+ and [Ru(phen)3]2+. Interestingly, on comparing the overall 
reactivity of these metallointercalators with three different duplexes, there was some 
indication of sequence selectivity. To study this in detail, graphs were plotted for 
each drug separately with three different duplexes using the same data as above, in 
Fig. 3.22. 
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Figure 3.21: Relative affinity of metallointercalators for D4, D5 and D6. Percentage 
of total ion abundance of complexes in reaction mixtures containing a 6:1 ratio of 
metallointercalator with either D5, D4 or D6 in (a), (b) or (c) respectively. 
[Ru(phen)3]2+ (),[Ru(phen)2(dpq)]2+ (),[Ru(phen)2(dpqC)]2+ () and 
[Ru(phen)2(dppz)]2+ (). 
 
Owing to low reactivity of [Ru(phen)3]2+ with DNA, a higher ratio (20:1) of 
drug/DNA was used. The results (Fig. 3.22(a)) showed that [Ru(phen)3]2+ formed a 
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higher percentage of complexes with 1 and 2 molecules bound to each DNA 
sequence, in particular to D5. As seen in the Figure 3.22(b), [Ru(phen)2(dpq)]2+ 
formed a higher percentage of complexes containing 2, 3 or 4 molecules bound to 
DNA in experiments with D5, compared to experiments with the other two duplexes. 
Similarly, [Ru(phen)2(dppz)]2+ and [Ru(phen)2(dpqC)]2+ showed a higher percentage 
of binding with D5 as compared to D4 and D6 (Fig. 3.22(b) and (c)). 
 
This shows that these metallointercalators displayed a preference for binding to DNA 
sequences in D5. Previous NMR studies showed that ∆-[Ru(phen)2(dppz)]2+ 
intercalates into DNA from the minor groove, particularly at purine–
purine/pyrimidine–pyrimidine sequences [32]. One of the principal mechanisms of 
binding of this compound to D5 may therefore involve intercalation into the 
GGCC/GGCC sequence in the middle of the duplex. Intercalation was also expected 
to be favourable with D4 owing to its high GC content. The lower degree of 
interaction observed may be a result of the binding sites in this duplex being too 
close to each other. Groove binding interactions between DNA and dpq may also 
occur, however the lower level of reactivity towards the AT rich duplex D6 suggests, 
but does not prove, that these are less important than intercalation. 
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Figure 3.22: Relative affinity of metallointercalators for D4, D5 and D6. Percentage of total ion abundance of complexes in reaction mixtures 
containing a 6:1 ratio of metallointercalator with three duplexes (except (a) where a ratio of 20:1 was used): (a) [Ru(phen)3]2+, (b) 
[Ru(phen)2(dpq)]2+, (c) [Ru(phen)2(dpqC)]2+  and (d) [Ru(phen)2(dppz)]2+. D4 (), D5 () and D6 (). 
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3.4 Conclusions 
In this chapter work in which ESI-MS was used to study different aspects of non-
covalent complexes involving dsDNA and dsDNA/drugs belonging to different 
classes has been described. In first part of this study, conditions were optimized for 
the analysis of dsDNA and dsDNA/drug complexes in positive ion ESI-MS. The 
stabilities of non-covalent complexes of the four drugs belonging to three major 
classes: daunomycin (an intercalator), distamycin, Hoechst 33258 (minor groove 
binders) and cisplatin (coordinate binder) with dsDNA were studied in the gas phase. 
This was carried out using three different ESI-MS techniques: thermal dissociation, 
in-source CID and CID (MS/MS). The results obtained in positive ion ESI-MS were 
closely followed and compared with negative ion ESI-MS that is more commonly 
used to study DNA and DNA/drug complexes. The results show that intercalators 
and minor groove binders stabilised dsDNA after binding and agree with other 
solution and gas phase studies. The binding of cisplatin to dsDNA did not enhance its 
stability. Sequence selectivities of Hoechst 33258 and daunomycin were probed with 
different dsDNA sequences and results clearly indicated the preference of Hoechst 
33258 for AT-rich sequences whereas daunomycin showed some preference for GC-
rich sequences. Different solution studies and other techniques have reported the 
same. This is the only study done so far on the stability of dsDNA and drug/dsDNA 
complexes using positive ion ESI-MS. 
 
The second part of this study involved the ESI-MS study of complexes of Ru-based 
metallointercalators with different sequences of dsDNA. Being the only second study 
involving metallointercalators, ESI-MS conditions were optimised for the analysis of 
dsDNA/metallointercalators. Relative binding affinities and sequence selectivities of 
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the four drugs used were studied with three different sequences of 16 mer dsDNA. 
Based on different stoichiometries of dsDNA/drugs obtained and results from 
competition experiments, the order of binding affinities was: [Ru(phen)2(dppz)]2+ > 
[Ru(phen)2(dpqC)]2+  > [Ru(phen)2(dpq)]2+ > [Ru(phen)3]2+. This is consistent with 
the proposal that the drugs with an extended planar structure bind to dsDNA more 
readily than compared with [Ru(phen)3]2+ with a smaller, non-extended 
phenanthroline ligand, and also agrees with other solution studies done with related 
ruthenium compounds containing the extended planar ligands dpq, dpqC and dppz.  
 
In summary, ESI-MS was successfully used to obtain stoichiometries and study the 
relative binding affinities of metallointercalators, however, limited structural 
information could be obtained using this technique. X-ray crystallographic studies 
have been carried out using ≤ 6 mer DNA sequences. These sequences do not reflect 
the structure of dsDNA as they cover less than one turn of a helix. Crystallization is 
complicated when longer sequences are used since complexes with several 
stoichiometries will be present. This heterogeneity is expected to inhibit crystal 
formation. This can be solved by using a low drug/DNA ratio, but even then there is 
a possibility of getting drug binding at different positions. These complications 
highlight the usefulness of competition experiments, where two or more drugs in a 
mixture can be analysed by ESI-MS that will give useful information based on the 
stoichiometries observed. 
 
 Furthermore, there was an interesting observation made owing to the difference in 
ESI mass spectra obtained from the same dsDNA/drug mixture in negative and 
positive ion mode. Based on several pieces of evidence, it is proposed that in positive 
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ion mode, the charges present on nucleobases of dsDNA cause complexes with 
positively charged drugs to be less stable. As this is one of the few studies of dsDNA 
in positive ion ESI-MS, more work and investigation with other drugs (with and 
without positive charge) and different dsDNA sequences is required before making 
any further conclusions. 
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Chapter 4: ESI-MS of θ-ε186 complex, a protein-protein complex 
from DNA polymerase III 
4.1 Introduction 
Non-covalent interactions involving proteins and other biomolecules play a key role 
in all the cellular processes such as replication, transcription, translation, cell 
signaling and homeostasis. Replication is a complicated process and has been studied 
extensively, especially in E. coli, since it serves as a relatively simple model for 
eukaryote replication [226]. Replication involves three steps: initiation, elongation 
and termination. There are two replication forks (Figure 4.1) formed during the 
replication process moving away from the origin in opposite directions. Leading and 
lagging strands are synthesized in a direction opposite to the movement of each 
replication fork.  
Figure 4.1: A cartoon representation of the replication fork. As seen in the figure, 
two daughter strands are being synthesized (red) in the 5′ → 3′ direction from the 
parent strand (blue). Proteins such as helicase, primase, pol III and pol I can also be 
seen carrying out different functions such as unwinding, stabilizing and synthesizing 
DNA. Adapted from [227]. 
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Replication is initiated at a 245 bp locus, known as the origin, oriC. There are many 
different proteins and molecules involved in carrying out this bidirectional process 
(5′ → 3′ on each complementary strand) (Fig. 4.1).  The protein DnaA is essential for 
initiation of replication as it binds specifically to a sequence at oriC and causes the 
DNA to melt (i.e. to separate into each strand). A hexameric helicase called DnaB 
unwinds the DNA with the help of another protein, DnaC in an ATP-dependent 
manner [228]. There are other proteins that take part in elongation and termination. 
Primase lays down an RNA primer necessary for DNA polymerase activity, and 
DNA polymerase III (pol III) is responsible for DNA synthesis. DNA polymerase I 
(pol I) removes the RNA primers and fills in the resulting gaps, while DNA ligase 
seals nicks in DNA strands. Single-stranded DNA binding protein stabilises single-
stranded DNA that has been unwound by helicase, and Tus binds to specific DNA 
sequences (TerA-G) terminating the DNA replication [229]. 
 
The Holoenzyme, DNA polymerase III (pol III) in E. coli is the most well studied 
polymerase both genetically and biochemically. It is very similar to chromosomal 
replicases in eukaryotes both in architecture and function. DNA polymerase III 
consists of 10 different subunits (17 proteins in all since several are repeated) and 
contains two polymerase cores that are capable of simultaneous replication in leading 
and lagging strands [226,230]. The catalytic core of pol III consists of three subunits: 
α, ε and θ, that are products of genes, dnaE, dnaQ and holE, respectively. The 
α subunit (130 kDa) is responsible for 5′ → 3′ polymerase activity, and ε (27.5 kDa) 
is a 3′ → 5′ proofreading exonuclease. The function of smaller subunit, θ (9 kDa), is 
still undetermined.  
Chapter 4 
 115 
4.1.1 Epsilon (ε) 
The two domains of ε have distinct functions; the N-terminal domain containing the 
amino acids 2-186 (ε186, 21 kDa) contains the exonuclease active site and the 
binding site for θ, whereas the C-terminal domain contains the residues (187-243) 
that include the α binding site [185]. The 3′ → 5′ proof reading exonuclease activity 
is also present in exonuclease domain of DNA polymerase I and DNA polymerase II 
belonging to the Pol A and Pol B families, respectively [231]. Exonucleolytic 
proofreading of mis-incorporated nucleotides by ε contributes to the high fidelity of 
DNA replication (4.6 million base pairs in E. coli are replicated with an error 
frequency ~10-10 per base pair). This high fidelity is maintained by base selection, 
proofreading and post-replicative mismatch repair by pol III [232]. In addition to the 
proofreading function, ε (28 kDa) plays an important role in the structure of pol III 
core as it interacts strongly with both α and θ [185,233,234].  
 
There has been considerable research on the replication fidelity of pol III, but little is 
known about the structural details of the polymerase subunit, α. Many groups have 
focused their research on the exonuclease domain, ε186, of ε since it plays an 
important role in DNA replication. The study of ε186 structure has posed a number 
of challenges owing to protein aggregation and insolubility at elevated temperatures. 
Some preliminary results with X-ray crystallographic and NMR spectroscopy 
techniques were reported by Hamdan et al. [184]. The structure of the whole 
ε subunit is not known, but recently the structure of ε186 was determined using a 
combination of NMR spectroscopy and molecular modelling [235] that agrees with 
the X-ray crystal structure at a resolution of 1.7-1.8 Å [236]. 
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The recent NMR data suggest that ε contains five β strands and six α helices.  The 
majority of the β strands are concentrated at the N-terminal organizing into a five-
stranded β sheet whereas the α helices are localized in the C-terminal region of ε186 
(Fig. 4.2) [235]. The preliminary three-dimensional characterization of the protein 
structure indicated that ε186 shows structural homology to the proofreading domain 
of the Klenow fragment (part of pol I) although they share a very limited sequence 
homology. Comparison of the crystal structure of the Klenow exonuclease domain 
and ε186 shows that there are four conserved acidic residues. These are, in 
ε186/Klenow, respectively: aspartic (D12/D355), glutamic (E14/E357) and two 
aspartic acid residues (D103/D424 and D167/D501) (Fig. 4.2) [235]. Modelling of a 
complex of ε186 with the trinucleotide ACG showed that nearly all the acidic 
residues in the catalytic core are in close contact with the DNA (Fig. 4.3) [235]. 
These residues play a crucial role in exonuclease activity in both Klenow 
exonuclease and ε186 [237-239]. 
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Figure 4.2: Active site of ε186, showing four acidic residues, D12, E14, D103, and 
D167 that play a critical catalytic role. Adapted from [235]. 
Figure 4.3: (a) Model of exonuclease domain of ε186 based on NMR data. (b) 
Model of the complex between ε186 and a trinucleotide ACG. Adapted from [235]. 
 
The X-ray crystallographic studies were performed on ε186 complexed with two 
active site Mn(II) ions and a molecule of thymidine-5′-monophosphate (TMP) at two 
pH values, 5.8 and 8.5 [236]. Hamdan et al. [236] confirmed the structural homology 
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in three families of DNA polymerases (central five stranded β sheet) as studied by 
DeRose et al. [235]. The exonuclease domain of pol I showed the highest structural 
and sequence resemblance to ε186 (16.4% sequence homology) [236]. Similarities in 
the active site of ε186 with DNA polymerase I and other polymerases in the Pol A 
and Pol B families suggest the conservation of the proofreading mechanism 
throughout evolution [236]. 
 
4.1.2 Theta (θ) 
A preliminary study of θ by circular dichroism revealed the presence of significant 
amounts of secondary structure. In agreement with this, NMR spectra of θ in solution 
were consistent with molten globule behavior with limited tertiary but substantial 
secondary structure [240]. Although much is known about the function of α and ε, 
the function of θ is unknown. Keniry et al. reported a solution structure of θ 
determined using triple resonance multidimensional NMR spectroscopy [183]. 
Although it is a small protein (Mr 8848 Da), θ still posed many challenges for 
interpretation of its NMR spectra; one third of the protein is unstructured, and some 
parts of the structured regions exhibit intermediate intramolecular exchange. The 
NMR data suggested that the surface of θ is bipolar, with one surface containing 
acidic residues and other surface containing basic residues. Furthermore, chemical 
shift studies indicated that a highly hydrophobic loop region of θ, Ala21-Glu29 
(AAAGVAFKE), might associate with ε. Recently, chemical shift mapping 
experiments by DeRose et al. defined a region in ε possibly involved in complex 
formation. The results provided a structural basis for stabilization of ε by θ [241]. 
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In Gram negative bacteria such as E. coli, the holE gene, encoding for θ is highly 
conserved. Furthermore, the replicative polymerases have the polymerase and 
proofreading activities on separate polypeptides. In contrast, in Gram positive 
bacteria and higher organisms, both the activities are present on the same polypeptide 
of their replicative polymerases and there is no other protein or subunit homologous 
to θ [241]. Hamden et al. recognized a region in the C-terminal of exonuclease I 
(from E. coli), a nuclease related to ε, that showed structural homology to θ, 
suggesting similarity in location and function [236]. These observations raise the 
question as to what is the function of θ. It is possible that θ is important in binding 
the separate polymerase and proofreading subunits of Gram negative polymerases 
together in close proximity. In Gram positive bacteria and higher organisms, θ is not 
necessary. 
 
In addition to this, many studies have shown that θ has a stimulation effect on ε186 
exonuclease activity and it is also suggested that θ may stabilise ε186 and this is 
discussed further below [183,185,233,234,240]. 
 
4.1.3 θ-ε186 complex 
The two subunits, θ and ε186, form a tight complex [185]. It was not long after the 
structural details of the two subunits constituting the θ-ε186 complex were reported 
[183,235,236], that further details of the interface between the two proteins in the 
complex have become available from experiments using 3D triple resonance NMR 
spectroscopy [241].  
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Comparison of the resonances from ε186, [235] either free or with θ in the complex 
suggested no significant structural changes occurred in ε186 after binding with 
θ [241]. Amide chemical shift experiments suggested that the ε catalytic site is a 
potential binding site between ε186 and θ. As shown in Fig. 4.4, the helix α1 and β-
strands 2 and 3 and the region at the beginning of α-helix 7 exhibited significant 
amide resonance shifts. Residues Lys158-Leu161 (KRTL) may also be significant 
for interaction of ε186 with θ [241]. 
 
Figure 4.4: Model of ε186 representing major chemical shifts. Color coding is used 
to show the changes after binding to θ. Color coding represents intensities of 
chemical shift changes (white for minimum and red for maximum chemical shift 
change). The side chains with green color show major shifts (±1.0 ppm) and side 
chains with blue color show minor shifts (±0.3 ppm). Adapted from [241]. 
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DeRose et al. [241] studied the stabilization of ε by θ using one of the ε mutants 
prepared by Taft-Benz and Schaaper [238]. This dnaQ49 mutation results from a 
V96G substitution in ε. This V96G variant is an unstable protein with a strong 
mutator phenotype even at low temperatures, which suggests that V96 plays a critical 
role in structural stabilization of wild type ε (unpublished data, quoted in [241]). In 
this work, model studies with ε186 indicated its important role in the binding surface 
of θ-ε. As seen in Fig. 4.5, V96 is present in a hydrophobic pocket of ε with L171 
and Y175 in helix α7. It was suggested that hydrophobic interactions of V96 with 
these residues are important in holding helix α7 in place, and that this is also 
important for the proper positioning of D162 and H162 in the catalytic core that are 
located on the same strand. 
Figure 4.5: Model of ε186 showing residue V96 in the hydrophobic pocket. This 
residue plays an important role in structural stabilization. Adapted from [241]. 
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4.2 Scope of this chapter 
ESI-MS has widespread routine use as a proteomics tool for primary structure 
determination and for characterization of purified proteins [242]. Application of ESI-
MS to detection and characterization of non-covalent complexes of biomolecules is 
not as well-established, but there are numerous examples of non-covalent 
interactions that have been studied in the gas phase including those between protein 
subunits, proteins and nucleic acids, and enzymes and substrates [147].  
 
The stability of the complex (dissociation constants), the types of non-covalent 
interactions (e.g. polar vs non-polar), and conformational changes in the binding 
partners upon complex formation are important when considering the mechanism of 
the biological action of biomolecular complexes (e.g. protein-protein, protein-DNA). 
There is a suite of biophysical techniques that can be applied to study these 
properties. These include monitoring changes in fluorescence or surface plasmon 
resonance for determination of dissociation constants, circular dichroism and NMR 
spectroscopy for following conformational changes, and NMR and X-ray 
crystallography for more complete structural elucidation revealing the nature of the 
interactions between the binding partners.   
  
In spite of advantages in speed and sensitivity, data obtained from ESI-MS studies 
need to be interpreted with caution. Firstly, the ionisation process itself might perturb 
equilibria [82]. Secondly, there is a paucity of information available concerning 
changes in the strength or specificity of non-covalent interactions that occur on 
transfer from the condensed to the gas phase during the ionisation process. The 
stabilities of complexes between biological macromolecules involve contributions 
from ionic, H-bonding, hydrophobic and van der Waals interactions. Several ESI-MS 
Chapter 4 
 123 
studies support the proposal that electrostatic interactions are strengthened in vacuo, 
while hydrophobic interactions are unaffected or weakened through loss of water 
during desolvation and/or ionisation [147].  For these reasons it is important to study 
the behaviour of non-covalent complexes that have been well-characterized in 
solution to enable comparisons with data obtained from ESI-MS experiments. 
 
Previously in our laboratory, as part of a study aimed at investigating the behaviour 
of non-covalent complexes on transferal from solution to the gas phase, ESI-MS was 
used to study the well-characterized Tus–Ter (protein–DNA) complex that 
terminates DNA replication in E. coli. It was shown that relative binding affinities of 
mutant Tus proteins for Ter dsDNA were the same in the gas phase as in solution, 
and similarly, that the relative binding affinities of Tus protein for various dsDNA 
sequences were unchanged on transferal to the gas phase. The X-ray structure of the 
complex shows there are substantial polar and electrostatic contacts between binding 
partners  [243]. Consistent with this, ESI mass spectra showed that the complex 
dissociated when treated with ammonium acetate at concentrations over the range 1–
2 M [146]. In the present study, ESI-MS is used to investigate the interactions 
between the two protein subunits of DNA polymerase III from E. coli: the θ subunit 
and the N-terminal domain (residues 1-185) of the ε subunit (ε186). 
 
In this work, ESI-MS has been used to supply a “snapshot” of components of 
mixtures of ε186 and θ. The stability of the θ-ε186 complex was studied under 
various solution and instrumental conditions. The behaviour of this complex was 
consistent with significant contribution of hydrophobic interactions to its stability, 
and contrasted with the previously reported behaviour of the Tus-Ter complex [146]. 
In addition, ESI-MS experiments suggested that the θ subunit is involved in 
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stabilization of ε186. This is consistent with earlier experiments in which θ was 
shown to stabilise ε against thermal inactivation [244]. 
 
4.3 Results and Discussion 
4.3.1 Preliminary experiments 
In this study, our first aim was to develop conditions to detect intact θ-ε186 complex 
in the Q-Tof2 mass spectrometer. As a starting point, the complex provided by Dr N. 
Dixon, and prepared for analysis by dialysis against 10 mM NH4OAc, pH 6.8 was 
studied under the same conditions developed by Kapur et al. for studying the Tus-
Ter complex [146]. The parameters used were: capillary voltage, 2500 V; skimmer 
cone voltage, 50 V; desolvation temperature, 240°C; source block temperature, 60°C. 
Under these conditions only the free subunits, θ and ε186 were detected (Fig. 4.6(a)). 
The calculated values of m/z for θ, ε186 and θ-ε186 complex are shown in Table 4.1. 
For θ, [M+4H]4+, [M+5H]5+, [M+6H]6+, [M+7H]7+ and [M+8H]8+ ions and for ε186, 
[M+5H]5+, [M+6H]6+, [M+7H]7+, [M+8H]8+, [M+9H]9+, [M+10H]10+ and 
[M+11H]11+ ions were observed. The calculated mass of the complex is 29434.9 Da. 
 
Attempts were made to observe ESI mass spectra of θ-ε186 complex using different 
solvent conditions. Solvents containing acetonitrile and methanol in NH4OAc at 
various pH values, but using the instrument parameters outlined above were 
employed. Organic solvents such as acetonitrile and methanol are known to denature 
proteins, but have been used to improve ionisation efficiency in MS in the presence 
of acetic acid or formic acid [245,246]. Since this initial work was aimed at obtaining 
high quality (high signal-to-noise, narrow peaks) mass spectra, we did not hesitate in 
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trying harsh conditions that might disrupt non-covalent interactions. In all the 
conditions used, there were ions of low or negligible abundance from the θ-ε186 
complex, and the spectra obtained were similar to that shown in Fig. 4.6(a). 
 
Table 4.1: Ions (m/z) expected in positive ion ESI mass spectra of the E. coli. 
proteins, θ, ε186 and the θ-ε186 complex. 
 
No. of 
charges 
Theta 
(θ) 
Epsilon 
(ε186) 
Complex 
(θ-ε186) 
0 8848.0 20586.9 29434.9 
1 8849.0 20587.9 29435.9 
2 4425.0 10294.4 14718.4 
3 2950.3 6863.3 9812.6 
4 2213.0 5147.7 7359.7 
5 1770.6 4118.4 5888.0 
6 1475.7 3432.1 4906.8 
7 1265.0 2942.0 4206.0 
8 1107.0 2574.4 3680.4 
9 984.1 2288.4 3271.5 
10 885.8 2059.7 2944.5 
11 805.4 1872.5 2676.9 
12 738.3 1716.6 2453.9 
13 681.6 1584.6 2265.2 
14 633.0 1471.5 2103.5 
15 590.9 1373.5 1963.3 
 
 
A spectrum of θ-ε186 complex with higher signal-to-noise ratio was achieved using 
100 mM NH4OAc, pH 8, as solvent, and using a lower desolvation temperature 
(150°C compared with 240°C). As seen in Fig. 4.6(b), the [M+11H]11+ and 
[M+12H]12+ ions from θ-ε186 complex were observed at low abundance. 
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A substantial increase in the abundance of ions from θ-ε186 complex was observed 
when the skimmer cone voltage was lowered from 50 V to 30 V (Fig. 4.6(c)). These 
ESI-MS conditions were used in subsequent experiments to detect the non-covalent 
θ-ε186 complex (protein-protein complex).  The effect of each variable was studied 
individually. Higher desolvation temperature (> 150 °C) disrupted the θ-ε186 
complex more readily. The effects of skimmer cone voltage and ammonium acetate 
as solvent are discussed in section 4.3.2. 
 
Most ESI-MS protein studies of protein-protein complexes have used NH4OAc or 
ammonium bicarbonate [89,143,149,163,247,248]. As discussed above proteins 
exhibit higher order structures at near physiological conditions and the choice of 
solvent for ESI-MS is important if these structures are to be maintained in the gas 
phase. In a detailed study of the role of NH4OAc in ESI mass spectra of proteins, it 
was suggested that NH4+ ions are the reagents that are responsible for multiple 
protonation in globular proteins, making ammonium acetate the solvent of choice to 
study proteins in their native state by positive ion ESI-MS [249]. 
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Figure 4.6: Positive ion ESI mass spectra of θ-ε186 complex acquired using 
different experimental conditions: (a) θ-ε186 at cone voltage 50 V, desolvation 
temperature 240°C, solvent 10 mM NH4OAc at pH 8; (b) θ-ε186 at cone voltage 50 
V, desolvation temperature 150°C, solvent 100 mM NH4OAc at pH 8; and (c) θ-
ε186 at cone voltage 30 V, desolvation temperature 150°C, solvent 100 mM 
NH4OAc at pH 8. In each experiment capillary voltage was kept constant at 2.5 kV. 
Ions from θ-ε186 complex (); Ions from free θ ();  Ions from free ε186 (). 
 
Felitsyn et al. summarized the source of charges on proteins in positive ion ESI mass 
spectra [249]. A typical protein in the presence of NH4OAc at near physiological pH, 
has both its acidic and basic side chains ionised. Generally, the concentration of 
NH4OAc used is at least 100 times higher than the protein concentration 
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(concentration of protein used, 10-5 M, and that of NH4OAc is 10-3 M) so there is an 
excess of salt ions in solution. In the source of the mass spectrometer, as the charged 
droplets carrying the protein reduce in size through desolvation, both types of side 
chains are neutralized by reacting with the counter ions in the evaporating aqueous 
solution according to equations 4a and 4b.  
protein….NH3+ + OAc- (aq)  →  protein …NH2 + HOAc                      (4a) 
 
protein….CO2- + NH4+ (aq)     →        protein …CO2H + NH3                     (4b) 
 
With further evaporation of the droplet, as there are fewer monolayers of solvent left 
over the protein, the charging of basic side chains at the surface of protein takes 
place. The bridged adducts are the most stable product, as shown in equation 4c. 
 
protein….NH2 + NH4+ →  protein …NH2-H-NH3+                                     (4c)                                                           
   
The protonation of the side chain occurs as shown in equation 4d and probably takes 
place in the later stages of desolvation. The presence of another basic side chain can 
lead to Coulombic repulsion. In that case, charge loss may take place as shown in 
equation 4e. 
     
protein … NH2-H-NH3+ →  protein …NH3+ + NH3    (4d) 
 
protein … NH2-H-NH3+ →  protein …NH2 + NH4+    (4e) 
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Generally the proteins have more than enough basic residues on their surface for its 
ionisation. Many workers have studied the correlation between molecular mass and 
the maximum charge state of proteins observed in the mass spectrometer [250-257]. 
Recently, Fernandez de la Mora [257] put forward an interesting proposal based on 
the data interpretation of the pioneer work of Tolic et al. [250] and Standing et al. 
[251]. Fernandez proposed that production of ions by electrospray from compact 
dendrimers and globular proteins in their native state with masses from 3.3 kDa up to 
1.4 MDa are produced by the charged residue mechanism (CRM) (Dole et al. [69]). 
The corresponding charges observed on the ions above were within 60-110 % of the 
Rayleigh limit ( see below) based on a solvent drop having the radius of the dry 
ion [257]. It was also proposed that in the presence of sufficiently volatile buffer ions 
in small drops (below the Rayleigh limit), the charge on the evaporating drop was 
determined by the ion evaporation model [78] and not by the Rayleigh limit. 
 
Felitsyn et al. also stated that the number of charges observed on a protein in the 
mass spectrometer was not only in close agreement with the CRM, but also the 
number of basic residues present on the protein surface with sufficient basicity to 
hold maximum charge (Fig. 4.7) [249]. Most of the proteins contain more than 
enough basic residues to hold the charge as predicted by CRM, e.g. carbonic 
anhydrase and cytochrome c [249]. An example of an exception is the case of pepsin, 
as it has large number of acidic residues (~30) as compared to basic residues (4) near 
its surface [249].  
 
 
 
 A droplet tends to have a spherical shape because of the surface tension of the liquid (σ). If the 
droplet is electrically charged, the electrostatic repulsion between ions might overcome the surface 
tension, leading to the droplet breakup. Rayleigh limit is an upper estimate for the charge in a droplet of 
radius r and is given in following equation: 
q2 = 64π2 ε r3 σ 
where ε is the permittivity of the medium surrounding the droplet. 
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Figure 4.7: Reproduction of a plot shown in [249]. Number of charges observed by 
mass spectrometry, Zobs, () highest, () lowest, under non-denaturing conditions 
vs the mass of the proteins (MDa), regenerated from data in the literature from [250] 
with the assumed radius of protein on the upper horizontal axis. The Fig. also 
includes data () from [258]. 
 
4.3.2 Stability of θ-ε186 complex     
The stability of the θ-ε186 complex in different concentrations of NH4OAc was 
studied under the conditions developed above for optimal detection of θ-ε186 ions. 
The complex was stable over a range of concentrations of NH4OAc at pH 8. The Z-
spray configuration of the instrument used in this study allowed the study of the 
complex at very high salt concentrations. The complex was studied in solutions 
ranging from 100 mM to 9000 mM NH4OAc. The relative abundance of the ions 
from θ-ε186 complex did not change significantly over all the concentrations studied 
(Fig. 4.8). It is seen clearly in Fig. 4.8, that the [M+11H]11+ (m/z 2676.9) and 
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[M+12H]12+   (m/z 2453.9) ions from θ-ε186 complex are the major ions present in all 
the spectra. The same experiment was repeated after one hour of incubation of θ-
ε186 complex in ammonium acetate and similar results were obtained (data not 
shown). The stability of the θ-ε186 complex in very high concentrations of 
ammonium acetate (up to at least 9000 mM), suggests that electrostatic interactions 
do not play a predominant role in maintaining the complex. 
Figure 4.8: Positive ion ESI mass spectra of θ-ε186 at different concentrations of 
NH4OAc, pH 8.0: (a) 100 mM NH4OAc, (b) 1000 mM NH4OAc, (c) 2000 mM 
NH4OAc, and (d) 9000 mM NH4OAc. Ions from θ-ε186 complex (); Ions from 
free θ ();  Ions from free ε186 (). 
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One difference observed when comparing the spectra shown in Fig. 4.8 is at higher 
concentrations (≥ 1000 mM). At the higher NH4OAc concentrations, the [M+11H]11+ 
ion is the most abundant (Fig. 4.8(b)-(d)) whereas at low concentrations, the 
[M+12H]12+ ion is the most abundant ion. One explanation for this observation is that 
at higher concentrations of NH4OAc, θ-ε186 complex is more folded (in its native 
state) so fewer charges are exposed on the surface. There is no literature available 
involving the study of protein complexes at such high salt concentrations (9000 
mM), so the influence on side chain basicities is unclear. One of the recent studies 
successfully used a high concentration of NH4OAc (≤ 3200 mM) to investigate the 
dissociation of Tus-Ter (protein-DNA) complex [146]. Being a protein-DNA 
complex, strong electrostatic interactions between the two biomolecules existed and 
NH4OAc was used to weaken the interaction and study the dissociation. 
 
 
The gas phase stability of the θ-ε186 complex was further studied by in-source CID 
(collision-induced dissociation) and CID (collision-induced dissociation) or tandem 
mass spectrometry (MS/MS) experiments (Figures 4.9 and 4.10, respectively). CID 
experiments have been used previously to study the gas phase stability of non-
covalent complexes [105,107,143]. In-source CID involves increasing the cone 
voltage and hence the acceleration of ions through the intermediate pressure region 
in the source.  
 
As seen in Figure 4.9, the θ-ε186 complex dissociated when the cone voltage was 
50-60 V (Fig. 4.9(c) and (d)). At cone voltages of 25 and 40 V, the predominant ions 
were from θ-ε186 complex (Fig. 4.9(a) and (b)). Previous in-source CID studies on 
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the Tus-Ter complex (protein-dsDNA) showed that it was stable at cone voltages up 
to 100 V [146] which was consistent with the higher degree of stability in gas phase 
of other protein-DNA complexes, [143] although it is difficult to make direct 
comparisons for complexes of different molecular weight and different charge states. 
 
Figure 4.9: Effect of increasing cone voltage on the ESI-mass spectra of θ-ε186 
complex. (a) 25 V (b) 40 V  (c) 50 V (d) 60 V. Ions from θ-ε186 complex (); Ions 
from free θ ();  Ions from free ε186 (). 
 
MS/MS (CID) experiments were performed by selecting the [M+12H]12+ ion (m/z 
2453.9) from the θ-ε186 complex as precursor ion, and studying its dissociation at 
different applied collision cell voltages. It was observed that with an increase in 
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collision cell voltage, the extent of dissociation of θ-ε186 complex was also 
increased. It can be seen in Fig. 4.10(a) at a collision cell voltage of 10 V, there is 
some dissociation of the [M+12H]12+ ion from θ-ε186 complex resulting in the 
[M+6H]6+ (m/z 1475.7) ion of θ and also the [M+6H]6+ (m/z 3432.1) of  ε186. This 
indicates that in the [M+12H]12+ ion from θ-ε186 complex, half the number of 
charges (6+) is carried by each subunit, θ and ε186. Despite the significant difference 
in masses (ε186 = 20586.9 and θ = 8848.0), each subunit carries 6+ charges. When 
ε186 and θ were studied in the mass spectrometer separately (Fig 4.15), the most 
abundant ions were the 10+ and 6+ ions, respectively. This may be due to the 
difference in the pI of each subunit (theoretical pI of ε186 and θ is 5.33 and 9.15 
respectively) or a difference in the charge distribution on dissociation of the θ-ε186 
complex in the gas phase. Higher dissociation was observed at elevated collision cell 
voltages (15, 20 and 25 V), [M+5H]5+ (m/z 1771.6 and 4118.4) and [M+7H]7+ (m/z 
1265.0 and 2942.0) ions from θ and ε186 respectively, were observed (Fig. 
4.10(b),(c), and (d) respectively).  
 
There is a lot of interest in the MS community regarding what happens to the charges 
in CID of protein complexes. MS/MS experiments have been used to determine 
whether complexes are non-covalent, based on the ease with which they dissociate, 
and can provide additional information on their composition and stoichiometry based 
on the subunit dissociation at higher collision energies [89,95,259]. There were no 
multimeric non-specific interactions (dimers, trimers or other non-specific 
combinations) observed between the subunits of θ-ε186 complex in any of the 
experiments in this study. 
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Figure 4.10: ESI-MS/MS of the ion at m/z 2453.9 of θ-ε186 complex. (a) 10 V (b) 
15 V  (c) 20 V (d) 25 V. Ions from θ-ε186 complex (); Ions from free θ ();  Ions 
from free ε186 (). 
 
4.3.3 Effect of organic solvents on θ-ε186 complex 
The results with high salt concentrations suggest that electrostatic interactions do not 
play a major role in stabilizing θ-ε186. This is consistent with NMR chemical shift 
mapping experiments  that suggested the hydrophobic residues in the sequence 
Ala21–Glu29 of θ (AAAGVAFKE) are involved in its association with ε [183]. The 
dissociation of the θ-ε186 complex under relatively mild interface conditions is 
consistent with the proposition that non-covalent interactions involving considerable 
hydrophobic interactions in the gas phase are not strengthened. During the ionisation 
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process, as the ions are desolvated, it has been proposed that removal of water 
decreases the driving force for hydrophobic interactions between binding partners 
[147]. The hydrophobicity of the interface in the θ-ε186 complex was probed using 
different organic solvents: methanol, ethanol, 1-propanol, 1-butanol, isopropanol, 
acetone and acetonitrile. Dissociation of the θ-ε186 complex as judged by ESI-MS 
was observed with an increase in the concentration of all the organic solvents. 
 
Figure 4.11 shows the positive ion ESI mass spectra of the θ-ε186 complex treated 
with methanol and 1-propanol in 100 mM NH4OAc, pH 8. At lower concentrations 
of organic solvents (Fig. 4.11(a), (b), (e) and (f)), the spectra show ions 
predominantly from complex () with ions of lower abundance from free θ () 
and free ε186 (). At higher concentrations of organic solvent (Fig. 4.11(c), (d), (g) 
and (h)), there was an increase in the intensities of ions from free θ and free ε186 and 
a decrease in the amount of complex. A similar effect was seen for all the organic 
solvents examined here (data not shown).  
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Figure 4.11: Effect of treatment of θ-ε186 complex with organic solvents. ESI mass spectra of θ-ε186 complex at different concentrations of 
methanol: (a) 1.0 M (b) 5.0 M (c) 9.0 M (d) 10.0 M. ESI mass spectra of θ-ε186 complex at different concentrations of 1-propanol: (e) 1.0 M (f) 
1.4 M (g) 1.8 M (h) 2.0 M. Ions from θ-ε186 complex (); Ions from free θ ();  Ions from free ε186 (). 
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In a preliminary study aimed at determining the effect of organic solvents on the 
stability of θ-ε186 complex, the concentration of organic solvent was increased by 1 
M increments (with the exception of 1-propanol and 1-butanol where the 
concentration was increased by 0.2 M each time) until ions of negligible intensity 
from the complex were observed. It was seen that the complex dissociated between 
9.0-10.0 M methanol, 5-6 M ethanol, 1.4-2.0 M 1-propanol, 1.0-1.4 M 1-butanol, 3-4 
M isopropanol, 4-5 M acetone and 4-5 M acetonitrile. 
 
A similar experiment was repeated for all the organic solvents but the dissociation 
was studied in more detail within the 1 M range of the solvent where the dissociation 
was observed. Fig. 4.12 gives the spectra showing the dissociation of the complex by 
acetonitrile (4-5 M) and ethanol (5-6 M).  
 
The data obtained above can be represented graphically. The intensity of ions from 
the complex (θ-ε186) as a percentage of the total intensity of all ions in a spectrum (θ 
+ ε186 + θ-ε186) was plotted against the concentration of the organic solvent (Fig. 
4.13). From the graph, the concentration of each organic solvent where 50% 
dissociation of complex was observed could be obtained. For primary alkanols, 
concentrations at which 50% of complex was dissociated were 9.0, 4.8, 1.7 and 1.1 
M for methanol, ethanol, 1-propanol and 1-butanol, respectively. The propensity to 
dissociate the complex increased with increasing dielectric constant of the primary 
alkanol as summarized in Table 4.2. 
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Figure 4.12: Effect of organic solvents on θ-ε186 complex. Positive ion ESI mass spectra of θ-ε186 complex at different concentrations of 
CH3CN: (a) 4.2 M (b) 4.4 M (c) 4.6 M (d) 4.8 M. Positive ion ESI mass spectra of θ-ε186 complex at different concentrations of ethanol: (e) 5.0 
M (f) 5.2 M (g) 5.4 M (h) 5.8 M.  Ions from θ-ε186 complex (); Ions from free θ ();  Ions from free ε186 (). 
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Figure 4.13: Effect of organic solvents on ions from θ-ε186 complex in ESI-MS. 
Percentage of the total ion intensity from θ-ε186 complex at different concentrations 
of organic solvents. Methanol (), ethanol (), 1-propanol (),1-butanol (), 
isopropanol (), acetone () and  acetonitrile (). 
 
Table 4.2: Effect of organic solvents on θ-ε186 complex. 
 
Organic 
Solvent 
Concentration 
(M) for 50% 
dissociation 
Concentration 
(v/v) % 
Dielectric 
constant 
[187] 
Methanol 9.0 36.0 32.6 
Ethanol 4.8 27.9 24.3 
1-Propanol 1.7 12.8 20.1 
1-Butanol 1.1 10.1 17.1 
Isopropanol 3.2 24.6 18.3 
Acetone 4.2 30.9 20.7 
Acetonitrile 4.4 23.2 38.8 
Water NA NA 78.5 
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The corresponding values for isopropanol, acetone and acetonitrile were 3.2, 4.2 and 
4.4 M, respectively. Acetonitrile has the highest dielectric constant as shown in Table 
4.2, and would be expected to be the least effective solvent in dissociating the 
complex if the dielectric constant were the only factor involved. This clearly is not 
the case, suggesting that other intrinsic physical and structural features of the 
solvents (such as H-bonding) may also be important.  
 
In summary, the above results suggest that organic solvents disrupt the non-covalent 
interactions that play an important role in the stability of the complex between the 
two subunits. As the non-polarity of the primary alkanols increased, the 
concentration of solvent required to dissociate the complex decreased. These results 
are supported by the observations made by Keniry et al. that suggested that a 
hydrophobic loop containing residues Ala21–Glu29 of θ (AAAGVAFKE) is 
involved in its association with ε [183]. 
 
In–source CID (collision-induced dissociation) experiments have been used 
previously to probe the gas phase stability of non-covalent complexes [107,115]. It 
was reasoned that if electrostatic interactions do not contribute overall to the stability 
of θ-ε186, that  changing the ionic strength of the solution would have little impact 
on the stability of the complex in CID experiments. In contrast, organic solvents 
would be expected to destabilise the complex. ESI mass spectra of θ-ε186 in 0.01, 
0.1 and 2 M NH4OAc, pH 8, or 0.01, 0.1 and 2 M ethanol in 0.1 M NH4OAc, pH 8, 
were acquired using the cone voltage range 20-60 V (increasing in 5 V increments). 
The total intensity of ions from the complex was expressed as a percentage of the 
summed intensities of all ions in the spectrum and plotted against the cone voltage 
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(Fig 4.14). In 0.01, 0.1, 2 M NH4OAc, pH 8, or 0.1 M ethanol in 0.1 M NH4OAc, 
the cone voltages required to cause dissociation of 50 % of the complex were 35.8, 
37.5, 40.5 and 32.5 V, respectively (Fig. 4.14). The data show that there was only a 
small change in the cone voltage required for 50% dissociation of the complex in the 
different solutions, and that θ-ε186 was marginally more stable when the solution 
was of higher ionic strength. The presence of 0.1 M ethanol in the mixture had a 
significant effect on stability of the complex and the complex dissociated more 
readily with an increase in the concentration of ethanol from 0.01 to 2 M ethanol. 
 
An interesting observation was made in this study. Significant changes in the 
dissociation of the complex were observed when the desolvation gas was at low 
pressure. The desolvation gas was nitrogen gas here that was delivered as a coaxial 
sheath to the nebulised liquid spray by the desolvation nozzle. It was seen that the 
complex dissociated at a lower concentration of the organic solvent as compared to 
the studies done when the gas pressure of desolvation gas was in usual or “normal” 
range. For isopropanol and 1-butanol, significant dissociation of the complex was 
observed at 2.2 M and 0.8 M respectively as compared to 3.2 M and 1.1 M under 
normal conditions (Table 4.2) (data not shown). To be consistent the above results 
were repeated in the normal conditions of desolvation gas pressure. All the ESI mass 
spectra shown here were acquired under normal conditions of desolvation gas 
pressure and results were reproducible. 
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 Figure 4.14: Effect of cone voltage on ions from θ-ε186 in different concentrations, 
either 0.01, 0.1 or 2 M of NH4OAc, pH 8, or 0.1 M ethanol in 0.1 M NH4OAc, pH 8. 
 
Furthermore, the increasing organic solvent composition of the solvent shifted the 
charge distribution to lower values of m/z. Loo et al. [85] first showed the 
denaturation of proteins in the presence of organic solvents by ESI-MS. In a recent 
study, H/D exchange followed by ESI-MS and CD spectroscopy was used to show 
that with progressive increase in the concentration of methanol (more than 35%), 
myoglobin lost its tertiary structure and finally goes into a helical denatured state 
[246].  
 
The data in Figures 4.11 and 4.12 clearly show, at higher concentrations of organic 
solvents, as the complex dissociated (), ion intensity from free subunits, θ () and 
ε186 () subsequently increased. This indicates that non-covalent interactions that 
play an important part in maintaining the complex were weakened with the increase 
in the concentration of organic solvents that led to the subsequent dissociation of the 
complex. These data (Fig. 4.11 and 4.12) also show that there was no significant 
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change in the charge state distribution of the two free subunits (only ion intensity 
was increased showing progressive dissociation of θ-ε186 complex with 
concentration). 
 
Organic solvents perturb the aqueous environment of proteins and protein complexes 
and lead to unfolding of proteins from their native form [260-262]. In a circular 
dichroism study by Wilkinson et al. [262], the lowering of the dielectric constant by 
addition of alcohol resulted in hydrophobic interactions of solvent with protein that 
caused conformational changes. The conformational changes involved the full 
exposure of methionine and tyrosine residues to the solvent that are buried in the 
native conformation, and an increase in α-helix content. Similar observations have 
been made by other workers [263,264].  
 
While it seems likely that the dissociation of θ-ε186 complex as judged by ESI-MS 
was caused by disruption of non-covalent (non-polar) interactions on addition of 
organic solvents, there are other factors to be considered, including differences in 
response factor, structural changes and/or precipitation of one of the mixture 
components. 
 
(i) Response factor 
The extent of dissociation could be over-estimated if increasing concentrations of 
organic solvents increase the relative “response factor” for the free subunits (θ and 
ε186). Relative responses of analytes (response factors) play an important role in the 
electrospray process [265,266] and are proportional to the evaporation rates of 
solvent from the analytes. According to the proposed equilibrium partitioning model 
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of Enke and co-workers [267], ions are produced from molecules present at the 
surface of the droplet during the desolvation process. Response factor is dependent 
on the concentration of the analyte; at micromolar and lower levels a higher 
proportion of analyte ions can more easily make it to the surface whereas at higher 
concentrations there is competition among the analyte ions for surface access [267]. 
 
(ii) Structural change in either or both of the subunits 
A second possibility is that at higher concentrations of organic solvents, θ and/or 
ε186 undergoes a structural change leading to the decreased stability of the complex 
that is independent of the interface between the two subunits. The denaturation of 
proteins in different organic solvents has been studied using ESI-MS by Loo et al. 
[85]. 
 
The above possibilities (i) and (ii) could occur simultaneously. The possibilities were 
tested by acquiring ESI mass spectra of free θ and free ε186 separately under 
identical experimental conditions to those where θ-ε186 complex was studied (100 
mM NH4OAc, pH 8.5). The concentration of θ was kept constant while organic 
solvent concentration was varied; these data are shown in Fig. 4.15. The data (Fig. 
4.15(a)-(d)) show that the mass spectrum of θ was unchanged at concentrations of 
ethanol up to 10 M. Although the θ-ε186 complex dissociated in 5-6 M ethanol, the 
ion current from θ was stable in ethanol up to 10 M. The effect of concentrations 
above 10 M was not studied. These results were reproducible, and θ  ion current was 
stable in all the organic solvents used in this study (data not shown).  
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In ESI mass spectra of ε186 slightly higher ion currents were observed when the 
ethanol concentration of the solution was increased up to 2 M. Similar observations 
were made for methanol (4 M), 1-propanol (1 M), acetonitrile (1 M), isopropanol (1 
M) and acetone (2 M). These observations are consistent with the proposal that 
detection of ions is enhanced as evaporation of solvent droplets surrounding ions in 
the electrospray is facilitated. However, as the ethanol concentration was increased to 
2 M and above (4 M for methanol, 1 M for 1-propanol, 1 M for acetonitrile, 1 M for 
isopropanol and 2 M for acetone) a dramatic decline in ion current was observed for 
ε186.  
 
The effect for ε186 is illustrated in Figures 4.15(e)-(h). At lower ethanol 
concentrations less than and equal to 3 M (Fig. 4.15(e) and (f) respectively) the ion 
current is similar, but at the higher concentration of 4 M, (Fig. 4.16(g)), there is a 
dramatic decrease in the ion current and at 5 M, (Fig. 4.16(h)), there is no ion current 
from ε186. This significant decrease in the ion current of ε186 (between 4 and 5 M) 
is in the same range where dissociation of θ-ε186 complex was observed (Fig. 4.12) 
in ethanol. This effect was reproducible and was also observed for the other organic 
solvents (data not shown).  These results are consistent with a change in structure of 
ε186 at the critical concentration of organic solvent (more below). 
 
(iii) Precipitation (associated with a structural change) of either of the subunits 
The structural change may result in a decrease in solubility (precipitation) of ε186 
precluding its transfer to the gas phase. It is also possible that soluble aggregates of 
ε186 may form that are not readily ionised. The possibility that θ-
ε186, ε186  and/or θ might be unstable with respect to precipitation under the 
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conditions of the ESI-MS experiments was tested by monitoring the absorbance at 
360 nm of θ-ε186, ε or θ in each of the solvent mixtures containing methanol, 
ethanol or 1-propanol at concentrations just above or just below the critical 
concentration over a 20 min time period. The concentrations of alkanols used in this 
experiment were 8.0 M and 10.0 M for methanol, 4.0 M and 5.0 M for ethanol and 
1.6 M and 2.0 M for 1-propanol. 
 
When θ (alone) was treated with the alkanols in 0.1 M NH4OAc, pH 8, at 
concentrations above or below the critical concentration, no increase in A360 was 
observed over 20 min (Figure 4.16). This stability of θ was also observed at high 
concentrations of the alkanols (e.g. 10.0 M ethanol). In contrast, some precipitation 
of ε186 as shown by an increase in A360 was observed within 5 min of treatment with 
either 1.6 or 2.0 M 1-propanol. The increase in A360 observed for 1.6 M 1-propanol 
was slower than for 2.0 M 1-propanol (Fig. 4.16). Similar results were reproducibly 
obtained for the other alkanols. 
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Figure 4.15: Effect of ethanol on ESI mass spectra of θ and ε186. θ in different concentrations of ethanol: (a) 1.0 M (b) 3.0 M (c) 5.0 M (d) 10.0 
M. ε186 in different concentrations of ethanol: (e) 1.0 M (f) 3.0 M (g) 4.0 M (h) 5.0 M. Also shown (top left corner in each spectrum) is the ion 
current from the most abundant ion in the spectrum. Ions from free θ (); Ions from free ε186 (). 
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Figure 4.16: A360 of the θ-ε186 complex and its binding partners in different 
concentrations of 1-propanol. 
 
Based on these results a working hypothesis was put forward to explain the 
interaction between θ and ε186 under different conditions and is represented in Fig. 
4.17. The binding of θ and ε186 in NH4OAc (pH 8), forms a tight complex that is 
quite stable even at very high salt concentrations (up to 9000 mM NH4OAc, Fig. 
4.8). A stable ion current from θ at high concentrations of all the organic solvents 
studied (Fig. 4.15(a)-(d)) shows that it is quite stable and is ionised in those 
conditions. In contrast, the ion current from ε186 reduces dramatically near the 
critical concentration of all the organic solvents studied (Fig. 4.15(e)-(f)) which 
suggests that it changes structure and is not detected in the mass spectrometer either 
as a result of formation of a soluble aggregates that are not readily ionised and/or 
because of precipitation. 
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Figure 4.17: Working hypothesis to explain the effect of organic solvents on θ-ε186 complex and its two subunits. (a) θ and ε186 in NH4OAc 
form a complex; (b) no change in θ is observed at higher than the critical concentrations of organic solvents; (c) ε186 changes structure and is not 
detected in mass spectrometer; (d) would there be any complex formed when ε186 is treated with the critical concentration and mixed with θ in 
NH4OAc? 
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This also raised a question as to whether there would be any complex formation if ε 
is treated with an organic solvent at higher than the critical concentration and is 
mixed with θ in NH4OAc. 
 
4.3.4 Stabilization of epsilon (ε186) by theta (θ) 
The working hypothesis was tested by carrying out another set of experiments 
(Section 2.2.5) as follows: 
(a) ε186 was pre-treated with alkanol, followed by addition of θ (in NH4OAc); 
the solution was mixed and spectra were acquired immediately (within one 
minute of mixing). 
(b)  θ was pre-treated with alkanol, followed by addition of ε186 (in NH4OAc); 
the solution was mixed and spectra were acquired immediately. 
(c) A control was set up where both θ and ε186 (in NH4OAc) were added, the 
solution was mixed, and spectra were acquired immediately without any 
alkanol present. 
 
These experiments were carried out using the first three alkanols in the primary 
alkanol series. This work was not pursued with 1-butanol, since it was not 
completely miscible in water at higher concentrations (>1 M). The effect of the 
alkanols was studied at two concentrations: first at lower than the critical 
concentration (< 4.8 M for ethanol, <1.7 M for 1-propanol and <9.0 M for methanol), 
where more than half of the complex was still intact, and second, at higher than the 
critical concentration, where less than half of the complex was intact. In the studies 
done separately on θ and ε186 (Section 4.3.3), it was observed that at higher 
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concentrations of alkanols, there was no change in ion current from θ but a decrease 
in ion current from ε186. This suggested that θ is stable at high concentrations of 
primary alkanols, whereas ε186 is stable only at lower concentrations but gets 
unstructured progressively with an increase in the concentrations of alkanols. 
 
As described above, in 1.6 M 1-propanol (in 100 mM NH4OAc, pH 8.0) more than 
half of the θ-ε186 complex was intact (Table 4.2). The complex was observed in all 
the three stages of the experiment outlined above. As seen in Fig. 4.18(a) where ESI 
mass spectra of θ-ε186 in NH4OAc were obtained, the majority of the ions are from 
the complex as previously observed (Fig. 4.6(c)). In the experiments where either 
ε186 or θ were pre-treated with 1.6 M 1-propanol (Fig. 4.18(b) and (c), respectively) 
ESI mass spectra were also predominated by ions from the complex indicating that 
both subunits are still structured and the order of mixing of the subunits does not 
make any difference.  
 
The same experiments were carried out using 1.8 M 1-propanol (more than the 
critical concentration) and dramatic differences were observed. At this concentration 
of 1-propanol more than half of θ-ε186 complex was dissociated (Table 4.2), and in 
ESI mass spectra of θ and ε186 separately, there was significant ion current observed 
from θ whereas no ion current from ε186. This suggested that the structure of ε186 
had been altered. Figure 4.18(d) shows again the control spectrum of θ-ε186 in 100 
mM NH4OAc, pH 8.0, in the absence of any alkanol. The most abundant ions are 
from θ-ε186 complex. When ε186 was pre-treated with 1.8 M 1-propanol, no ions 
from θ-ε186 were observed. Furthermore, no ions from ε186 were observed (Fig. 
4.18(e)) consistent with the results above that show that ε186 is unstable at this 
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concentration of 1-propanol. In contrast, when θ was pre-treated with 1.8 M 1-
propanol, ions from θ-ε186, θ and ε186 were observed in ratios consistent with those 
observed when θ-ε186 was prepared in 100 mM NH4OAc, pH 8.0 (no alkanol) 
followed by addition of 1-propanol to 1.8 M. A similar effect was seen with the other 
primary alkanols, methanol and ethanol. The two concentrations for methanol were 8 
and 10 M whereas in case of ethanol, it was 4 and 5 M (data not shown). All the 
results were reproducible. 
 
In these experiments, pretreatment of the subunits with the alkanols lasted <1 minute. 
In another experiment, θ, ε186 and θ-ε186 were pretreated separately at more than 
the critical concentration of the alkanols for 3 hours, followed by addition of its 
binding partner and immediate MS analysis. The same results were observed as for 
the short pretreatment period; complex was observed when θ was pretreated with 
alkanol and ε186 was added later, and no complex was observed if the order was 
reversed (data not shown). This suggests the dynamic nature of θ in stabilizing ε186 
immediately as it enters the mixture. So in the short time before ε186 is unstructured 
by alkanol, θ acts as a “chaperone” and forms a complex. This behaviour was probed 
further by monitoring the mixtures for a longer period of time. 
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Figure 4.18: Stabilization of ε186 by θ. (a) Control, θ and ε186 (in NH4OAc) without any alkanol; (b) ε186 treated with 1.6 M 1-propanol and 
θ (in NH4OAc) added later; (c) θ treated with 1.6 M 1-propanol and ε186 (in NH4OAc) added later; (d) Control, θ and ε186 (in NH4OAc) 
without any alkanol; (e) ε186 treated with 1.8 M 1-propanol and θ (in NH4OAc) added later; (f) θ treated with 1.8 M 1-propanol and ε186 (in 
NH4OAc) added later.  Ions from θ-ε186 complex (); Ions from free θ ();  Ions from free ε186 (). 
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The experiment involving θ and ε186 at more than the critical concentration of 1-
propanol (1.8 M) was repeated and monitored for 9 hours. Fig. 4.19 shows the results 
after 9 hours. That is, the three experiments described in section 4.3.4 were repeated, 
but ESI mass spectra were acquired at various time intervals up to 9 hours after the 
separate subunits were mixed. There was no change with time in the control 
experiment (Fig. 4.19(a)). This indicates that θ-ε186 is stable in 100 mM NH4OAc, 
pH 8.0 over a period of at least 9 hours.  
 
In the experiment where the effect of 1.8 M 1-propanol was studied and ε186 was 
pre-treated with alkanol, no significant change was observed (Fig. 4.19(b)). This 
spectrum is similar to that obtained in Fig. 4.18(e). This shows that θ remained stable 
in 1.8 M 1-propanol for up to 9 hours. In the mixture where θ had been briefly 
pretreated with 1.8 M 1-propanol followed by addition of  ε186 (small volume so 
that the concentration of 1-propanol was not changed significantly) the complex 
formed initially in the amounts observed when 1-propanol (1.8 M) was added to pre-
formed θ-ε186 complex (Fig. 4.11(g)). When this mixture was allowed to stand at 
room temperature for 9 hours the complex progressively dissociated (Fig. 4.19(c)). 
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Figure 4.19: Stabilization of ε186 by θ monitored after 9 hours. (a) Control, θ and 
ε186 (in NH4OAc) without any alkanol; (b) ε186 treated with 1.8 M 1-propanol and 
θ (in NH4OAc) added later; (c) θ treated for with 1.8 M 1-propanol and ε186 (in 
NH4OAc) added later. () Ions from θ-ε186 complex; () Ions from free θ; () 
Ions from free ε186. 
 
The same experiment was carried out using more than the critical concentration of 
ethanol (5 M). The reaction was monitored for up to 12 hours. Similar observations 
were made as for 1-propanol at a concentration of 1.8 M. As seen in panel I of Fig. 
4.20, complex is formed when θ is first treated with 5 M ethanol (higher than critical 
concentration) and ε186 is added later. When the mixture was allowed to stand, with 
time the complex dissociates, with considerable dissociation with in the first 3 hours 
(Fig. 4.20(a)-(c)). A negligible amount of θ-ε186 complex is observed when the 
order of addition is reversed i.e. when ε186 is first treated with 5 M ethanol and θ is 
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added later (Fig. 4.20(e)-(h)). The results strongly suggest that ε186 is stabilised by 
θ.  
  
Fig. 4.21 summarizes an hypothesis explaining the effect of alkanols on the θ-ε186 
complex. When θ-ε186 is preformed and treated with alkanol it dissociates into its 
constituent subunits as judged by ESI-MS (Fig. 4.21(a)). The initial snapshot 
(relative amounts of complex and free subunits) of the mixture, depends in part on 
the organic solvent concentration and presumably on the relative times taken for θ to 
sequester and stabilise ε186 compared with the time taken for a structural 
change/precipitation of ε186. Over the short time frame of these experiments, ions 
from θ as well as ions of low abundance from ε186 were observed in ESI mass 
spectra (Fig. 4.21(a)). When ε186 is pre-treated with alkanol (above the critical 
concentration), no complex is formed (Fig. 4.21(b)) and ions from ε186 are not 
observed in ESI mass spectra. In contrast, when θ was pre-treated with alkanol under 
the same conditions before addition of its binding partner ε186, some the complex 
was formed as judged by ESI-MS. This observation suggests that under the 
experimental conditions θ is able to bind and stabilise a significant amount of the 
ε186 that is added to the solution before ε186 can undergo the structural change 
induced by the alkanol. The complex dissociates with time (over some hours), 
however, as ε186 experiences the impact of solvent. 
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Figure 4.20: Stabilization of ε186 by θ monitored with time. In panel I, θ was treated with 5 M ethanol and ε186 (in NH4OAc) added later and 
analysed by ESI-MS after different time intervals and in panel II, ε186 was treated with 5 M ethanol and θ (in NH4OAc) added later. (a), (e) 0 
min (within <1min.); (b), (f) 30 min; (c), (g) 3 hours, and (d), (h) 12 hours. () Ions from θ-ε186 complex; () Ions from free θ; () Ions 
from free ε186. 
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Figure 4.21: Representation of the working hypothesis (continued) explaining the effect of organic solvents on θ-ε186 complex and its two 
subunits. (a) θ-ε186 complex in higher than critical concentration of organic solvents is observed with significant amounts of dissociation; (b) no 
θ-ε186 complex is formed when ε186 is first treated with higher than critical concentration of organic solvents and θ is added later (in NH4OAc); 
(c) complex is formed when θ is first treated with higher than critical concentration of organic solvents and ε186 is added later, suggesting that θ 
stabilises ε186 and with time the complex dissociates. 
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4.4 Conclusions 
This study describes a novel use of ESI-MS in taking a snapshot of the equilibrium 
position of a complex of two subunits of DNA polymerase III. Instrument and 
solvent conditions were optimised for ESI-MS detection of the θ-ε186 complex. The 
remarkable stability of θ-ε186 complex under high salt conditions suggests that 
electrostatic interactions are not important in the maintenance of this complex (cf an 
earlier study of Tus-Ter). The stabilities of the complex in different organic solvents 
were also tested. The complex dissociated in all the organic solvents and the 
propensity to dissociate the complex increased with increasing dielectric constant of 
the primary alkanol. The concentration at which 50% of the complex was dissociated 
was measured and called the “critical concentration”. 
 
Experiments using organic solvents to dissociate θ-ε186 complex, suggested that 
hydrophobic interactions may be involved in binding but were complicated by 
changes in the structure/solubility of ε186.  Under the experimental conditions, the 
instability of ε186 was revealed by the dramatic diminishing of ion current in ESI 
mass spectra over small concentration range of each organic solvent. Binding with 
the θ subunit was shown to protect ε186 from the effects of organic solvents.  
 
 In mixtures where ε186 had been pre-treated for 1 min with an alkanol at higher 
than the critical concentration, the ESI mass spectrum showed no ions from either 
ε186 or complex. In the mixture where θ had been pre-treated with an alkanol at 
higher than the critical concentration followed by addition of ε186, the spectrum 
obtained showed the amount of complex present was comparable to that observed in 
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control mixtures in the absence of alkanols. When the mixture was left at room 
temperature for an extended period of time, the ESI mass spectrum contained no ions 
from the complex. ESI mass spectra acquired at various time points up to 9 h, 
showed that the complex progressively dissociated over the time period. The 
decreasing amount of complex with time may reflect the effects of an equilibrium 
between free ε186, free θ and θ-ε186 complex. When ε186 is free from the complex 
it experiences the critical concentration of solvent, and undergoes a structural change 
that prevents its association with θ. Consistent with the observations described 
above, ions from ε186 are not evident in ESI mass spectra once this change occurs; θ 
however, remains stable under these conditions. 
 
The function of θ in the E. coli replisome is unknown; no enzymatic activity has 
been assigned to the subunit. Several studies have suggested a role for θ in the 
stabilisation of ε. Structural stabilisation has been evidenced by biochemical studies 
in which the exonuclease activity of both ε186 and ε was increased in the presence of 
θ [185,233]. This was supported by recent NMR chemical shift mapping results with 
V96G mutant of ε186 that suggested N-terminal residues of helix α7 in ε186 interact 
with θ for stabilisation [241]. Furthermore, θ has been shown to stabalise ε186 by 
~14°C against thermal inactivation [244]. This is consistent with the ESI-MS results 
obtained in this study showing θ subunit is involved in stabilization of ε186. 
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Chapter 5: A study of the interaction of cisplatin with 
oligonucleotides by enzymatic digestion and ESI-MS 
5.1 Introduction 
Cisplatin (Figure 1.7(a)), a platinum-based coordinate complex is one of the most 
widely used and extensively studied anticancer drugs that bind DNA. The historical 
background of cisplatin, its modification of DNA, recognition of modified DNA by 
HMG proteins and anti-tumour activities have already been covered in detail (section 
1.3.3). 
 
It has been well established by different studies that cisplatin binds to two adjacent 
purines on a single DNA strand (~ 65% and 25% GpG and ApG, respectively of the 
total platinated DNA) [132]. The chemistry of aquation of cisplatin and events 
leading to its binding to DNA are illustrated schematically in Figure 5.1. In vivo, 
cisplatin loses its chloride ions in aqueous solution, forming a species with a readily 
exchangeable aqua group that binds DNA. The extra- and intracellular concentrations 
of chloride ions play an important role in its activity. When administered 
intravenously, cisplatin remains intact as the concentration of chloride ions is 
relatively high (~100 mM). The chloride ions are lost once cisplatin reaches the 
inside of the cell where the intracellular chloride concentration is low, ~4 mM 
[268,269]. These aquated species are more reactive and they enter nuclei and bind 
DNA. There is some evidence that S donor ligands such as methionine and 
glutathione play an important role in the transfer of platinum to DNA. Both aqua 
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species and thioether adducts play significant roles in forming DNA-adducts 
[270,271]. 
 
Hydrolysis of the first chloride ion in cisplatin is the rate-limiting step that is 
subsequently followed by the coordination of platinum primarily to the N7 position 
of guanine and adenine bases to form monofunctional adducts (Fig. 5.1(d)) [272]. 
These monofunctional adducts then react with a second purine base forming 
bifunctional adducts or crosslinks (Fig. 5.1(e)) [132]. These crosslinks modify DNA 
by bending, unwinding and shortening [273]. This modification in DNA by cisplatin 
is recognised by different repair proteins and HMG (high mobility group) proteins. 
The binding of HMG proteins induces antitumor activities in the cells by interfering 
with cell machinery [55]. 
Figure 5.1: Scheme for the mechanism of cisplatin binding to DNA and protein 
recognition [274]. 
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5.1.1 Aquation 
It is almost certain that cisplatin is aquated before binding, but there is debate over 
which aquated species of cisplatin  (mono- or diaqua) preferentially binds to DNA 
[275-279]. The aquation process of cisplatin involves many different species [280] 
that can follow different paths of reactions before and during binding to DNA [277]. 
To get a better understanding of the mechanism of action of cisplatin there have been 
numerous studies on the kinetics of DNA platination using mainly NMR 
spectroscopy, HPLC techniques and HPLC-MS analysis [126,272,275-277,281-284]. 
The majority of these studies have used DNA containing a GG site as it is the 
preferred coordination site. The studies have been carried out using cisplatin and 
other cisplatin-related species such as cis-[PtCl(NH3)2H2O]+, cis-
[Pt(NH3)2(H2O)2]2+, trans-[Pt(NH3)2Cl2], cis-[PtCl(NH3)3]+, [Pt(NH3)3(H2O)]2+, 
cis-[Pt(OH)(NH3)2H2O]+ with different lengths of ssDNA and dsDNA.  
 
In studies using hairpin-duplex DNA by Kozelka et al. it was reported that the 
diaquated form of cisplatin, cis-[Pt(NH3)2(H2O)2]2+ or its deprotonated form, cis-
[Pt(OH)(NH3)2H2O]+ contributes to the major platinated DNA product [275,285]. 
However, the majority of studies have shown that monofunctional adducts with one 
chloride ligand bound are the primary intermediates [272,277-279,283]. Recently, 
Davies et al. used NMR spectroscopy to show that the monoaquated species cis-
[PtCl(NH3)2H2O]+ accounts for at least 98% of the total platination whereas cis-
[Pt(OH)(NH3)2H2O]+ accounts for only about 1% [277]. In the same study it was 
also reported that the rate of aquation of cisplatin is slowed by 30-40% in the 
presence of DNA [277]. Studies on cisplatin, cis-[Pt(NH3)2(H2O)2]2+ and 
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[Pt(NH3)3(H2O)]2+ have revealed that the platination rate constants increased with 
increasing oligonucleotide length [283] and more so at the 5′-G than the 3′-G [276]. 
 
The closure of the monofunctional adduct to a form a bifunctional adduct is thought 
to be necessary to induce anticancer activity in the cells. Sadler [278] and Chottard 
[286] with their colleagues determined the rates of formation of the intrastrand 
bifunctional adducts by NMR spectroscopy and HPLC techniques, respectively. 
Interestingly, studies with dsDNA have shown that closure of a 3′ monofunctional 
adduct is faster than the closure of 5′ adduct irrespective of the sequence (GG, AG or 
GA) suggesting that DNA structure plays an important role on the rate of this process 
[277-279,286]. There is no clear data on whether a chloride ligand of monofunctional 
adducts is replaced by water before ring closure to form a bifunctional adduct [275]. 
No aquated monofunctional adducts were observed with GG sequences [277,278], 
however, small amounts of aquated monofunctional adducts were observed for AG 
and GA sequences[279]. One possible explanation of this could be that a longer time 
is taken for ring closure for AG and GA monofunctiona1 adducts compared with that 
for GG. 
 
5.1.2 Why cisplatin does not bind bifunctionally to GA? 
Although there has been some evidence for formation of bifunctional cisplatin 
aduucts with GA, the majority of studies of reactions between DNA and cisplatin 
have reported the absence of GA-cisplatin adducts, with GG, AG and GNG adducts 
being the only products formed [132,136,287-290]. Eastman used the technique of 
enzymatic digestion followed by HPLC analysis and reported that in all the 
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adenine/guanine adducts detected, A was invariably present at the 5′ end 
[132,287,290]. Reedijk’s group used NMR spectroscopy, circular dichroism and 
HPLC techniques to identify enzymatic products of cisplatin-treated salmon sperm 
DNA and did not detect any GA-cisplatin adducts [288,289]. It was believed that 
there is something inherently less favourable about GA sites that does not allow 
bifunctional cisplatin binding [274]. 
 
The first detailed evidence for the formation of bifunctional GA adducts was 
reported in 1998 by Hambley and co-workers [279] although there was some earlier 
evidence provided by Leng and co-workers in a DNA footprinting study in 1993 
[291]. In the detailed work by Hambley and co-workers [279], reaction rates of 15N-
cisplatin and cis-[Pt(15NH3)2(H2O)2]2+ with self-complementary 14 mer duplexes 
containing AG and GA sites were measured using NMR spectroscopy. The rate of 
formation of monofunctional adducts from cis-[Pt(15NH3)2(H2O)2]2+ was similar for 
AG and GA sequences, whereas for 15N-cisplatin a clear preference for AG was 
observed over GA. Ring closure to form the bifunctional adduct was more rapid in 
AG than GA for both the species, with a greater difference observed for cis-
[Pt(15NH3)2(H2O)2]2+. The results showed that cisplatin binding to DNA is 
substantially controlled by the rate of formation of monofunctional adducts at the 
different X-purine-purine-X sequences. Furthermore, a slower rate of ring closure is 
responsible for the non-formation of bi-functional GA adducts. This will be discussed 
in more detail later in the context of results obtained in the present work. 
 
Out of the five major groups involved in the study of DNA/cisplatin adducts 
(Chottard, Lippard, Sadler, Reedijk, and Hambley,) it is only Hambley’s group that 
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has probed the formation of bifunctional AG and GA adducts. In a continuation of 
the above study, Hambley and co-workers showed that reaction rates for reactions 
between the same 14 mer self-complemetary oligonucleotides used above, are 
slowed down substantially in the presence of chloride (60-80 mM) [292]. We studied 
the formation of GG, AG and GA adducts of 8 and 16 mer ssDNA with cisplatin 
using enzymatic digestion and exploiting the sensitivity of ESI mass spectrometry. 
 
5.1.3 Enzymes used in this study 
Enzymatic digestion is used widely for the study of modified and unmodified DNA 
[128,134-136]. Exo- and endonucleases are used that digest DNA at specific sites. 
The enzymes used in this study were phosphodiesterase I, phosphodiesterase II, 
nuclease PI, and alkaline phosphatase. Phosphodiesterase I and II are exonucleases 
that break down DNA into smaller fragments by cleaving phosphodiester bonds 
[293-296].  
 
Both these enzymes have similar activities for releasing terminal nucleotides with 
phosphodiesterase I operating at the 3′-end of DNA whereas phosphodiesterase II 
operates at the 5′-end as shown in Figure 5.2. Phosphodiesterase I hydrolyses 
phosphodiester bonds from the 3′-end that is not phosphorylated and releases 5′-
mononucleotides (phosphate present at the 5′-end). Conversly, phosphodiesterase II 
hydrolyses phosphodiester bonds from a 5′-end that is not phosphorylated and 
releases 3′-mononucleotides. Furthermore, both Pd I and Pd II are non-processive 
enzymes that dissociate from DNA after removal of each nucleotide and bind to 
DNA again to catalyze the release of the next nucleotide [295,296]. 
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Figure 5.2: Actions of phosphodiesterase I (Pd I) and phosphodiesterase II (Pd II) on 
DNA. Pd I (a) releases 5′-mononucleotides and Pd II (b) releases 3′-mononucleotides 
by hydrolyzing phosphophodiester bonds between the sugar and phosphate from the 
3′-end and 5′-end respectively [295,296]. 
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Nuclease PI is an endonuclease that cleaves DNA at internal sites (the 
phosphodiester bonds) in the DNA sequence, releasing 5′-nucleotides with 3′-
hydroxyl groups  as shown in Figure 5.3. 
Figure 5.3: Actions of nuclease P1 on DNA. Solid arrows show the cleavage sites of 
nuclease P1 whereas dashed arrows show possible cleavage sites that are barred 
since nuclease P1 is an endonuclease. 
 
5.2 Scope of this chapter 
Much is known about the mechanism and kinetics of cisplatin binding to GG sites on 
DNA [126,128,136,276,281-284,286,297]. Studies carried out using GG- and AG- 
containing DNA with cisplatin have shown its clear preference for 5′-GG-3′ over 5′-
AG-3′ [132,285,287-289,298]. Little is known about the interactions of cisplatin with 
5′-GA-3′- containing DNA sequences. This work was carried out to study the 
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formation of bifunctional cisplatin adducts with oligonucleotides containing different 
cisplatin binding sites. 
 
DNA-cisplatin adducts with oligonucleotides containing three different cisplatin 
binding sites: 5′-GG-3′, 5′-AG-3′ and 5′-GA-3′ were prepared in this study. 
Conditions were optimized for HPLC purification of the cisplatin adducts from 
unreacted ssDNA. The next aim was to optimize conditions for exonuclease 
digestion of ssDNA-cisplatin adducts and to probe the bifunctional binding of 
cisplatin with ssDNA ESI-MS. The sensitivity of ESI-MS enabled reproducible 
detection of low levels of bifunctional adducts.  
 
5.3 Results and Discussion 
5.3.1 Preparation of cisplatin adducts with ssDNA 
Ten different sequences of non-self complementary ssDNA were used in this study 
and labeled Enz1- Enz10 (Table 5.1). Enz9 and Enz10 were not reacted with 
cisplatin and were only used in the preliminary experiments for developing 
enzymatic digestion methods. Enz1- Enz8 have the potential cisplatin binding sites, 
5′-GG-3′, 5′-AG-3′ or 5′-GA-3′ in the centre. Enz1-5, Enz9 and Enz10 are 16 mer 
oligonucleotides and Enz6-8 are 8 mers. Enz6, Enz7 and Enz8 have the same eight 
base pair sequences (bp 5-12) as in the centre of Enz3, Enz4 and Enz5, respectively 
(Table 5.1). 
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Table 5.1: Single-stranded DNA sequences used in this study. Cisplatin binding sites 
in ssDNA are shown in bold. 
 
Single-stranded DNA Label 
5′-CCTCTCTGGACCTTCC-3′ Enz1 
5′-CCTCTCCGGTCCTTCC-3′ Enz2 
5′-CCTCTCCGGACCTTCC-3′ Enz3 
5′-CCTCTCCAGTCCTTCC-3′ Enz4 
5′-CCTCTCCGATCCTTCC-3′ Enz5 
5′-TCCGGACC-3′ Enz6 
5′-TCCAGTCC-3′ Enz7 
5′-TCCGATCC-3′ Enz8 
5′-GGAGGTATTTGGCAGC-3′ Enz9 
5′-GCTGCCAAATACCTCC-3′ Enz10 
 
 
Preparation of cisplatin-DNA adducts was carried out in two steps, reacting cisplatin 
with ssDNA followed by purification of the adducts using HPLC. In previous 
studies, cisplatin-DNA adducts have been prepared by reacting cisplatin and ssDNA 
in 1:1 molar ratio at room temperature or 37°C in the dark over a long period of time 
(1-5 days) [122,124,125,136,299].  Alternatively, the diaqua derivative of cisplatin 
has been prepared and reacted with ssDNA for a shorter period of time [50,123,300]. 
In this study we developed a new method for the synthesis of cisplatin-DNA adducts 
(section 2.2.3). Briefly, cisplatin-DNA adduct, {cis-[Pt(NH3)2]Enz1} was prepared 
by reacting single-stranded oligonucleotide (Enz1, see Table 5.1) with cisplatin in 5 
mM NH4OAc pH 6.8, in equimolar amounts (0.2-0.5 mM) in a volume of 200-500 
µL. The mixture was heated at 73°C at pH 6.8 for 4-5 hours in dark. {cis-
[Pt(NH3)2]Enz1} was separated later by HPLC from unreacted (Enz1). The purity of 
the separated {cis-[Pt(NH3)2]Enz1} was tested by dissolving it in 50% acetonitrile 
(in 5 mM NH4OAc) and analysing by negative ion ESI-MS using the conditions 
outlined in Table 2.5.  
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An experiment was set up to compare this method with the method used in other 
studies that involved reaction of cisplatin and DNA over 1-5 days at 37°C. Three 
identical reaction mixtures were set up containing cisplatin and Enz1 in equimolar 
amounts (0.2 mM), in 5 mM NH4OAc pH 6.8. Reaction one was set up at room 
temperature and was monitored for 3 days. In reaction two, the mixture was heated at 
73°C for 4 hours and reaction three was set up as a control of reaction two at room 
temperature for 4 hours. All the reaction mixtures were monitored with time by ESI-
MS and also purified later by HPLC followed by ESI-MS analysis.  
 
Figure 5.4(a) and (b) show ESI mass spectra of reaction one after 1 and 3 days, 
respectively. The most abundant peaks in Fig. 5.4(a) peaks are from unreacted 
ssDNA, Enz1, with ions of lower intensity from platinated Enz1 also present. With 
time the platination progressed slowly and after 3 days (Fig. 5.4(b)) the most 
abundant peaks were still from unmodified Enz1. The rate of platination was 
comparatively much faster at 73°C. The ESI mass spectrum shown in Fig. 5.4(c) was 
obtained for reaction two (73°C) after 4 hours; the most abundant ions are from 
platinated Enz1. The amount of platination was higher than when the reagents were 
allowed to react for 3 days at room temperature (reaction one). The ESI mass 
spectrum in Fig. 5.4(d) shows that no reaction had occurred after 4 hours at room 
temperature (reaction three).  Therefore, treatment of ssDNA (containing a GG 
platination site) with cisplatin at 73°C enable rapid preparation of platinated DNA 
that can be used for further analysis. 
 
A method was developed for separation of {cis-[Pt(NH3)2]Enz1} from unreacted 
(Enz1). Initially an attempt was made to separate reaction mixtures using a C18 
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HPLC column equilibrated with 0.01 M NH4OAc (1 mL /min) and eluting with a 0-
60% linear gradient of acetonitrile over 30 minutes. The resulting elution profile is 
shown in Fig. 5.5(a); there is little separation of the two peaks A and B.  
 
A variety of different linear gradients were trialed in order to improve the separation. 
Better separations were achieved with a gradient of 0-30% acetonitrile over 45 
minutes, 0-10% over 60 minutes (shown in Fig. 5.5(b) and (c) respectively). ESI-MS 
analysis of all the separated peaks obtained using the different gradients showed 
contamination from nearby peaks (data not shown). Finally, a less hydrophobic C8 
column was used with a linear gradient of 0-10% over 60 minutes (section 2.2.3).  
Here, peaks were well separated (Fig. 5.5(d)) and ESI-MS analysis did not show any 
contamination from nearby peaks. The HPLC elution profiles of the reaction 
mixtures one, two and three are shown in Fig. 5.6(a), (b) and (c) respectively. 
Analysis of the peaks by ESI-MS confirmed that unreacted Enz1 oligonucleotide 
eluted between 30-35 minutes (peak A), and platinated Enz1 ({cis-[Pt(NH3)2]Enz1}) 
eluted at 42 minutes (peak B). The ratios of the areas under the peaks in the HPLC 
elution profile compare favourably with the ratios of intensities of ions observed in 
ESI mass spectra before HPLC separation (compare Fig. 5.4(b) with 5.6(a); Fig. 
5.4(c) with 5.6(b) and Fig. 5.4(d) with 5.6(c)). All the calculated m/z values for the 
observed ions in Fig. 5.4 are included in Table 5.2. 
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Figure 5.4: Negative ion ESI mass spectra of reaction mixtures of cisplatin with 
oligonucleotide Enz1. Reaction one: at room temperature for 3 days, reaction two: at 
73°C for 4 hours and reaction three: at room temperature for 4 hours. (a) Reaction 
one (at RT) after 1 day, (b) reaction one (at RT) after 3 days, (c) reaction two (at 
73°C) after 4 hours, and (d) reaction three (at RT) after 4 hours. Unmodified Enz1 
(); {cis-[Pt(NH3)2] Enz1} (). 
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Figure 5.5: HPLC elution profiles of reaction mixture containing {cis-[Pt(NH3)2]Enz1} and unreacted oligonucleotide using different linear 
gradients of acetonitrile. A C18 column was used in (a), (b), and (c) with a C8 in (d). (a) Linear gradient 0-60% acetonitrile in 10 mM NH4OAc 
over 30 minutes, (b) Linear gradient of 0-30% acetonitrile 10 mM NH4OAc over 45 minutes, (c) Linear gradient of 0-17% in 10 mM NH4OAc 
over 45 minutes, and (d) Linear gradient of 0-10% in 10 mM NH4OAc over 60 minutes. Unmodified Enz1 (A); {cis-[Pt(NH3)2] Enz1} (B). 
Chapter 5 
 176 
 
Figure 5.6: HPLC elution profile of separated products from the reaction between 
cisplatin and oligonucleotide Enz1. (a) Reaction one: at room temperature for 3 days, 
(b) reaction two: at 73°C for 4 hours, and (c) reaction three: at room temperature for 
4 hours. Unmodified Enz1 (A);{cis-[Pt(NH3)2] Enz1} (B). 
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All the other ssDNA sequences (Enz2-Enz8, Table 5.1) were reacted and purified by 
the method developed here. The elution profiles for reaction mixtures containing 
Enz2 and Enz3 were similar to those obtained for Enz1 (Fig. 5.5(d)). This is 
understandable as all the three ssDNA are 16 base pairs long with a similar base 
sequence. All contain the cisplatin binding site (5′-GG-3′) at the centre with the only 
difference being a single base flanking either side of the cisplatin binding site (Table 
5.1). 
 
Table 5.2: Calculated m/z values for the observed reaction products between 
cisplatin and Enz1. 
Calculated m/z  
 [M - 3H]3- [M - 4H]4- [M - 5H]5- [M - 6H]6- [M - 7H]7- 
Enz1 (M) 1656.1 1241.8 993.2 827.5  
 [M - 5H]3- [M - 6H]4- [M - 7H]5- [M - 8H]6- [M - 9H]7- 
{cis-
[Pt(NH3)2]Enz1} (M) 
1580.4 1185.0 947.8 789.7 676.7 
      
 
Reaction of cisplatin with sequences containing 5′-AG-3′ or 5′-GA-3′ 
Significant differences were observed in the elution profiles from reaction mixtures 
of ssDNA containing the other possible cisplatin binding sites 5′-AG-3′ or 5′-GA-3′. 
Figure 5.7(a), (b) and (c) show the separation of reaction mixtures after heating at 
73°C for 4 hours with cisplatin and ssDNA Enz3, Enz4 or Enz5, respectively. Enz3, 
Enz4 and Enz5 contain cisplatin binding sites of 5′-GG-3′, 5′-AG-3′ and 5′-GA-3′, 
respectively. Peak B in each elution profile corresponds to the ssDNA-cisplatin 
adduct. The amount of modified Enz5 and Enz6 was considerably lower (Fig 5.7(b) 
and (c)) than for Enz4 containing GG site (Fig. 5.7(a)). The small amount of {cis-
[Pt(NH3)2]Enz5} (AG site) is consistent with studies that have shown a lower 
percentage of AG crosslinks with cisplatin are formed than GG crosslinks 
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[132,289,301-303]. Furthermore, kinetic studies showed that rates of formation of 
both mono- and bifunctional adducts with AG containing DNA are slower than DNA 
with GG sites (Table 5.1) [279,292,298]. 
Figure 5.7: Elution profile of separation of reaction mixture containing {cis-
[Pt(NH3)2]ssDNA} and unreacted oligonucleotide containing different cisplatin 
binding sites. Panels I & II show separation in 16 and 8 mer oligonucleotides, 
respectively. DNA in (a) and (d) contained a GG site, (b) and (e) contained a AG site 
and (c) and (f) contain GA site. Single-stranded DNA (A); single-stranded {cis-
[Pt(NH3)2] DNA} (B). 
 
A small amount of {cis-[Pt(NH3)2]Enz6} (GA site) (peak B in Fig. 5.7(c)) was 
observed, which was less than for either of {cis-[Pt(NH3)2]Enz4} or {cis-
[Pt(NH3)2]Enz5} containing GG and AG sites, respectively (Fig. 5.7(a) and (b)). 
Similar results were obtained with shorter ssDNA sequences containing the cisplatin 
binding sites of 5′-GG-3′, 5′-AG-3′ and 5′-GA-3′ in Enz6, Enz7 and Enz8, 
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respectively (Fig. 5.7(d), (e) and (f)). The three ssDNA: Enz6, Enz7 and Enz8 are 8 
mers and have the same central sequences as Enz3, Enz4 and Enz5 respectively 
(Table 5.1). ESI mass spectra of the peaks from Fig. 5.7(f) showed that there were 
two platinated oligonucleotide products corresponding to the mass of bifunctional 
adduct, {cis-[Pt(NH3)2]Enz8}. A possible explanation for the presence of these two 
platinated peaks (B) may be that one or both of these represent monofunctional 
adducts with a fourth chloride or water ligand {cis-[Pt(NH3)2Cl]Enz8} or {cis-
[Pt(NH3)2OH2]Enz8} that is fragmented from the complex in the ionisation source. 
Alternatively, ring closure to form a bifunctional adduct may have occurred after 
HPLC, but prior to analysis. The products of the reaction of cisplatin with Enz8 were 
not pursued further. 
 
Other studies investigating sequence effects in reactions of cisplatin with DNA have 
not found cisplatin 5′-GA-3′ bifunctional adducts with DNA at the detection limits of 
the analytical techniques employed [132,136,288,289,301,304]. In a study carried out 
involving enzymatic digestion of products of the reaction between 5′-GGTCGACC-
3′ and cisplatin followed by analysis of products by HPLC, only evidence of G(1) 
and G(2) bound to cisplatin was obtained with lack of cisplatin binding to G(5) of 
GA [136], although other studies have clearly shown the formation of a monoadduct 
in sequences containing G next to A or alone [279,305]. This highlights a need for a 
more sensitive technique for the analysis of minor products in these reaction 
mixtures. 
 
Evidence for pre-association between cationic cisplatin complexes and anionic DNA 
preceding substitution has been found by immobilizing oligonucleotides and using 
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quartz crystal microbalance electrodes [306]. These results are further supported by 
NMR data that showed there were decreased rates of aquation of cisplatin in the 
presence of oligonucleotides [277,307]. Hambley et al. found support for the 
formation of GA crosslinks using molecular mechanics and molecular dynamics to 
investigate pre-association of cis-[PtCl(NH3)2(H2O)]2+ with DNA [274]. The models 
showed that irrespective of the sequence (GG, AG or GA), cis-[PtCl(NH3)2(H2O)]2+ 
can form strong associations with purine-purine sequences of DNA by as many as 
four hydrogen bonds (Fig. 5.8) [274]. Furthermore, in all the sequences (Fig. 5.8(a), 
(b) and (c)) Pt is favourably placed with respect to the lone pair of the N7 atom of the 
3′ purine, one of the two coordination sites. This is consistent with the observation 
that 3′ binding is preferred over 5′ in GG and AG sequences [277-279]. 
 
Although an enormous amount of work has been done on reaction of cisplatin and 
related compounds with DNA containing GG and AG sites, only a few researchers 
have focused on GA sites. In a recent study involving hairpin-stabilised duplex 
oligonucleotides reacting with [Pt(NH3)2(H2O)2]2+, the order of reactivity towards G 
followed the order TGG > GGT > TGA ≈ AGT > GGC ≈ TGT > TGC [305].  
 
Hambley and coworkers have studied bifunctional adducts of cisplatin with DNA 
containing GA sites [274,279,292].  In the kinetic studies performed by Hambley et 
al. on the formation of mono- and bifunctional adducts of ds and ssDNA-cisplatin 
adducts, it was shown that the rates of formation of a preliminary monofunctional 
adduct with purines at the 3′-end is greater than with the 5′-end. More importantly, 
the relative rates of reaction vary according to GG > AG >> GA. 
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Figure 5.8: Pre-association between cis-[PtCl(NH3)2(H2O)]2+ and oligonucleotides 
with cisplatin binding sites, GG (a), AG (b) and GA (c), calculated using computer 
simulations. Hydrogen bonds are shown in black arrows [274]. 
 
Chapter 5 
 182 
Studies have shown that initial formation of monofunctional adduct at 5′-GG-3′ and 
5′-AG-3′ is preferred at the 3′ base over the 5′ base [277,278,308]. This reflects an 
important role of DNA structure (since in 5′-GG-3′ both purines are chemically 
equivalent) and a preference for guanine over adenine [278,279]. This binding 
preference is reversed for 5′-GA-3′ and it is not clear whether this is the result of a 
change in DNA structure or the inherently lower reactivity of adenine. Closure to 
form bifunctional adducts occurs approximately 10 times faster from a 3′ 
monofunctional adduct than from a 5′ adduct [277-279,286]. The effect of adenine is 
not marked here. The question as to whether closure occurs via an aquated Pt 
intermediate is still under scrutiny. Some studies have been able to show aquated 
intermediates at AG and GA sequences, but not at GG [277,278]. The possibility that 
two monofunctional (perhaps aquated) intermediates was raised earlier as a possible 
explanation for the observation of two HPLC peaks (Fig. 5.7(f))) that later ESI-MS 
analysis showed were consistent with addition of {Pt (NH3)2} to ssDNA. The results 
obtained in this study for ssDNA containing GG, AG and GA cisplatin binding sites 
are consistent with these studies. As seen in the Fig. 5.7(a) and (b), the amount of 
{cis-[Pt(NH3)2]Enz4} (containing AG binding site) is about half the amount of {cis-
[Pt(NH3)2]Enz3}(containing GG binding site). Similarly, for 8 mer ssDNA, the 
amount of {cis-[Pt(NH3)2]Enz7} is about half the amount of {cis-[Pt(NH3)2]Enz6}, 
Fig. 5.7(d) and (e). 
 
Most likely, in the ssDNA-cisplatin adducts obtained above, cisplatin is bound to the 
5′-GG-3′, 5′-AG-3′ or 5′-GA-3′ sites present on ssDNA as a bifunctional adduct. 
This was tested (more below) by analysing the cisplatin adducts using enzymatic 
digestion combined with ESI mass spectrometry. 
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5.3.2 Enzymatic digestion/ESI-MS analysis of ssDNA-cisplatin adducts 
Two exonucleases, phosphodiesterase I (Pd I) and phosphodiesterase II (Pd II) were 
used in this study. As described in section 5.1.3, both Pd I and Pd II remove 
mononucleotides sequentially from DNA by hydrolyzing the phosphodiester bonds. 
Pd I releases 5′-mononucleotides and Pd II releases 3′-mononucleotides by 
hydrolyzing phosphodiester bonds between the sugar and phosphate from the 3′-end 
and 5′-end, respectively. Time-controlled digestion by these exonucleases forms a 
complete set of DNA fragments differing from each other by one mononucleotide. 
The mass analysis of these fragments provides a “sequence ladder” with the mass 
difference between the adjacent peaks corresponding to mass of a single 
mononucleotide within the sequence [134,135].  
 
There are numerous studies on the use of MALDI-TOF mass spectrometry and ESI-
MS for sequencing DNA [134,135,309-313]. Two types of enzymatic digestion were 
used here: partial digestion and total digestion. In partial digestions, either of the 
exonucleases were used. Previous studies have established that these exonucleases 
are incapable of hydrolyzing the phosphodiester bond of DNA at a platinated site 
[128,136,314,315].  Therefore, it is predicted that the exonuclease will hydrolyze 
mononucleotides from one end of the DNA until it encounters a platinated site.  In a 
study by Troujman and Chottard, partial digestion of an 18 mer cisplatin adduct with 
the sequence AACG٭G٭TTAACCGTTAATT (G٭ indicating cisplatin binding site) 
using Pd I exonuclease gave as the final product AACG٭G128] ٭]. Based on this and 
other studies, we expected that partial digestion of ssDNA-cisplatin adducts such as 
{cis-[Pt(NH3)2]Enz1} with Pd I, would result in removal of seven bases from the 3′-
end, leaving cisplatin bound to the GG site and the other seven unmodified bases 
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intact at 5′-end (Fig. 5.9(a)). Conversely, for Pd II, the final product of hydrolysis 
would have seven bases removed from the 5′-end leaving cisplatin bound to the GG 
site with the other seven unmodified bases intact at the 3′-end (Fig. 5.9(b)). 
 
Figure 5.9: Expected partial digestion products from cisplatin adducts with 16 mer 
ssDNA used in this study using Pd I (a) and Pd II (b). XX represents cisplatin 
binding sites (5′-GG-3′, 5′-AG-3′ or 5′-GA-3′) on ssDNA. Note that the sugar-
phosphate backbone is not shown in this representation. 
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Furthermore, digestion of {cis-[Pt(NH3)2]Enz1}with both Pd I and Pd II together in 
the same digestion mixture (total digestion), is expected to remove seven unmodified 
bases from each end giving rise to a final product  containing two guanine bases 
modified by cisplatin (Fig. 5.10). The analogous products are expected for cisplatin 
bifunctional adducts with AG or GA binding sites. The products of partial and total 
digestion of cisplatin adducts with 8 different ssDNA (Enz1-Enz8) were analysed. 
 
Analyses of the digestion mixtures after appropriate time intervals were carried out 
by ESI-MS. This was a great advantage for this study as the masses of the 
intermediates in the reaction mixture gave a clear picture of the extent of the 
reaction. Furthermore, the exact binding site of the compound under investigation 
could be determined. 
Fig. 5.10: Expected total digestion product from cisplatin adducts with 16 mer 
ssDNA using Pd I and Pd II. XX represents the cisplatin binding sites (5′-GG-3′, 5′-
AG-3′ or 5′-GA-3′) on ssDNA. Note that the sugar-phosphate backbone is not shown 
in this representation. 
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5.3.2a  Optimization of conditions for exonuclease digestion  
In order to identify the products of reactions of cisplatin with DNA sequences 
containing GG, AG or GA binding sites by this method it was necessary to optimize 
the conditions for the enzymatic reactions in the digestion of ssDNA-cisplatin 
adducts. This was carried out using two unmodified 16 mer ssDNA sequences, Enz9 
and Enz10 (Table 5.1). The partial digestion mixtures were set up as described in 
section 2.2.6. An equal volume of either of the enzymes (5 µL) was used initially. 
The digestion was monitored with time by ESI-MS analysis after 30 min, 1 and 1.5 
hours. ESI mass spectra of an enzymatic digestion of Enz9 and Enz10 after 30 min 
and 1.5 hours are shown in Figure 5.11. All the spectra of the digestions were 
aquired in positive ion mode with instrument conditions as outlined in chapter 2. 
Positive ion ESI-MS was used as it displays better sensitivity than negative ion 
mode. Moreover most of the MS studies of positively charged cisplatin-DNA have 
been carried out in positive ion mode. The calculated m/z values of the ions observed 
from the partial digestion mixture containing unmodified ssDNA are shown in Table 
5.3. Fig. 5.11(a) shows a sequence ladder formed after digestion with Pd I for 30 
min. Ions corresponding to sequences arising from loss of one, two, three, four and 
five mononucleotides from Enz9 and undigested Enz9 at m/z 1563.7, 1454.0, 1349.6, 
1253.2, 1143.4 and 1660.1, respectively are evident. All the peaks carried 3+ charges 
denoted [M + 3H]3+, where M is the mass of the particular oligonucleotide 
with/without loss of mononucleotides; Table 5.3). As the digestion progressed, more 
mononucleotides were lost from Enz9 by the action of Pd I (operating from the 3′ 
end of DNA). Fig. 5.11(b) shows the ESI mass spectra of digestion products of Enz9 
after 1.5 hours. Doubly charged ions from Enz9 which had lost four, five, six, seven, 
eight and nine mononucleotides were observed (m/z 1879.3, 1714.7, 1550.0, 1397.9, 
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1245.9 and 1093.8). Similar results were obtained from digestion of Enz10 with Pd I 
for 30 min and 1.5 h (Fig. 5.11(e) and (f), respectively), the only difference being 
that a loss of up to 13 mononucleotides was observed after 1.5 hours whereas for 
Enz9 a maximum of 9 mononucleotides were removed. Under the experimental 
conditions, Pd I digested Enz9 and Enz10 at a faster rate than Pd II. For Enz9, loss of 
up to two mononucleotides was observed and for Enz10, loss of up to four 
mononucleotides was observed (Fig. 5.11(c), (d), (g) and (h)).  
 
A number of studies have used Mg2+ in the form of MgCl2 or MgSO4 at different 
concentrations [314-317] to enhance phosphodiesterase activity. We studied the 
digestion of ssDNA by Pd I and Pd II, both in presence and absence of MgCl2. 
Under our experimental conditions, no significant differences were observed when 
Mg2+ was present. In the following experiments, rates of reactions catalyzed by Pd I 
and Pd II were adjusted when necessary by allowing longer reaction times or 
increasing the amounts of enzymes added to the digestion mixture. 
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Figure 5.11: Optimization of conditions for digestion of ssDNA with phosphodiesterases. Digestion of Enz9 with Pd I and Pd II after 30 min (a) 
and (c), respectively, and after 1.5 hours (b) and (d), respectively. Digestion of Enz10 with Pd I and Pd II after 30 min (e) and (g), respectively, 
and after 1.5 hours (f) and (h), respectively. The sequence of ssDNA is shown at the top of each panel and peaks are labeled showing the number 
of bases removed from DNA. Undigested DNA (). 
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Table 5.3: Calculated m/z values for the products observed in the partial digestion of unmodified nucleotide using either phosphodiesterase I or 
phosphodiesterase II. The letter “M” will be used in the text for the mass of ssDNA with/without the loss of number of mononucleotides as 
specified. 
 
Calculated m/z values using phosphodiesterase I 
Unmodified 
oligonucleotide 
[M + 2H]2+ [M + 3H]3+ Unmodified 
oligonucleotide 
[M + 2H]2+ [M + 3H]3+ 
Enz9  1660.1 Enz10   
Enz9-1B  1563.7 Enz10-3B  1302.2 
Enz9-2B  1454.0 Enz10-4B 1808.2 1205.8 
Enz9-3B  1349.6 Enz10-5B 1663.6 1109.4 
Enz9-4B 1879.3 1253.2 Enz10-6B 1507.0 1005.0 
Enz9-5B 1714.7 1143.4 Enz10-9B 1041.7  
Enz9-6B 1550.0  Enz10-10B 885.1 1769.2 
Enz9-7B 1397.9  Enz10-11B  1480.0 
Enz9-8B 1245.9  Enz10-12B  1190.8 
Enz9-9B 1093.8  Enz10-13B  861.6 
Calculated m/z values using phosphodiesterase II 
Unmodified 
oligonucleotide 
[M + 3H]3+ [M + 4H]4+ Unmodified 
oligonucleotide 
[M + 3H]3+ [M + 4H]4+ 
Enz9 1660.1 1245.3 Enz10 1596.4  
Enz9-1B 1550.4 1163.0 Enz10-1B 1486.7 1115.2 
Enz9-2B 1440.6 1080.7 Enz10-2B 1390.3  
Enz9-3B   Enz10-3B 1288.9  
Enz9-4B   Enz10-4B 1179.1  
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5.3.2b  Partial digestion of ssDNA-cisplatin adducts 
Similar digestions to those described above were carried out on cisplatin adducts 
with ssDNA: Enz1, Enz2 and Enz3 (giving {cis-[Pt(NH3)2] Enz1}, {cis-[Pt(NH3)2] 
Enz2} and {cis-[Pt(NH3)2] Enz3}, respectively) prepared as described in section 
2.2.3. ESI mass spectra in Figure 5.12 show ions from products of the digestion 
mixture of {cis-[Pt(NH3)2] Enz2} with Pd I after 30 min, 1 and 5 hours. In Fig. 
5.12(a) ions from loss of one mononucleotide and undigested {cis-[Pt(NH3)2] Enz2} 
were observed ([{cis-[Pt(NH3)2] Enz2} + H]3+ and [{cis-[Pt(NH3)2] Enz2} + 2H]4+ 
at m/z 1553.7, 1650.1 and 1165.5, 1237.8 respectively).  The calculated m/z values of 
the ions observed from the partial digestion mixture containing ssDNA-cisplatin 
adducts are shown in Table 5.4. Under the same conditions, the Pd I digestion of 
unmodified ssDNA of the same length (Fig. 5.11(a) and (e)), loss of up to six 
mononucleotides was observed. This shows that the presence of cisplatin has an 
inhibitory effect on Pd I. Similar observations have been made in other enzymatic 
digestion studies [136,314,315]. The digestion progressed slowly for the platinated 
adducts and it was observed that even after 1 hour, only three mononucleotides were 
lost (Fig. 5.12(b)). The digestion was monitored with time and after 5 hours digestion 
the product pattern was similar to that for unplatinated DNA after 1.5 hours. Figure 
5.12(c) shows the ESI mass spectrum obtained after a digestion time of 5 hours. The 
most abundant ions correspond to products with five, six and seven mononucleotides 
removed from {cis-[Pt(NH3)2] Enz2} (m/z 1158.1, 1061.7 and 960.3, respectively  
assigned to [{cis-[Pt(NH3)2] Enz2} + H]3+. Ions from a product corresponding to the 
ssDNA-cisplatin adduct minus more than seven mononucleotides were absent. This 
suggests that cisplatin is bound to bases 8 and 9 (shown as G* in Fig. 5.12); Pd I 
could not apparently hydrolyze the phosphodiester bond between nucleotides 8 and 9 
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from the 3′-end. The m/z values at 960.3 and 1440.0 correspond to the triply and 
doubly charged ions of partially digested {cis-[Pt(NH3)2] Enz2} as proposed in Fig. 
5.9(a). As there are no purines other than the preferred cisplatin binding site, GG in 
the sequence, most likely, cisplatin is bound as a bifunctional adduct at this site. 
Similar results were obtained for {cis-[Pt(NH3)2] Enz1} and {cis-[Pt(NH3)2] Enz3} 
(data not shown). 
 
Partial digestion of the ssDNA-cisplatin adducts was also studied using Pd II. The 
results obtained were similar to those obtained for Pd I except that Pd II removed 
mononucleotides from the 5′-end in all the ssDNA-cisplatin adducts studied. Figure 
5.13 shows ESI mass spectra of ions present in digestion mixtures containing {cis-
[Pt(NH3)2] Enz1},{cis-[Pt(NH3)2] Enz2} or {cis-[Pt(NH3)2] Enz3}, with Pd II. 
After 30 min, in the digestion mixture containing {cis-[Pt(NH3)2] Enz1}, ions from 
undigested and from products corresponding to removal of one, two and three 
mononucleotides from {cis-[Pt(NH3)2] Enz1} were observed at m/z values 1658.1, 
1561.7, 1465.3 and 1363.9 (triply charged) and, 1243.8, 1171.5 and 1099.2 
(quadruply charged),   (Fig. 5.13(a)).  
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Figure 5.12: Partial digestion of {cis-[Pt(NH3)2] Enz2} with phosphodiesterase I at 
different time intervals: 30 min (a), 1 hour (b), and 5 hours (c). The sequence of {cis-
[Pt(NH3)2] Enz2} is shown at the top (G* stands for platinated guanines). 
Undigested {cis-[Pt(NH3)2] Enz2} (); the number in other labels (eg 5B) 
represents the number of mononucleotides removed from {cis-[Pt(NH3)2] Enz2}. 
 
The digestion progressed with time but did not go to completion as depicted in Fig. 
5.9(b). For all the three cisplatin adducts studied above, the final product observed 
corresponded to removal of only six mononucleotides from the 5′-end (an extra base 
remained bound to the 5′ side of the purine-purine cisplatin binding site). Figures 
5.13(b), (c) and (d) show ESI mass spectra of partial digestions of {cis-[Pt(NH3)2] 
Enz1},{cis-[Pt(NH3)2] Enz2} and {cis-[Pt(NH3)2] Enz3} with Pd II after 5 hours. 
Ions from cisplatin adducts that lost three, four, five and six mononucleotides were 
observed in all the three digestion mixtures. For {cis-[Pt(NH3)2] Enz1}, triply 
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charged ions from products corresponding to removal of three, four, five and six 
mononucleotides were observed at m/z 1363.9, 1267.5, 1166.1 and 1069.7, 
respectively. Similarly, for {cis-[Pt(NH3)2] Enz2}, m/z values were 1355.9, 1259.5, 
1158.1 and 1061.7, and for {cis-[Pt(NH3)2] Enz3}, 1358.9, 1262.5, 1161.1 and 
1064.7, respectively. The mass spectra obtained after 24 hours of digestion were 
essentially the same as for 5 hours. Under these experimental conditions, the 
digestion product had a base remaining on the 5′ side of platinated GG site. 
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Table 5.4: Calculated m/z values for the products observed in the partial digestion of 
ssDNA-cisplatin adducts using Pd I and Pd II. The letter “M” will be used in the text 
for the mass of the ssDNA with/without the loss of number of mononucleotides as 
specified. 
 
Calculated m/z values of digestion products observed using Pd I 
ssDNA-cisplatin  
adduct 
[M+  
Pt(NH3)2 - H ]1+ 
[M+ 
Pt(NH3)2 + 
H]3+ 
[M+ 
Pt(NH3)2 + 2H]4+ 
{cis-[Pt(NH3)2] Enz2}  1650.1 1237.8 
{cis-[Pt(NH3)2] Enz2}-
1B 
 1553.7 1165.5 
{cis-[Pt(NH3)2] Enz2}-
2B 
 1457.3  
{cis-[Pt(NH3)2] Enz2}-
3B 
 1355.9  
{cis-[Pt(NH3)2] Enz2}-
5B 
 1158.1  
{cis-[Pt(NH3)2] Enz2}-
6B 
 1061.7  
{cis-[Pt(NH3)2] Enz2}-
7B 
 960.3  
{cis-[Pt(NH3)2] Enz6}-
3B 
1707.1   
{cis-[Pt(NH3)2] Enz7}-
3B 
1691.1   
{cis-[Pt(NH3)2] Enz8}-
3B 
1691.1   
    
Calculated m/z values of digestion products observed using Pd II 
ssDNA-cisplatin  
adduct 
[M+ 
Pt(NH3)2]2+ 
[M+  
Pt(NH3)2 + 
H]3+ 
[M+ 
Pt(NH3)2 + 2H]4+ 
{cis-[Pt(NH3)2] Enz1}  1658.1 1243.8 
{cis-[Pt(NH3)2] Enz1}-
1B 
 1561.7 1171.5 
{cis-[Pt(NH3)2] Enz1}-
2B 
 1465.3 1099.2 
{cis-[Pt(NH3)2] Enz1}-
3B 
 1363.9  
{cis-[Pt(NH3)2] Enz1}-
4B 
 1267.5  
{cis-[Pt(NH3)2] Enz1}-
5B 
 1166.1  
{cis-[Pt(NH3)2] Enz1}-
6B 
 1069.7  
{cis-[Pt(NH3)2] Enz2}-
3B 
 1355.9  
{cis-[Pt(NH3)2] Enz2}-  1259.5  
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4B 
{cis-[Pt(NH3)2] Enz2}-
5B 
 1158.1  
{cis-[Pt(NH3)2] Enz2}-
6B 
 1061.7  
{cis-[Pt(NH3)2] Enz3}-
3B 
 1358.9  
{cis-[Pt(NH3)2] Enz3}-
4B 
 1262.5  
{cis-[Pt(NH3)2] Enz3}-
5B 
 1161.1  
{cis-[Pt(NH3)2] Enz3}-
6B 
 1064.7  
{cis-[Pt(NH3)2] Enz6}-
1B 
1147.8   
{cis-[Pt(NH3)2] Enz6}-
2B 
1003.2   
{cis-[Pt(NH3)2] Enz7} 1287.4   
{cis-[Pt(NH3)2] Enz7}-
1B 
1135.3   
{cis-[Pt(NH3)2] Enz7}-
2B 
990.7   
{cis-[Pt(NH3)2] Enz8}-
1B 
1135.3   
{cis-[Pt(NH3)2] Enz8}-
2B 
990.7   
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Figure 5.13: Partial digestion of cisplatin adducts with phosphodiesterase II at 
different time intervals: (a)  {cis-[Pt(NH3)2] Enz1} after 30 min, (b), (c) and (d) {cis-
[Pt(NH3)2] Enz1}, {cis-[Pt(NH3)2] Enz2}  and {cis-[Pt(NH3)2] Enz3}, respectively, 
after 5 hours. Undigested {cis-[Pt(NH3)2] Enz1} (); numbers in other labels 
represent loss of number of that number of mononucleotides from the corresponding 
cisplatin adduct. 
 
The conditions developed above for partial digestions using Pd I and Pd II gave an 
opportunity to probe reactions at other binding sites (AG and GA) in ssDNA-
cisplatin adducts (Table 5.1). These experiments used two sets of ssDNA-cisplatin 
adducts prepared with different lengths of ssDNA (Enz3, Enz4 and Enz5 as 16 mers 
and Enz6, Enz7 and Enz8 as 8 mers). This was carried out by partial digestion, as 
outlined above with {cis-[Pt(NH3)2] Enz1},{cis-[Pt(NH3)2] Enz2} and {cis-
[Pt(NH3)2] Enz3} and total digestion, using both the exonucleases Pd I and Pd II 
(Fig. 5.9 and 5.10). 
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The results obtained for partial digestion of all the cisplatin adducts, {cis-[Pt(NH3)2] 
Enz3}, {cis-[Pt(NH3)2] Enz4}, {cis-[Pt(NH3)2] Enz5}, {cis-[Pt(NH3)2] Enz6}, {cis-
[Pt(NH3)2] Enz7} and {cis-[Pt(NH3)2] Enz8} were similar to those described above. 
Partial digestion with Pd I produced products formed by removing mononucleotides 
from the cisplatin binding site: 5′NNNNNNNG∗G∗←3′ or 5′NNNG∗G∗←3′, 
5′NNNNNNNA∗G∗←3′ or 5′NNNA∗G∗←3′ and 5′NNNNNNNG∗A∗←3′ or 
5′NNNG∗A∗←3′ (where N= a nucleotide) as shown in Fig. 5.9(a). In all the 8 mer 
cisplatin adducts, {cis-[Pt(NH3)2] Enz6}, {cis-[Pt(NH3)2] Enz7} and {cis-
[Pt(NH3)2] Enz8} loss of three 5′ mononucleotides was observed to give the 
proposed final partial digestion product (Fig. 5.14(a), (b) and (c)). The digestion time 
required to remove three mononucleotides from 8 mer cisplatin adducts was only 30 
min as compared with 5 hours from 16 mers (Fig. 5.12(c)). As shown in the ESI 
mass spectrum in Fig. 5.14(a) the most abundant ion was from a product 
corresponding to removal of three mononucleotides from {cis-[Pt(NH3)2] Enz6} at 
the 3′-end (m/z 1707.1 assigned to [M+Pt(NH3)2-H]1+). Similarly, products with 
three mononucleotides lost from {cis-[Pt(NH3)2] Enz7} and {cis-[Pt(NH3)2] Enz8} 
were observed in ESI mass spectra from partial digests containing {cis-[Pt(NH3)2] 
Enz7} and {cis-[Pt(NH3)2] Enz8} (m/z 1691.1 assigned to [M+Pt(NH3)2-H]1+). 
 
Partial digestion of {cis-[Pt(NH3)2] Enz3}, {cis-[Pt(NH3)2] Enz4}, {cis-[Pt(NH3)2] 
Enz5}, {cis-[Pt(NH3)2] Enz6}, {cis-[Pt(NH3)2] Enz7} and {cis-[Pt(NH3)2] Enz8} 
with Pd II produced similar results to those described above. The partial digestion 
with Pd II showed the digestion products with mononucleotides removed from the 5′-
end. Results were in agreement with those obtained with {cis-[Pt(NH3)2] Enz1}, 
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{cis-[Pt(NH3)2] Enz2} and {cis-[Pt(NH3)2] Enz3} (Fig. 5.13(b), (c) and (d) 
respectively), where Pd II was unable to remove mononucleotides from the 5′ side of 
the cisplatin binding site. That is, →CG∗G∗NNN was observed for {cis-[Pt(NH3)2] 
Enz6} containing a 5′-GG-3′ site, with →CA∗G∗NNN for {cis-[Pt(NH3)2] Enz7} 
containing a 5′-AG-3′ site and →CG∗A∗NNN for {cis-[Pt(NH3)2] Enz6} containing 
a 5′-GA-3′ site (A∗ or G∗ used for platinated nucleobases, adenine and guanine and N 
for a nucleotide).  
 
The results obtained with partial digestion of ssDNA-cisplatin adducts followed by 
ESI-MS analysis strongly indicated that cisplatin forms a bifunctional adduct on 
DNA at 5′-GG-3′, 5′-AG-3′ or 5′-GA-3′. Total digestion was employed to confirm 
this. 
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Figure 5.14: Partial digestion of cisplatin adducts (8 mers) with phosphodiesterase I and phosphodiesterase II. Panel I shows digestion of {cis-
[Pt(NH3)2] Enz6}, {cis-[Pt(NH3)2] Enz7} and {cis-[Pt(NH3)2] Enz8} in (a), (b) and (c), respectively, by Pd I after 30 min. Panel II shows 
digestion of {cis-[Pt(NH3)2] Enz6}, {cis-[Pt(NH3)2] Enz7} and {cis-[Pt(NH3)2] Enz8} in (d), (e) and (f), respectively, by Pd II after 5 hours. 
Undigested {cis-[Pt(NH3)2] Enz1} (); numbers in other labels (e.g. 3B) represent loss of the number of mononucleotides from the 
corresponding cisplatin adduct. 
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5.3.2c  Total digestion of ssDNA-cisplatin adducts 
The total digestion of {cis-[Pt(NH3)2] Enz3}, {cis-[Pt(NH3)2] Enz4}, {cis-
[Pt(NH3)2] Enz5}, {cis-[Pt(NH3)2] Enz6}, {cis-[Pt(NH3)2] Enz7} and {cis-
[Pt(NH3)2] Enz8} was carried out as described in section 2.2.6. In some “total 
digestion” experiments an endonuclease nuclease PI was also present. In these 
experiments, the results obtained were the same as when only Pd I and Pd II were 
present and are not discussed separately here. As proposed earlier (Fig. 5.10), total 
digestion using both the exonucleases would remove mononucleotides from each end 
to give a final product of a dinucleotide with cisplatin bound (Fig. 5.10). Figure 5.15 
shows the final digested products expected from total digestion of all the ssDNA-
cisplatin adducts prepared. Figure 5.15(a) shows the final digested product from {cis-
[Pt(NH3)2] Enz3} and {cis-[Pt(NH3)2] Enz6}, Fig. 5.15(b) shows the final digested 
product from {cis-[Pt(NH3)2] Enz4} and {cis-[Pt(NH3)2] Enz7} and finally Fig. 
5.15(c) corresponds to final digested product from {cis-[Pt(NH3)2] Enz5} and {cis-
[Pt(NH3)2] Enz8}. 
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Figure 5.15: Expected total digestion products from ssDNA-cisplatin adducts used 
in this study: (a) shows the final product from {cis-[Pt(NH3)2] Enz3} and {cis-
[Pt(NH3)2] Enz6}, (b)  shows the final product from {cis-[Pt(NH3)2] Enz4} and 
{cis-[Pt(NH3)2] Enz7}, and (c) shows final product from {cis-[Pt(NH3)2] Enz5} and 
{cis-[Pt(NH3)2] Enz8}. Cisplatin-bound bases are shown as A* and G*. The 
phosphodiester bonds are not shown in the Figure. 
 
Consequently, if the total digestion proceeds as outlined above, ions from the final 
products should be observed at same m/z values for {cis-[Pt(NH3)2] Enz3} and {cis-
[Pt(NH3)2] Enz6}(m/z, 824.2), and also for {cis-[Pt(NH3)2] Enz4}, {cis-[Pt(NH3)2] 
Enz7}, {cis-[Pt(NH3)2] Enz5} and {cis-[Pt(NH3)2] Enz8} (m/z, 808.2) (Fig 5.15 and 
5.17). Furthermore, as the final products of the latter four ssDNA-cisplatin adducts 
have the same mass (differing only in the position of A or G), all these ions are also 
expected to have same m/z values. The total digestion of ssDNA-cisplatin adducts 
(containing 16 mer ssDNA), {cis-[Pt(NH3)2] Enz3}, {cis-[Pt(NH3)2] Enz4}, {cis-
[Pt(NH3)2] Enz5} took 5 hours for complete digestion under our experimental 
conditions. Fig. 5.16(a), (b) and (c) show ESI mass spectra of digestion mixtures 
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containing {cis-[Pt(NH3)2] Enz3}, {cis-[Pt(NH3)2] Enz4} or {cis-[Pt(NH3)2] Enz5}, 
respectively, after 5 hours. The ESI mass spectrum obtained for the total digests of 
{cis-[Pt(NH3)2] Enz3} showed most abundant ions at m/z 904.3 and 887.3, assigned 
to [M+Pt(NH3)2-H]1+ ions (Fig. 5.16(a)). Similarly, ESI mass spectra from {cis-
[Pt(NH3)2] Enz4} and {cis-[Pt(NH3)2] Enz5} showed most abundant ions at m/z 
values of 888.3 and 871.3, assigned to [M+Pt(NH3)2-H]1+ (Fig. 5.16(b) and (c)). 
 
Similarly, ESI mass spectra from the total digestion of shorter cisplatin adducts (8 
mer ssDNA),  {cis-[Pt(NH3)2] Enz6} produced ions at m/z 904.3 and 887.3 (Fig. 
5.16(d); {cis-[Pt(NH3)2] Enz7} and {cis-[Pt(NH3)2] Enz8} both produced ions at 
m/z 888.3 and 871.3 (Fig. 5.16(e) and (f), respectively. The time taken for complete 
digestion of {cis-[Pt(NH3)2] Enz6}, {cis-[Pt(NH3)2] Enz7} and {cis-[Pt(NH3)2] 
Enz8} was just 30 min as compared with {cis-[Pt(NH3)2] Enz3}, {cis-[Pt(NH3)2] 
Enz4} and {cis-[Pt(NH3)2] Enz5} that took 5 hours. 
 
The mass expected of each of the final products was 825.2 (for G*G*) and 809.2 (for 
A*G* and G*A*). This raises the question of the identity of products giving m/z 
values of 871.3, 887.3, 888.3 and 904.3. The molecular structures of the above 
expected products from total digestion are given in Fig. 5.17(a), (b) and (c). The 
(monoisotopic) m/z values calculated for each of the ions from each of the above 
molecules assigned to [M+Pt(NH3)2-H]1+ were 824.2 and 808.2 respectively (Table 
5.5). In the ESI-MS mass spectra from the total digestion mixtures these ions were 
absent (Fig. 5.16).  Instead, the most abundant ions in each of ESI mass spectra were 
at m/z 904.3  (Fig. 5.16(a) and (d)), 888.3 (Fig. 5.16(b) and (e)) and 888.3 (Fig. 
5.6(c) and (f)), respectively. The molecular structures of these ions are shown in Fig. 
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5.17(d), (e) and (f) with their calculated m/z values that were assigned to 
[M+Pt(NH3)2-H]1+. As seen in Fig. 5.17(d), (e) and (f) all the molecules are similar 
to the expected products proposed but with a phosphate group (HPO3) shown in left. 
 
In order to confirm the molecular structures proposed in Fig. 5.17(d), (e) and (f), 
“Isotope modeling” was carried out. This is one of the features present in Mass Lynx 
software provided by Micromass used for data acquisition and data processing in the 
Q-Tof-2 mass spectrometer. On providing the molecular formula for the proposed 
molecular structure, a theoretical ESI mass spectrum based on the isotope 
distributions of that compound is generated. The theoretical ESI mass spectrum 
obtained can be compared with the experimental ESI mass spectrum. 
 
Table 5.5: Calculated m/z values for the products expected/observed in total 
digestion of ssDNA-cisplatin adducts. 
 
Calculated m/z values for the products 
expected/observed in total digestion of ssDNA-
cisplatin adducts 
ssDNA-cisplatin  
adduct 
[M+Pt(NH3)2-H]1+ 
5′G∗G∗3′ 824.2 
5′pG∗G∗3′ 904.1 
5′A∗G∗3′ 808.2 
5′pA∗G∗3′ 888.1 
5′G∗A∗3′ 808.2 
5′pG∗A∗3′ 888.1 
ssDNA-cisplatin  
adduct 
[M+Pt(NH3)-H]1+ 
5′pG∗G∗3′ 887.1 
5′pA∗G∗3′ 871.1 
5′pG∗A∗3′ 871.1 
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Figure 5.16: Total digestion of cisplatin adducts with phosphodiesterase I and phosphodiesterase II. Panel I shows digestion of {cis-[Pt(NH3)2] 
Enz3}, {cis-[Pt(NH3)2] Enz4} and {cis-[Pt(NH3)2] Enz5} in (a), (b) and (c), respectively, after 5 hours. Panel II shows digestion of {cis-
[Pt(NH3)2] Enz6}, {cis-[Pt(NH3)2] Enz7} and {cis-[Pt(NH3)2] Enz8} in (d), (e) and (f), respectively, by Pd II after 30 min.  
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Figure 5.17: Molecular structure of some of the proposed and observed total 
digestion products of ssDNA-cisplatin adducts. Molecular mass is shown at the 
bottom of each molecule. Proposed structures of digestion products of adducts with 
three different cisplatin binding sites; (a), (b) and (c) and, structure of products 
corresponding to observed m/z are shown in (d), (e) and (f) respectively. Cisplatin-
bound bases are shown as A* and G*. 
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Isotope modeling was performed for the molecular structures proposed for the 
molecular masses 905.1, 889.1 and 889.1 shown in Figure 5.18.  Figure 5.18(a) and 
(b) shows theoretical mass spectra generated from isotope modeling of the ion 
observed at m/z 904.3 compared with the observed mass spectrum after total 
digestion of {cis-[Pt(NH3)2] Enz6} (Fig. 5.16(d), shown as ()). The three most 
abundant peaks shown in Fig. 5.18(a) and (b) are from the three isotopes of platinum, 
194Pt, 195Pt and 196Pt respectively. The close resemblance of the two spectra clearly 
shows that ions belong to the proposed molecular structures as shown in Fig. 5.17(d). 
The mass difference of 0.2 between theoretical and observed mass could be due to 
calibration errors and is within experimental error. The same isotopic distributions at 
the same m/z values were obtained for the ion observed at m/z 904.3 in the total 
digestion of {cis-[Pt(NH3)2] Enz6} (Fig. 5.16(d), shown as ()), data not shown. 
 
Similarly, isotope modeling was carried out for the structure proposed in Fig. 5.17(e) 
and (f) for the ion observed at m/z 888.3 present in the total digestion of  {cis-
[Pt(NH3)2] Enz4}, {cis-[Pt(NH3)2] Enz5}, {cis-[Pt(NH3)2] Enz7} and {cis-
[Pt(NH3)2] Enz8} (Fig. 5.16(b), (c), (e) and (f), respectively). For all these ions the 
same isotopic distributions were expected as they all have the same molecular 
composition (Fig. 5.17(e) and (f)).  The isotopic distributions of ions observed here 
also matched exactly with the theoretical isotopic distributions. Figure 5.18(c) and 
(d) shows the theoretical and observed isotopic distributions for the ion at m/z 888.3 
observed in the ESI mass spectrum from the digestion of {cis-[Pt(NH3)2] Enz7} 
(Fig. 5.16(e)). 
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The other major ion observed in the ESI mass spectra from all the total digestions 
carried out was 17 amu lower, Fig. 5.16 (shown as, -NH3). Most likely this ion is 
from the loss of one ammine ligand (NH3) from the bound cisplatin molecule. 
Similar observations were made in other MS studies of cisplatin modified 
oligonucleotides [123,125,281]. In an ESI-MS/MS study in our laboratory of 
cisplatin adducts with the self-complementary DNA of sequence 5′-CAGGTG-3′, 
loss of one and two ammine groups from platinum was observed both in positive and 
negative ion mode [125]. Similar observations were made by Costello et al. in FAB-
MS studies [123]. In another study involving enzymatic digestion of monofunctional 
adducts of 14 mer DNA (5′-ATACATGGTACATA-3′) with cisplatin (and related 
compounds), using PdI and Pd II enzymes, loss of one ammine group was observed 
in both positive and negative ion mode using MALDI-TOF mass spectrometry [281].  
 
The results for partial digestion of ssDNA-cisplatin adducts showed that Pd II was 
unable to remove one mononucleotide on the 5′ side of the platinated site (5′→ 
XB∗B∗−3′); Fig. 5.13 and 5.14). The results obtained for total digestions showed that 
all the mononucleotides were hydrolyzed to the modified nucleobases. Possible 
explanations are that Pd I may under some experimental conditions have a low level 
activity able to hydrolyze nucleotides from the 5′-end or that the Pd I contains a 
contaminant with this activity. In partial digestions of ssDNA-cisplatin adducts using 
Pd I, minor peaks were observed at m/z corresponding to a totally digested 
bifunctional product as shown in Fig. 5.17 (d), (e) and (f) supporting these 
explanations.  
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Figure 5.18: Isotope modeling of the structures relating to major ions observed in ESI mass spectra of total digestion mixtures of ssDNA-
cisplatin adducts. Theoretical and observed isotope distributions of ions from Fig. 5.16(d) are shown in (a) and (b), respectively. Theoretical and 
observed isotope distributions of ions from Fig. 5.16(e) are shown in (c) and (d), respectively. 
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In another experiment when 10 times more Pd I was used (with no Pd II), more 
intense peaks were observed at m/z 904.3 and 888.3, suggesting total digestion by Pd 
I (or a contaminant) alone. Other studies have shown that Pd I has some  activity 
from the 5′-end [318]. In a study of Pd I from different sources, Pd I was able to 
hydrolyze mononucleotides from oligonucleotides selectively blocked at either 
terminus, from either end, with the 5′-end activity slower than the 3′-end activity 
[313]. 
 
In work carried out by Gonnet et al. [126], ESI-MS analyses of digestion mixtures 
containing Pd I were not possible owing to the precipitation of Pd I. These analyses 
were performed by MALDI mass spectrometry. In the literature, no studies have 
been carried out using ESI-MS analysis of enzymatically digested bifunctional 
adducts. One related study used MALDI-TOF for digestion of monofunctional 
adducts. A 14 mer DNA (5′-ATACATGGTACATA-3′) was reacted with cisplatin 
and digested using Pd I and Pd II [281]. In that study, the authors proposed that 
cisplatin was bound to either 5′ G or 3′ G, in-spite of the presence of A in the 
sequence. Peaks were observed at m/z values corresponding to the monoadduct 5′-
ATACATG∗-3′ and 5′-G∗GTACATA-3′ with {PtCl(NH3)2} using Pd I and Pd II 
respectively. Interestingly, peaks were also observed at m/z corresponding to 5′-
GGTACATA-3′ using Pd I. There were no results that clearly identified the exact 
binding site of cisplatin [281]. 
 
The results above for total digestion of ssDNA-cisplatin adducts analysed by ESI-MS 
strongly suggest that cisplatin forms bifunctional adducts at purine-purine cisplatin 
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binding sites, 5′-GG-3′, 5′-AG-3′ or 5′-GA-3′ in DNA.  The structures of the 
products detected by ESI-MS were confirmed by isotope modeling. 
 
5.4 Conclusions 
This work involved the study of cisplatin interactions with oligonucleotides 
containing different cisplatin binding sites available for formation of bifunctional 
adducts. Adducts were purified by HPLC and analysed by enzymatic digestion and 
ESI-MS. A faster reaction method to obtain appropriate amounts of ssDNA-cisplatin 
adduct was developed. Furthermore, new conditions for the separation of unreacted 
oligonucleotides from ssDNA-cisplatin bi-functional adducts were developed. A 
larger amount of cisplatin adduct with 5′-GG-3′-containing ssDNA was obtained 
compared with ssDNA containing 5′-AG-3′ or 5′-GA-3′ sites. Previously, there have 
only been limited reports that cisplatin can bind the 5′-GA-3′ site bifunctionally. 
 
Different bifunctional ssDNA-cisplatin adducts containing the cisplatin binding sites 
of 5′-GG-3′, 5′-AG-3′ and 5′-GA-3′ of different lengths were studied here. Two types 
of digestions, partial and total digestion were used to obtain evidence for the binding 
site of cisplatin. Both Pd I and Pd II hydrolyzed platinated oligonucleotides more 
slowly than unmodified oligonucleotides. Neither enzyme could hydrolyze the 
phosphodiester bond between the cisplatin-modified bases. The total digestion of the 
ssDNA-cisplatin adducts resulted in a product identified as two purines attached as a 
bifuctional adduct to cisplatin. This was confirmed using isotope modeling, where 
the theoretical mass spectrum for the proposed structures of digestion products was 
in agreement with the ESI mass spectra. This is the first report that has used 
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enzymatic digestion followed by ESI mass spectrometry to provide evidence of the 
formation of ssDNA-cisplatin bifunctional adducts with three different cisplatin 
binding sites, 5′-GG-3′, 5′-AG-3′ or 5′-GA-3′. Similar ESI-MS/digestion protocols 
have been used for the study of modified and unmodified DNA [128,134-136], 
however, the work presented here strengthens its applicability for the study of drug-
DNA binding sites.  
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